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Abstract: 
Glioblastoma multiforme (GBM) is a lethal disease of the whole brain. Despite complete 
surgical resection of the tumor, recurrence is inevitable and leads to patient death. Several 
molecularly-targeted agents have shown promising results preclinically, although clinical 
results have been disappointing. One plausible explanation for clinical failure of drugs is 
their inability to effectively target the invasive glioma cells that reside in areas away from 
the tumor core. These regions of the brain have an intact blood brain barrier (BBB), 
which through a combination of endothelial tight junctions and active efflux transporters 
restricts brain penetration of several drugs. The objective of this thesis was to investigate 
the influence of active efflux transporters, P-glycoprotein (P-gp) and breast cancer 
resistance protein (Bcrp) on the brain distribution of molecularly targeted agents. To 
enhance our understanding of brain distribution with statistical certainty, we proposed a 
population-based analysis method to estimate variability around the brain partition 
coefficient (Kp).  
 
We showed that the brain distribution of sunitinib (a tyrosine-kinase inhibitor) is limited 
by active efflux mediated by P-gp and Bcrp at the BBB. We further demonstrated that 
brain distribution could be enhanced by administration of a dual P-gp/Bcrp inhibitor. To 
statistically ascertain the variability associated with Kp in a serial sacrifice design, we 
v  
developed a pharmacokinetic model to simultaneously describe plasma and brain 
concentration time profile data. We further evaluated the influence of study design 
features such as between subject variability (BSV) and sample size at each time point on 
bias and precision of estimation of Kp. Our results show that bias is unaffected by the 
assumptions regarding the magnitude of BSV and sample size, however, precision 
improves with sample size. 
 
We further examined the influence of BBB on delivery and efficacy of dual PI3K/mTOR 
inhibitors, GNE-317 (higher BBB permeability) and GDC-0980 (restricted BBB 
penetration) using three glioma mouse models, GL261-luc-GFP model, GBM10 and 
U87. Disruption of the BBB in the tumor core resulted in higher drug concentrations for 
GDC-0980. However, intact BBB in the areas adjacent to the core restricted the brain 
concentrations of GDC-0980. Contrary to this, the brain concentrations of GNE-317 were 
similar in all the three regions of the brain. Furthermore, results from survival studies 
indicated that although both GNE-317 and GDC-0980 significantly improved survival 
compared to placebo, the treatment groups were not significantly different from each 
other. Therefore, it is important to consider that effective treatment of GBM relies not 
only on effective delivery across the BBB to invasive glioma cells but also on an 
effective drug. 
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1.1     INTRODUCTION 
Brain tumors are solid neoplasms that occur inside the cranium and the brain stem. They 
can be malignant or benign in nature. A brain tumor can either originate in the brain 
(primary brain tumor) or metastasize from peripheral sites to the brain (metastatic brain 
tumor). Metastatic brain tumors are more common than primary brain tumors. Almost 20-
40% of peripheral tumors spread to the brain, most commonly from lung, breast, 
melanoma and colon cancer (Soffietti et al., 2002). The Central Brain Tumor Registry of 
United States (CBTRUS) estimated approximately 70,000 cases of primary brain tumors 
to be diagnosed in 2013 based on age-sex-race groups (www.cbtrus.org) (Walker et al.). 
On an average, the prevalence of a brain tumor is 221.8 per 100,000 persons. In 2010 
alone, approximately 700,000 persons were living with a diagnosis of a primary brain 
tumor (Porter et al., 2010). 
 
Meningiomas are the most common primary brain tumor, representing 34% of all primary 
brain tumor cases reported. Glioma, a broad class of primary brain tumors that originate in 
the glial tissue of the brain represents 30% of all brain tumors, of which 80% are 
malignant (Porter et al., 2010) (www.cbtrus.org). Glial tumors can be astrocytic, 
oligodendroglial or oligoastocyitc in nature. The World Health Organization (WHO) has 
categorized astrocytic glial tumors into four grades, based on morphology, molecular 
genetics and biomarkers, prognosis and malignancy (Louis et al., 2007). Grade I, pilocytic 
astrocytomas, are rare, slow-growing benign tumors that are usually associated with 
prolonged survival. Grade II, astrocytomas, are relatively slow growing tumors. They tend 
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to infiltrate to other parts of the brain and can recur as a high-grade glioma. Median 
survival is approximately 10 years. Grade III, anaplastic astrocytoma, are malignant 
tumors with a greater tendency to spread in other parts of the brain and often recur as a 
higher-grade tumor. Median survival in these patients is usually 2 years. Grade IV, 
glioblastoma multiforme (GBM) is the most malignant and most common primary brain 
tumor in adults.  The median survival is approximately 14.6 months after radiation and 
chemotherapy (Stupp et al., 2005). The tumor cells in GBM have a characteristic 
morphology. The existing vasculature is highly permeable, with thickened basement 
membrane and hyperplasic endothelial cells. This makes GBM one of the most angiogenic 
solid tumors (Brem et al., 1972; Rong et al., 2006; Onishi et al., 2011). Certain reports in 
literature have indicated that growth of a glial tumor from low-grade to high-grade is 
dependent on the formation of new blood vessels (Brem, 1976).  Histological hallmarks of 
GBM include a necrotic center with extensive proliferation on the growing edge. This 
makes tumor cells appear as if arranged in a glomerular capillary loop in a garland-like 
fashion. Thus, highly hypoxic pseudo-palisading cells surrounding the necrotic tumor core 
define a unique framework to GBM tumor cells (Onishi et al., 2011). GBMs are 
particularly notorious for their heterogeneity and invasion into the other healthy parts of 
the brain (Levin et al., 1975; Berens and Giese, 1999).   
 
1.2     CURRENT  TREATMENT  OPTIONS: 
With high mortality rates, heterogeneous nature of the tumor and aggressive relapse, 
treatment of GBM remains difficult. Most patients undergo multi-modal treatments that 
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include surgery, radiation and chemotherapy. With the advancement in research and 
discovery of tumor growth pathways along with understanding of multiple mechanisms 
and barriers in drug delivery, molecularly targeted agents appear to be more promising. 
Several of these drugs are in clinical trials alone or in combination with chemotherapeutic 
agents or radiation (Bai et al., 2011). 
 
The first line of treatment for GBM is the surgical resection of the tumor without injuring 
the brain tissue and neurological functions such as motor skills. Most benign tumors are 
treated by surgery alone, however malignant tumors require radiation and/or 
chemotherapy in addition to surgery. Various surgical techniques can be utilized for 
efficient removal of the tumor such as stereotactic surgery (Romanelli et al., 2009), laser 
surgery (Lee Titsworth et al., 2014) and ultrasonic aspiration (Beckner et al., 2007). 
Surgery is usually guided by use of contrast agents (gadolinium) or fluorescent agents (5-
aminolevulinic acid (5-ALA)), which concentrate in the tumor core, making it easier for 
the surgeons to detect and remove tumor mass. Although surgery is the primary care for 
GBM patients, tumor recurrences have been observed due to tumor cells that infiltrate to 
zones beyond the tumor core. Cells in this region are highly migrating and infiltrative and 
often go undetected in MRI (Albert et al., 1994). Therefore, surgery is often followed by 
radiation therapy or chemotherapy to help the brain get rid of as many tumor cells as 
possible.  
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Radiation therapy (RT) forms an integral part of treatment option for high-grade gliomas. 
RT is a specific treatment that only targets the tumor tissue. In some cases, RT is used 
alone but otherwise it is often used in combination with surgery and/or chemotherapy.  
Here, high energy X-rays are directed at the tumor core. There are three primary ways by 
which a radiation therapy can be employed for treating brain tumor cells. External beam 
radiation therapy (EBRT) utilizes a machine that targets the cancer cells from outside 
while internal beam radiation therapy (IBRT) also known as brachytherapy, places a 
radioactive substance, usually sealed in needles or implants are placed near the tumor. 
Stereotactic radiation therapy (SRT), also called a gamma knife therapy, is a site-specific 
radiation therapy when the tumor is localized (Oh et al., 2012). In severe cases, patients 
receive whole brain radiation therapy (WBRT) when the tumor cells can be seen scattered 
in a MRI. The addition of RT to surgery has shown an increase in survival (Walker et al., 
1978; Stupp et al., 2005), but response of GBM patients to RT varies. Use of radio 
sensitizers, such as chemotherapeutics and anti-angiogenic drugs may show improvement 
in response to RT (Rodrigus, 2003; Duda et al., 2007).   
 
The goal of chemotherapy is to kill as many tumor cells as possible, which have been left 
behind after surgery and/or radiation therapy (Berens and Giese, 1999). Several reports in 
literature have suggested significant survival benefits in GBM patients on chemotherapy 
(Brandes et al., 1999; Stupp et al., 2005). Chemotherapeutics most commonly employed 
for GBM treatment are cytotoxic such as alkylating agents (temozolomide (TMZ)) and 
nitrosoureas (carmustine (BCNU) and lomustine (CCNU)) and cytostatic agents such as 
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thalidomide and tamoxifen) (Parney and Chang, 2003; van den Bent et al., 2006). With 
promising results in clinical trials of GBM, FDA approved TMZ as a single agent standard 
care of treatment in 2005 (Darefsky et al., 2012). Concomitant administration of TMZ and 
radiation was found to significantly increase the progression-free survival compared to 
radiation alone (14.6 months vs. 12.1 months) (Stupp et al., 2005). Since its approval, 
several other chemotherapeutics have been tried in combination with TMZ but none of the 
combinations showed encouraging results due to myelosuppression as a dose-limiting 
toxicity. Carmustine (BCNU) was the first systemic chemotherapeutic approved for the 
treatment of brain tumors in United States. It was formulated as interstitial wafers 
(Gliadel® wafers) and increased the 6-month survival rate by 20% compared to placebo, 
though serious intracranial infections were reported after (Brem et al., 1995; Bota et al., 
2007) 
 
1.3     MOLECULARLY-TARGETED THERAPY 
In recent years, understanding of the molecular mechanisms involved in tumor growth and 
identification of several aberrant pathways has led to the development of molecularly 
targeted agents. Several studies have evaluated the role of signal transduction pathways 
that are up regulated in GBM (Rasheed et al., 1999; Liang et al., 2002; Inda et al., 2010; 
Suvasini et al., 2011; Yi et al., 2011). These agents act by inhibiting the intracellular 
phosphorylation of protein-kinase domains (such as tyrosine, serine or threonine) of tumor 
growth pathway receptors or by interfering with the binding of the specific ligand to its 
receptor located on the tumor cell or on the blood vessel endothelium. The tumor growth 
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factor receptor pathways most commonly altered in GBM are vascular endothelial growth 
factor receptor (VEGFR) (Reardon et al., 2008), platelet derived growth factor receptor 
(PDGFR) (Kim et al., 2012), epidermal growth factor receptor (EGFR) (Inda et al., 2010), 
scatter factor/hepatocyte growth factor (MET) (Abounader and Laterra, 2005), neuronal 
and glioma-derived stem cell factor receptor (Sun et al., 2006) and fibroblast growth factor 
receptor (FGFR) (Stefanik et al., 1991).  
 
Bevacizumab, anti-VEGF monoclonal antibody, is an anti-angiogenic drug. It was 
approved in May 2009 by the US-FDA for treatment of recurrent glioblastoma. In 
combination with irinotecan, bevacizumab improved 6-month progression-free survival to 
46% compared to 21% with TMZ (Vredenburgh et al., 2007). Recently, dysregulation in 
downstream signaling pathways such as phosphatidylinositol-3-kinase (PI3K/mTOR) and 
Ras/MAPK pathway has been reported in GBM (Maity et al., 2000; Hu et al., 2005). 
Significant crosstalk among these pathways makes it difficult to treat a tumor, as 
inhibition of one pathway may lead to compensatory up-regulation of another target. More 
recently, the use of multi-targeted molecularly targeted agents has become an attractive 
treatment option, in conjunction with surgery, radiation and chemotherapy.  
 
1.3.1    VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR) 
AND PI3K/AKT/MTOR PATHWAY 
Glioma is a highly vascular tumor with significant infiltration into the surrounding healthy 
tissue of the brain. Immunohistochemistry analysis and ELISA of several brain tumors has 
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suggested that there is an increased expression of many tumor growth factors and their 
receptor pathways, in particular VEGF in GBM (Takano et al., 2010). VEGF is a pro-
angiogenic factor and one of the main mediators of glioma-angiogenesis (Wong et al., 
2009). VEGF is a ligand, which is released by tumor cells in response to several 
oncogenes as well as hypoxic or acidic conditions in the tumor core. Once released, VEGF 
binds to its receptors, located on the tumor cell surface and the blood vessel endothelium. 
There are six glycoprotein isoforms of VEGF; VEGFA-E and placental growth factor. 
VEGF is recognized by its receptors, VEGFR1, -2 or -3. VEGFR-1 is involved in 
activation of haematopoiesis, recruitment of monocytes and bone marrow derived cells for 
enhancing tumor growth and activation of matrix metalloproteinases (Gerber et al., 2002). 
VEGFR-3 mediates lymph-angiogenesis. VEGF-A, also known simply as VEGF, plays a 
prominent role in brain tumor growth. It was discovered as a permeability factor and is 
considered to increase BBB disruption. VEGF-A binds to two receptors, VEGFR1 and 
VEGFR2, which have been implicated as being most important in glioma-angiogenesis, 
with VEGFR-2 playing a dominant role in mediating the mitogenic, angiogenic and 
permeability enhancing effects of VEGFA (Xu et al., 2013a; Yao et al., 2013). Once 
VEGF is bound to its receptors, it causes dimerization of the intracellular tyrosine-kinase 
domains and phosphorylates tyrosine residues. This process promotes activation via 
phosphorylation of downstream secondary messengers of the PI3K/Akt/mTOR 
(phosphoinositide 3-kinase, the serine/threonine protein kinase AKT and the mammalian 
target of rapamycin (mTOR)) pathway. This pathway is considered central to VEGF 
signaling because it inhibits endothelial cell apoptosis by interfering with apoptotic 
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signaling (Cheng et al., 2009). It has also been reported that this pathway exhibits a 
feedback communication loop with the angiogenic factors via hypoxia inducible factor 
(HIF) which influences release of VEGF by the tumor cells (Mazure et al., 1997). In 
addition, VEGF-A also called as vascular permeability factor, is considered to be 
conducive for the disruption of BBB at the tumor “core”. Enhanced vessel leakiness in the 
tumor region increases the overall interstitial fluid pressure (IFP) of the tumor, thus 
compromising distribution of chemotherapeutics to the tumor core (Jain et al., 2007) 
(Figure 1.1).  
 
There are several small molecule drugs that inhibit VEGFR by inhibiting the intracellular 
tyrosine-kinase domains and interfering with the signaling cascade. These drugs include 
cediranib, vandetanib, pazopanib and sunitinib and have been tried in several preclinical 
models as an anti-VEGF agent (Wedge et al., 2005; Christensen, 2007; Siemann et al., 
2009). Sunitinib and sorafenib are two multi-targeted agents that inhibit VEGFR and 
PDGFR and possess both anti-tumor and anti-angiogenic activities. These drugs have been 
found to show anti-glioma and anti-VEGF activity in preclinical glioma xenograft models 
(Siegelin et al., 2010; D'Amico et al., 2012; Czabanka et al., 2013). Bevacizumab is an 
anti-angiogenic drug that binds to VEGF circulating in the blood stream and interferes 
with its binding to the VEGFR2. Aflibercept (a fusion protein), also called as a VEGF-
trap, is another drug that binds to circulating VEGFA, VEGFB and placental growth factor 
by acting as a soluble decoy receptor (Stewart, 2011). It is approved by the US-FDA for 
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wet macular degeneration (Ohr and Kaiser, 2012) and metastatic colorectal cancer (Andre 
and Chibaudel, 2013). 
 
1.3.2     PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) 
PDGFR is another commonly over-expressed tumor growth receptor in glioma and 
contributes significantly to the aggressive nature of the tumor (Nazarenko et al., 2012). 
This receptor plays a central role embryonic development and response to tissue damage 
in normal physiological conditions. In a tumor state, it is considered as being an essential 
pro-angiogenic factor involved in glioma-angiogenesis (Pierce et al., 1991). PDGFR-alpha 
and ß are the two major receptor isoforms of PDGFR that play an important role in the 
development and differentiation of the vessel wall (Zhang et al., 2009). Like VEGFR, 
downstream effects of PDGFR are mediated by receptor dimerization, phosphorylation of 
intracellular residues followed by activation and phosphorylation of intracellular signaling 
pathways, PI3K/Akt, MAPK/ERK and STAT3. Amplification of PDGF and PDGFR is 
observed in 11% of GBM patients (Hermanson et al., 1996; Lokker et al., 2002; 
Nazarenko et al., 2012) 
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Figure 1.1:  Schematic representation of receptor tyrosine kinase pathways and 
PI3K/mTOR pathways and therapies for glioblastoma 
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1.3.3     EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) 
EGFR is yet another tumor growth factor receptor involved in cellular proliferation via 
activation of downstream effector targets, PI3K/Akt/mTOR and ERK/MAPK pathway. 
EGFR-gene is one of the most frequently amplified and mutated forms in GBM 
pathophysiology, indicating high-grade glioma. The most common variant form of 
EGFR-gene is EGFRvIII, which results in a constitutively activated receptor, lacking a 
ligand-binding domain (Gupta and Salunke, 2012). Gefitinib and erlotinib are two 
tyrosine kinase inhibitors that showed potent anti-EGFR activity but failed to show 
significant survival benefit in GBM patients (Franceschi et al., 2007; Reardon et al., 
2010) 
 
1.3.4     PI3K/AKT/MTOR PATHWAY 
Current understanding in molecular mechanisms of GBM pathogenesis and limited 
efficacy of aggressive treatment modalities have led to development of molecularly-
targeted agents that inhibit intracellular pathways. Although treatment with bevacizumab 
improved survival compared to conventional chemotherapeutics, but effect on long-term 
efficacy was impeded by the heterogeneous nature of the tumor (Wen et al., 2012) and 
existence of tumor cells beneath an intact BBB forming a sanctuary. Hence, combination 
therapies have been proposed wherein the drugs in combination inhibit more than one 
target (Reardon and Wen, 2006; Lassen et al., 2013).  
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PI3K/Akt/mTOR belongs to a family of intracellular lipid kinases, comprising of three 
effectors; phosphoinositide 3-kinase (PI3K), the serine/threonine protein kinase AKT, and 
the mammalian target of rapamycin (mTOR).  Present downstream of several tumor 
growth receptors, this pathway has been implicated in several physiological and 
pathological functions such as cellular proliferation, cell differentiation, cell migration, 
metabolism and genetic mechanisms such as translation and transcription of tumor growth 
genes and cell cycle functions such as apoptosis. This makes it a very attractive target. 
(Guertin and Sabatini, 2007; Busaidy et al.; Wen et al., 2012). Alterations in the 
phosphatase and tensin homolog (PTEN) tumor suppressor gene have often been related to 
the activation of this pathway (Gruber Filbin et al., 2013) (Figure 1.1). 
 
Binding of ligands such as insulin growth factor (IGF) to insulin growth factor receptor 
(IGFR) or VEGF to VEGFR, activates intracellularly located PI3K, which is then 
transported to the plasma membrane catalyzing the formation of phosphatidylinositol 
3,4,5-triphosphate (PIP3) through phosphorylation of phosphatidylinositol-4,5-diphosphate 
(PIP2). PIP3 is a critical activator of Akt (also known as protein kinase B). Activation is 
mediated via recruitment of Akt to the membrane and phosphorylation of PDK1 and 
mTORC2. Akt subsequently activates mTOR complex. The mTOR complex comprises of 
two multi-protein isoforms, mTORC1 and mTORC2. In mTORC1, mTOR is associated 
with a regulator subunit, Raptor, which regulates mRNA translation and is sensitive to 
rapamycin and its analogs (Huang and Manning, 2009). Rapamycin and its analogs act by 
dissociating the raptor from mTORC1, leading to uncoupling of its substrate proteins. 
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mTORC2, on the other hand, is associated with a rapamycin insensitive protein called 
Rictor (Sarbassov et al., 2005; Guertin and Sabatini, 2007). Certain studies in literature 
suggest the existence of feedback loop for activation of Akt and mTORC1 via mTORC2 
in an Akt-independent manner (Matheny and Adamo, 2009). 
mTORC1 inhibitors (rapamycin, everolimus and temsirolimus) have undergone extensive 
preclinical and clinical evaluation, both as single agents and in combination for several 
cancers such as GBM (Goudar et al., 2005; Kreisl et al., 2009), breast cancer (Gadgeel et 
al., 2013; Ma et al., 2013), (Xu et al., 2013b) and prostate cancer (Zhang et al., 2012; 
Armstrong et al., 2013; Ellis et al., 2013). As a single agent, mTORC1 inhibitors have 
shown disappointing results in clinical trials (Cloughesy et al., 2008).  
 
Recent studies have indicated that inhibition of both mTORC1 and mTORC2, in addition 
to inhibition of PI3K and Akt, are needed to effectively suppress the activities of this 
pathway (Prasad et al., 2011; Fan and Weiss, 2012; Sami and Karsy, 2013). This led to the 
development of dual PI3K/Akt/mTOR inhibitors as an effective therapeutic approach. 
Some of the drugs in this category include GDC-0980, GNE-317, BEZ235, XL765, GDC-
0084 and PF-4691502.  
 
The current thesis is focused on  
• Sunitinib malate, an anti-angiogenic and anti-tumor agent with activity against 
VEGFR1-3, PDGFR-beta and other tumor growth regulators. It was approved as an anti-
angiogenic agent for the treatment of advanced renal cell carcinoma (RCC) in May 2006 
14  
and subsequently for imatinib-resistant gastro-intestinal stromal tumors (GIST) (Rock et 
al., 2007). Recently, sunitinib was approved for advanced pancreatic neuroendocrine 
tumor (PNET) (Delbaldo et al., 2012).  
• GNE-317 and GDC-0980, dual PI3K/Akt/mTOR inhibitors. GDC-0980 is 
currently in clinical trials for GBM and GNE-317 is currently under investigation. 
 
 
1.4     BARRIERS TO DRUG DELIVERY 
Despite major developments to improve brain delivery of drugs, treatment of primary and 
metastatic brain tumors remains one of the most challenging issues. Though brain is a 
highly perfused organ, it is well protected from the peripheral circulation by the presence 
of barriers that regulate the passage of several endogenous and exogenous (xenobiotics 
such as drugs and toxins) substances to the central nervous system (CNS) (Mangas-
Sanjuan et al., 2010). Several studies have suggested and indicated the correlation between 
physiochemical properties of drug molecules and BBB permeability such as lipophilicity, 
favorable size and charge state, appropriate polar surface area and its hydrogen-bonding 
potential. In spite of these favorable characteristics, several drug molecules still have 
limited distribution into the brain, which is affected by other factors that include plasma 
and/or brain protein binding and interaction with efflux transport systems (Summerfield et 
al., 2007; Hammarlund-Udenaes et al., 2008; Friden et al., 2009; Hammarlund-Udenaes et 
al., 2009). These barriers include the blood-brain barrier (BBB), blood-cerebrospinal fluid 
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barrier (BCSFB) and the ependyma (a layer of epithelial cells). Of these, the BBB is one 
of the most determinant barriers to drug delivery to the CNS (Abbott, 2000). 
 
 
1.4.1     BLOOD-BRAIN BARRIER (BBB) 
The BBB is not only a physical barrier but also a biochemical barrier that affects the rate 
and extent of drug distribution into the brain. The BBB is comprised of endothelial cells 
lining the cerebral microvessels. These cells confer a unique structure to the BBB 
compared to the microvessels elsewhere in the body, by the presence of tight-junctions 
and absence of fenestrae and pinocytic vesicles.  
 
1.4.1.1     Physical Barrier 
Presences of tight junction (TJ) protein complexes within the brain microvasculature 
restrict entry of solutes from the systemic circulation into the brain. zonulae occludentes 
are the extremely tight TJ and one of the key features of the BBB. They significantly 
affect paracellular diffusion across BBB (Begley and Brightman, 2003; Abbott et al., 
2010). Other junction complexes include adherens junctions wherein cadherin proteins 
provide a structural support to the tissue (Wolburg and Lippoldt, 2002). Further, TJ 
complexes comprising of occludins, claudins (-3, -5, -12), cingulins and junctional 
adhesion molecules (JAM-A, -B, -C) impede paracellular movement. In addition to TJ 
between endothelial cells, presence of astrocytic glial endfeet and pericytes at the 
abluminal side, maintain the barrier properties of the BBB, restricting transport of 
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hydrophilic and low-molecular weight compounds (Abbott et al., 2006). It has been 
observed that absence of TJ complex protein, claudin-3, is related to the loss of BBB 
integrity in GBM (Wolburg et al., 2003). Therefore, translocation of essential polar 
nutrients such as amino acids and glucose occurs by presence of specific solute carriers 
present on the luminal or abluminal side of the BBB (Betz et al., 1980; Abbott, 2002; 
Zhang et al., 2002). 
 
1.4.1.2     Biochemical Barrier 
Despite appropriate physiochemical properties, presence of solute carriers, other influx 
transport systems and carrier-mediated pathways at the BBB, small molecules that are able 
to diffuse across the endothelial cells are still subjected to active efflux back into the blood 
stream by efflux transport systems present at the BBB (Pardridge, 2007). Even though 
lipophilicity has been considered a favorable component for drug delivery, increasing the 
lipid solubility of a drug beyond a certain level can become counter-productive by 
increasing its likelihood of becoming a substrate for the ATP-Binding Cassette (ABC) 
family of efflux transporters (Begley, 2004; Eilers et al., 2008). These are ATP-dependent 
efflux proteins expressed on the luminal and/or abluminal side of the BBB (Kusuhara and 
Sugiyama, 2001). The three important members of the ABC family are P-glycoprotein (P-
gp, ABCB1), breast cancer resistance protein (BCRP, ABCG2) and multidrug-resistance 
associated proteins (MRPs, ABCC1-7).  
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P-glycoprotein (P-gp) is one of the most important and extensively studied ABC efflux 
protein. It is expressed and located on the luminal side of the brain capillary endothelial 
cells (Cordon-Cardo et al., 1989; Decleves et al., 2002). Several in-vivo studies have been 
conducted assessing the role of P-gp in restricting delivery of drugs to the brain. In mice, 
two genes mdr1a and mdr1b, encode for P-gp; however mdr1a is localized on the BBB 
(Demeule et al., 2002). Development of P-gp double knockout mice (Mdr1a/b(-/-)) has 
aided researchers in these studies extensively (Schinkel et al., 1994).  
 
Breast cancer resistance protein (BCRP) is another important member of ABC family that 
plays a significant role, often in tandem with P-gp, in limiting brain distribution of drugs. 
It was first identified when Doyle and colleagues observed resistance of anthracycline 
accumulation in breast cancer cell line, MCF-7 (Doyle et al., 1998). In a separate study 
around the same time, this transporter was observed to cause resistance to mitoxantrone 
accumulation in cancer cells in a P-gp independent fashion. BCRP is expressed in a 
variety of tissues which include placenta, intestine, kidney and BBB (Sharom, 2008). At 
the BBB, BCRP is located on the luminal side of the capillary endothelial cells. Several 
studies have shown overlapping substrate specificities of BCRP and P-gp (Schinkel and 
Jonker, 2003).  
 
Further, development of transgenic mouse model knocked out for both the genes 
(Mdr1a/b(-/-)Bcrp1(-/-)) significantly contributed to our understanding of the potential 
role of these two transporters in limiting the brain distribution of several drugs including 
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molecularly targeted agents such as tyrosine-kinase inhibitors (de Vries et al., 2007; Chen 
et al., 2009; Polli et al., 2009) and PI3K/Akt/mTOR inhibitors (Salphati et al., 2012). It 
has been shown that both P-gp and Bcrp show co-operation at the BBB and inhibition of 
both these transporters enhances brain delivery (Agarwal et al., 2011a). Moreover, recent 
studies have shown that lack of P-gp and BCRP results in greater than additive effect 
compared to absence of single transporter, P-gp or BCRP alone for several dual substrates 
such as lapatinib (Polli et al., 2009), dasatinib (Chen et al., 2009), gefitinib (Agarwal et al., 
2010) and imatinib (Breedveld et al., 2005). Until recently, compensation of the activity of 
one transporter by the other was considered as a plausible explanation for this effect. 
However, in a recent study by Agarwal et al., the authors showed via quantitative 
proteomics approach that genetic deletion of either P-gp or Bcrp does not influence the 
expression of other transport systems at the BBB and therefore, P-gp and Bcrp do not 
show compensation effect (Agarwal et al., 2012).  
 
The blood brain barrier is a major impediment in drug delivery into the brain parenchyma. 
The problem is further complicated by the fact that both P-gp and Bcrp work in tandem to 
limit brain distribution of drugs. Therefore, there is a need to develop and investigate 
strategies to effectively target tumors in the brain. 
 
 
1.5    CHARACTERIZATION OF BRAIN DISTRIBUTION IN A SERIAL 
SACRIFICE DESIGN USING POPULATION-BASED APPROACH 
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Preclinical pharmacokinetic investigations to estimate influence of drug efflux transporters 
are often determined in small animals such as mice and rats.  The size of these animals 
limits the number of samples that can be obtained from each animal. Therefore, for a time-
course study over 24 hours, cohorts of animals are sacrificed at each time point to obtain 
plasma and corresponding tissue concentrations. This kind of sample design is called as 
‘serial sacrifice design’ or destructive sampling design (Ette et al., 1995). Usually, data 
analysis in this case is determined using naïve-pooled average approach through non-
compartmental analysis (NCA) to estimate the exposures (area under the curve (AUC)) in 
the plasma and the corresponding tissue. The ratio of exposures is used to determine tissue 
distribution coefficient or Kp (brain distribution coefficient in this case). This approach of 
data analysis has disadvantages. First, we lose information on within animal correlations 
by averaging concentrations at each time point. Second, we cannot statistically compare 
between treatment/groups as we only obtain a point estimate of Kp, with no information on 
associated variance.  
 
To statistically compare transporter functions, we propose a population based modeling 
approach to estimate Kp of sunitinib in FVB-wild type, Mdr1a/b(-/-), Bcrp1(-/-), and 
Mdr1a/b(-/-)Bcrp1(-/-) mice. In addition, we investigated the influence of design elements 
(sample size at each time point and varying between-animal variability) on bias and 
precision of estimation of Kp using stochastic simulations and estimations.  
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STATEMENT OF PROBLEM 
 
Despite major advancements in discovery of novel targets and development of 
molecularly targeted drugs, treatment of GBM remains a challenge, particularly because 
of failure of drugs in improving efficacy and survival of patients in clinical trials. One of 
the explanations indicated for drug failure in clinical studies relates to the correct 
identification of the target or mutation in the gene. Development of resistance to 
previously responding drugs has also been attributed to various mechanisms such as 
upregulation of alternative signaling pathways, selection of more aggressive tumor cells, 
invasion and spread of glioma stem cells via different angiogenic mechanisms such as 
vessel cooption (Grepin and Pages, 2010). However, little attention is given to the issue of 
delivery of drugs across the BBB in treatment regimens. With prior knowledge and 
extensive research in preclinical xenograft glioma models we are aware of the mechanisms 
that can limit the delivery of several drugs into the brain and the tumor cell.  
 
The BBB not only poses a physical barrier by the presence of tight endothelial junctions 
but is also a functional barrier comprising of active efflux transporters, P-glycoprotein (P-
gp) and breast cancer resistance protein (BCRP). These two transporters work in concert 
to restrict drug delivery to the brain. Furthermore, presence of active efflux on the tumor 
cell also restricts delivery of drugs into the tumor cell (Agarwal et al., 2011b). These dual 
barriers, BBB and brain tumor cell barrier, in conjunction with biochemical and physical 
barriers, can significantly impair drug distribution to the tumor cell resulting in little to no 
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efficacy (Agarwal et al., 2013). Several molecularly targeted agents have been found to be 
substrates for P-gp and Bcrp. 
 
In addition, infiltration of highly invasive GBM cells into the surrounding brain tissue 
poses another challenge for effective treatment and drug delivery to the tumors.  
Harboring beneath an intact BBB, these tumor cells are not enhanced by contrast agents 
and are not removed by surgery.  These cells further escape the effects of chemotherapy 
leading to recurrence of the tumor.   
 
Therefore, effective treatment of glioblastoma multiforme requires identification of the 
correct target and an effective multi-targeted drug or combination of drugs that evade 
active efflux at the BBB. 
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RESEARCH OBJECTIVE 
 
Thus, the overall research objective of this thesis is to investigate the role of active efflux 
mechanisms, mediated by P-glycoprotein and breast cancer resistance protein, in the blood 
brain barrier in influencing the brain distribution of molecularly targeted agents. To 
achieve our research objective we used the following research approach: 
1. To pharmacokinetically assess the role of P-gp and Bcrp in limiting the brain 
distribution of sunitinib and examine influence of co-administration of 
pharmacological inhibitors in improving the brain delivery of sunitinib. 
2. To statistically evaluate variability associated with the brain partition coefficient 
(Kp) using non-linear mixed effect modeling approach and assess the influence of 
study design elements such sample size at each time point and between-subject 
variability on the estimation of Kp. 
3. To demonstrate that the blood brain barrier is heterogeneously disrupted in the 
tumor core and is intact in the areas away from the tumor core in glioma mouse 
models. 
4. To study the influence of P-gp and Bcrp on efficacy of dual PI3K/mTOR 
inhibitors with different brain permeability characteristics in three glioma bearing 
mouse models- GL261 syngeneic mouse model, patient-derived GBM10 xenograft 
model and cell-line derived U87 mouse model. 
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RESEARCH PLAN 
 
Chapter 2 reviews the different strategies to enhance brain drug delivery for the treatment 
of glioblastoma multiforme. This chapter reviews issues inherent to treatment of GBMs 
such as heterogeneity in the tumor and the microenvironment that influences drug 
delivery. Further, this chapter discusses strategies that can overcome tight junctions 
chemically or physically (such as transient BBB disruption by osmotic or ultrasound 
methods), evade or overcome active efflux mechanisms (by the use of pharmacological 
inhibitors or chemical modification of drugs), local delivery strategies (such as convection 
enhanced delivery, intracerebral, intracranial and intratumoral injections and intranasal 
delivery of drugs to the brain), use of drug carriers (such as nanoparticles and lipid based 
delivery methods) and drug modification by conjugating moieties like amino acids that 
can assist in drug delivery by using influx transport systems.   
 
Sunitinib malate (Sutent®) is an orally available anti-angiogenic drug approved for the 
treatment of imatinib resistant metastatic renal cell carcinoma (mRCC), gastro intestinal 
tumors (GIST) and pancreatic neuro-endocrine tumors (pNET). Since GBM is a highly 
angiogenesis driven tumor we investigated the role of efflux transporters, P-gp and BCRP, 
in limiting brain distribution of sunitinib in mice.  Chapters 3, 4 and 5 discuss 
pharmacokinetic and statistical analysis of brain distribution of sunitinib. 
Chapter 3 discusses the development and validation of a robust analytical method for 
determination of plasma and brain concentrations of sunitinib by liquid-chromatography 
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tandem mass spectrometry (LC-MS/MS). Sunitinib is a light sensitive drug that undergoes 
light-induced E-to-Z isomerism. All experiments and sample preparation was done in 
light-protected conditions and this is discussed in this chapter. 
 
Chapter 4 quantitatively assesses the role of transport mechanisms that restrict brain 
delivery of sunitinib and the use of combination strategies such as pharmacological 
inhibition of active efflux to improve its brain delivery. In addition, this chapter 
pharmacokinetically assesses the extent of brain distribution of sunitinib as calculated by 
AUC brain-to-plasma ratio, steady state brain-to-plasma concentration ratio and transient 
steady state brain-to-plasma ratio for a drug exhibiting non-saturable, linear distributional 
kinetics. 
 
Chapter 5 statistically examines the brain distribution coefficient in a serial sacrifice 
design using population based non-linear mixed effect modeling approach.  Further, this 
chapter evaluates the influence of design elements such as sample size at each time point 
and between-animal variability, on the estimation of Kp for sunitinib. 
 
The PI3K-pathway is considered central to the several surface receptor pathways such as 
vascular endothelia growth factor (VEGFR). Several dual PI3K/mTOR inhibitors are 
currently being investigated in clinical trials for GBM, including GNE-317 and GDC-
0980. Chapter 6 discusses the influence of BBB (tight junctions and active efflux) on the 
brain distribution of GNE-317 (brain penetrant) and GDC-0980 (brain impenetrant) in 
25  
GL261 tumor bearing mice and FVB non-tumor bearing mice. In addition, we studied 
brain permeability and heterogeneity in the tumor using Texas Red dextran, a permeability 
marker. We also evaluated the regional brain distribution of GNE-317 and GDC-0980 in 
tumor-bearing mouse models. 
 
To summarize, this dissertation shows that there are regions of partially intact BBB in the 
tumor core suggesting heterogeneity in the tumor that may impact drug distribution. The 
studies suggest that both P-gp and BCRP restrict delivery of molecularly targeted agents, 
sunitinib and GDC-0980, while sparing GNE-317. Further, we could statistically 
determine brain distribution using a novel population based approach to serial-sacrifice 
data. Simulations show that sample size and magnitude of between-animal variability does 
not influence the bias in estimate of Kp. However, an increase in sample size at each time 
point results in higher precision in estimating Kp. 
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 CHAPTER  II   
 
 
 
STRATEGIES FOR IMPROVING DELIVERY OF 
ANTI-CANCER DRUGS TO INVASIVE GLIOMA 
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2.1             INTRODUCTION 
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain 
tumor that remains essentially incurable despite decades of intensive research on 
conventional and novel therapeutic strategies. Due to the diffusely invasive nature of 
GBM, even aggressive surgical resection is insufficient to control tumors, and following 
maximal surgical resection, the addition of partial brain irradiation combined with 
temozolomide chemotherapy significantly extends time to recurrence and improves 
survival (Furnari et al., 2007). Unfortunately, despite this aggressive treatment regimen, 
the median survival for GBM patients remains approximately 12-15 months and only 2% 
of patients survive longer than 5 years (Stupp et al., 2005). GBM is highly vascular and 
invasive , and exhibit a complex pattern of molecular heterogeneity and variation 
(Agnihotri et al., 2013). With the increasing understanding of molecular mechanisms that 
mediate gliomagenesis and progression, integration of molecularly-targeted agents into 
the conventional chemo-radiation regimen may provide a significant therapeutic benefit 
for patients with GBM. However, several factors may limit the efficacy of promising 
therapeutic strategies: including intra-tumoral molecular heterogeneity, diffuse invasion 
of single cells well beyond the bulk tumor core that is delineated upon imaging or surgery, 
and the unique anatomic structure of the brain microvasculature that provides a protective 
blood-brain barrier (BBB) that prevents accumulation of xenobiotics within the central 
nervous system. These first 2 issues have been reviewed previously in this journal 
(Vartanian et al., 2014), and here we provide an overview of the influence of the BBB in 
28  
GBM on delivery, and hence, treatment efficacy and potential strategies to overcome this 
limitation.  
 
 
 2.2                 DRUG DELIVERY INTO THE CNS 
2.2.1              INFLUENCE OF THE BBB ON DRUG DELIVERY 
Despite progress in discovery and development of anticancer drugs for treatment of 
primary brain tumors, drug delivery into the CNS remains a major challenge, and the 
BBB is a predominant factor that limits the distribution of many drugs into the brain. The 
BBB is an anatomical and biochemical barrier that protects the brain from xenobiotics in 
the systemic circulation. Unlike the microvasculature for much of the rest of the body, 
brain capillary endothelial cells are interconnected by tight junctions, with limited 
fenestrations or pinocytic vesicles that form a physical barrier to prevent unimpeded 
diffusion into the brain. This physical barrier can significantly limit accumulation of 
small hydrophilic drugs, as well as large molecules that cannot diffuse readily across lipid 
bilayers such as antibodies and antibody-drug conjugates. For those molecules that are 
able to traverse the luminal endothelial cell membrane, many molecules are efficiently 
removed by the activity of efflux transporters that reside in the luminal capillary 
membrane. Many small molecule compounds employed in medicine are substrates for 
various efflux pumps located at the BBB. Therefore both physical and biochemical 
barriers within the BBB significantly limit the concentrations achievable within the brain, 
which consequently leads to limited efficacy (Figure 2.1). 
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Drug delivery of hydrophilic molecules by paracellular diffusion and penetration of 
macromolecules is severely restricted by the physical presence of ‘tight junctions’ called 
as zonulae occludentes. The junctional complex holding the endothelial cells together is 
comprised of a multiplex of proteins such as claudins (3, 5 and 12), occludins (1, 2 and 3) 
and junctional-adhesion molecules (JAM-A, -B and -C). In addition, CNS microvessels 
are surrounded by, and in communication with, a plethora of cells such as astrocytic glia 
cells, pericytes and neurons. These together not only provide structural support but also a 
vasodynamic environment, now known as the neurovascular unit (Hawkins and Davis, 
2005), that significantly increases resistance of the BBB towards drug transport (Mangas-
Sanjuan et al., 2010).  
 
In addition to the tight junctions, polarized expression of efflux transporters on the 
luminal and abluminal side of the BBB significantly limit delivery of numerous 
therapeutics that can otherwise diffuse across the BBB due to their favorable 
physicochemical characteristics. P-glycoprotein (P-gp) and breast cancer resistance 
protein (BCRP) are the two major efflux transporters on the BBB that have been 
extensively studied and reported to influence brain distribution of several cytotoxic and 
molecularly-targeted agents (Agarwal et al., 2011b). 
 
Although presence of active efflux restricts drug distribution, there are pathways that 
facilitate brain penetration of several small and large molecules. These pathways can be 
broadly classified into carrier-mediated influx transporters and receptor-mediated 
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endocytosis. Different transport pathways present at the BBB are shown in Figure 2.1. 
These nutrient based influx transporters, such as LAT1, OATPs, and GLUT1 translocate 
polar nutrients such as glucose, amino acids, vitamins and hormones (Tamai and Tsuji, 
2000). Receptor mediated endocytosis is involved in transporting large molecules such as 
insulin, transferrin and some vitamins, e.g., folic acid (Smith, 2003).  
 
In this review, we discuss current and novel strategies for circumventing or modulating 
the BBB with the goal of improving drug delivery to invasive glioma.  The overall goal 
of the review is to identify and discuss key factors that will help inform the discovery and 
choice of drug delivery strategies that can overcome these limitations.  The structure and 
function of the BBB provide a dynamic barrier, responsive to size, location and stage of 
gliomas that controls drug delivery into sites of invasive glioma. Some of these processes 
may exclude drug molecules while others may enhance drug penetration into the brain.  
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Figure 2.1: Schematic representation of the neurovascular unit (i.e., BBB) and the different 
pathways for drug transport 
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2.2.2             DRUG RELATED ISSUES 
Penetration of drugs across brain capillary endothelial cells not only relies on the physical 
structure of the BBB but is also highly dependent on the physicochemical properties of 
the drug candidate. The rate and extent of drug distribution into a tissue such as the CNS 
depends on the overall absorption, elimination, distribution and metabolism (ADME) 
processes that influence the drug concentrations in the plasma, the degree of specific 
protein-binding to the plasma proteins and non-specific binding to the lipophilic brain 
tissue, the intrinsic permeability of the molecule in lipid-membranes, and the presence of 
moieties that can be utilized to enhance drug penetration (Groothuis, 2000; Alavijeh et 
al., 2005). Systemic drug ADME depends upon several factors, including lipophilicity 
and solubility of the drug (Bergstrom, 2005). For many drugs, transcellular passage 
across the BBB occurs by simple passive diffusion across the endothelial cell 
membranes. In addition to increasing permeability, lipophilicity also increases the 
likelihood for metabolism and protein binding (Alavijeh et al., 2005). High binding of 
drugs to blood proteins affects distribution as only the unbound drug crosses the lipid 
bilayer and demonstrates pharmacological activity. High lipophilicity can further 
contribute to non-specific binding to brain tissue, which may influence active unbound 
concentrations.  
 
To summarize, there are major limitations in effective drug delivery to the brain tumors 
due to the restrictive nature of the BBB and the physiochemical properties of the drug 
33  
molecule. However, several strategies have been, and are being, investigated in 
preclinical and clinical studies to increase drug distribution to invasive glioma cells.  
 
2.2.3             BLOOD-BRAIN BARRIER WITHIN TUMORS 
Essentially all newly diagnosed GBM exhibit disruption of the BBB. Clinically, this is 
manifest as the accumulation of gadolinium-based contrast agent within regions of the 
tumor on magnetic resonance imaging. The various clinical formulations of gadolinium 
are hydrophilic and do not readily cross cellular membranes. As such, contrast does not 
accumulate in normal brain tissue where the tight-junctions between endothelial cells 
provide an intact physical BBB. As discussed below, cytokines secreted by GBM tumor 
cells can lead to disruption of the physical BBB, and in these regions, accumulation of 
contrast provides a visual demonstration that essentially all GBM patients have 
significant disruption of the BBB. In the past, this fact has been used by many to argue 
that the BBB is not a major factor that influences the efficacy of therapies in GBM (Vick 
et al., 1977). 
 
However, without a doubt, all GBM patients have regions of tumor with an intact BBB, 
as determined by MRI. Even when surgeons achieve a gross total resection of all 
contrast-enhancing regions of tumor, 100% of these patients will recur the GBM within 
several months of treatment (Hou et al., 2006). Several biopsy studies also have 
demonstrated that significant tumor burden exists in the T2/FLAIR regions outside of the 
contrast enhancing regions seen on MRI. Moreover, using an (18)F-DOPA radiotracer 
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that readily crosses the BBB, an anatomical comparison of (18)F-DOPA (3,4-dihydroxy-
6-[18F]fluoro-L-phenylalanine (18F-DOPA)) uptake versus contrast enhancement 
demonstrates significant regions of gross tumor in which there is no significant 
accumulation of contrast media (Figure 2.2) (Pafundi et al., 2013). In a comparison of 10 
patients with 23 biopsies, 13 of 16 high-grade biopsy specimens had regions of FDOPA 
positivity, and image-guided biopsies of these regions demonstrated significant tumor 
burden. Beyond grossly positive regions of tumor, the highly invasive nature of GBM is 
well known and in autopsy series, infiltrating single cells have been found throughout the 
brain (Onda et al., 1989). Again based on surgical biopsy studies demonstrating 
infiltration of single cells extending beyond the T2/FLAIR tumor volume, radiation target 
volumes for GBM typically extend 1-2 cm beyond any visible radiographic abnormality 
(Pafundi et al., 2013). Thus, based on well-established and accepted natural history, 
surgical and radiographic information on GBM, all GBM patients have regions of a 
disrupted BBB AND all GBM patients have significant regions of a relatively intact BBB 
sufficient to prevent the distribution of a small molecule to those invasive sites. These 
data all support our central contention that delivery of therapeutic agents across the BBB 
to all regions of a GBM is essential to make significant progress in GBM (Agarwal et al., 
2011b)).  
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Figure 2.2 (Pafundi et al., 2013): Representative image of (A) (18)F-DOPA PET-CT, 
(B) T1 CE-MRI, (C) T2-FLAIR MRI contours drawn by a neuroradiologist. 
 
 
 
 
During gliomagenesis, the BBB becomes more permeable due to release of chemical and 
chemotactic mediators such as adenosine triphosphate (ATP), nitric oxide (NO), 
macrophage inflammatory protein-2 (MIP-2), interleukin-β (ILβ) and tumor necrosis 
factor-α (TNF-α) which are produced by the astrocytes. (Ballabh et al., 2004). In 
particular, the angiogenic pathways are closely related to the invasiveness and 
proliferative potential of brain tumors mediated by release of vascular endothelial growth 
factor (VEGF), discovered as the vascular permeability factor (Lee et al., 2006; Jain et al., 
2007). Leibner et al. reported loss in expression of claudin-1 and significant down 
regulation of claudin-5 and occludin in brain microvessels in human GBM (Liebner et al., 
2000). Release of pro-angiogenic factors such as VEGF and scatter factor/hepatocyte 36  
growth factor (cMET) and inflammatory mediators such as cytokines have been linked to 
alterations in tight junction proteins (de Vries et al., 1996; Lamszus et al., 1999). 
Interacting with the brain tumor microenvironment, the inflammatory pathways and 
cascades are also involved which may promote protumorigenic activities, glioma growth 
and metastases with assistance from microglia and other supporting cell types via 
tumoral-stromal, pericytic-endothelial, and astrocytic-related communications (Charles et 
al., 2012). Although disruption of BBB in the tumor core (Lee et al., 2006) provides a 
window of opportunity for the use of novel therapeutics as the BBB becomes more 
“leaky” due to tumor infiltration, providing exposure to the underlying microenvironment 
which contains potentially viable molecular therapeutic targets involving the TGFβ(beta), 
VEGF, and hypoxia-driven pathways (Barcellos-Hoff et al., 2009), the real issue lies in 
effective drug delivery to invasive glioma cells that remain behind an intact BBB, 
escaping chemotherapy (Figure 2.3).  
 
As a result, determination of drug transport issues across an intact BBB becomes 
essential for maximizing the potential ability for novel neurotherapeutics to reach the 
microenvironment of the tumor, and to engage the target.   Brain delivery enhancing 
methods such as pro-drugs, brain drug-targeting and chimeric peptide technologies have 
been proposed as strategies for enhancing brain delivery by discovery (Scherrmann, 
2002) of BBB-penetrant drugs with desired anti-glioma activities clinically (Pardridge, 
2002; Mangas-Sanjuan et al., 2010; Salphati et al., 2012a).    
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Figure 2.3: Schematic representation of the issues for effective delivery of drugs to the 
tumor cells and the invasive glioma cells. The presence of intact blood brain barrier 
and expression of efflux transporters limit distribution of chemotherapeutics to the 
invasive glioma cells. 
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2.2.4  HETEROGENEITY OF BBB INTEGRITY AND DRUG 
CONCENTRATIONS 
Given the highly infiltrating nature of GBM cells, it is well established that the tumor 
cells are capable of extending into the surrounding tissue away from the tumor core 
(Berens and Giese, 1999; On et al., 2013). Although the BBB presents a physical and 
functional barrier to drug delivery, mounting evidence suggests that recurrence of GBM 
can be related to the residual group of cells that reside in regions adjoining the resected 
tumor core (Burger et al., 1983; On et al., 2013).  
 
This has significantly impacted the clinical outcome for patients; emphasizing the clinical 
risk presented by the migratory, infiltrative and invasive glioma cells. This characteristic 
of glioma invasion and migration questions the role of BBB in hindering drug delivery of 
chemotherapeutics to the invasive tumor cells. Ample preclinical evidence suggests 
breakdown of BBB in the core via increased accumulation of gadolinium-based contrast 
enhancement (Larsson, 1960), and high drug concentrations (e.g., PD991 (Michaud et al., 
2010)). However, drug concentrations measured in this area does not truly represent the 
drug concentrations in the tumor cells that are left behind and not removed by surgery 
(away from core). This intratumoral heterogeneity in BBB breakdown has also been 
observed in glioma patients as well, wherein the microvasculature in the core is highly 
tortuous, disorganized and permeable while areas adjacent to the core have nearly intact 
structural integrity (Brightman and Broadwell, 1976).  In a seminal study by de Groot and 
colleagues, the authors observed that tumor progression in GBM followed a unique 
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pattern of non-contrast enhancing tumor after treatment with an anti-VEGF agent (de 
Groot et al., 2010). These tumor cells are invisible to the surgeon and lie beneath an 
intact BBB and escape chemotherapy.   
 
This makes estimation of BBB permeability critical as different methods could influence 
our interpretation of an effective drug. The most commonly used in-vivo measurement is 
brain-to-blood (or plasma) equilibrium partition coefficient, commonly referred to as Kp 
brain (Mangas-Sanjuan et al., 2010). This parameter relates the extent of drug exposure in 
the brain to the extent of drug exposure in the blood or plasma, and is usually obtained by 
extensive preclinical studies. Nonetheless, attempts to increase BBB permeability and 
predicting efficacy solely based on Kp brain ratios is risky and often does not lead to 
desired brain concentrations at the target. Heterogeneity in BBB disruption and presence 
of invasive tumor cells some distance away from the tumor core can lead to different Kp 
brain ratios in different regions of the brain, depending upon the integrity of the BBB at 
the site of measurement. Therefore, it is critical to fully understand the pharmacokinetics 
and pharmacodynamics of the drug in a tumor-bearing brain, in order to achieve 
efficacious concentrations throughout. Agarwal et al. studied the regional brain 
distribution of erlotinib in U87 rat xenograft glioma model. The authors observed that 
erlotinib concentrations in the tumor core were significantly greater compared to the 
brain around the tumor core (brain-around-tumor (BAT) also called the tumor ‘rim’) and 
the contralateral hemisphere.  The corresponding Kp brain ratios in the core, rim and 
contralateral hemisphere suggest the presence of an intact BBB directly around the tumor 
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core and in areas away from the tumor, whereas the core had leaky vasculature, which 
then explained high drug concentrations measured within the core (Agarwal et al., 2013). 
 
 
2.3             STRATEGIES TO IMPROVE DRUG DELIVERY TO GBM 
GBM is a disease of the whole brain (Agarwal et al., 2011b) and its treatment remains 
one of the major challenges in clinical oncology. Since GBM is one of the most 
aggressive and infiltrative brain tumors, there are regions where the glioma cells reside 
behind an intact BBB, which results in poor penetration of drugs into this region of brain 
parenchyma. Therefore, in the context of invasive gliomas, there is an urgent need to 
develop effective strategies to enhance delivery of chemotherapeutics across the BBB. 
Penetration of drugs through BBB, like other membranes in the body, occurs by three 
major mechanisms: passive diffusion, endocytosis and carrier-mediated active transport. 
These mechanisms have been explored in various ways to enhance penetration of drugs 
into the brain. In the sections below, we have reviewed various methods that have been 
explored to increase delivery of chemotherapeutics into the brain. 
 
2.3.1            DISRUPTION OF TIGHT JUNCTIONS IN THE BBB 
Although the BBB integrity may be compromised in the regions of the core tumor mass, 
the infiltrating tumor cells beyond the tumor core are protected by an intact BBB. The 
BBB is one of the major physiological impediments for drug delivery to the brain. It acts 
as an endothelial physical barrier composed of tight junction proteins between the 
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endothelial cells that limit passage of chemotherapeutics from the systemic circulation 
into the brain parenchyma. However, if the tight junctions are pharmacologically or 
pathologically disrupted, one could increase penetration of drugs across the BBB 
throughout the region of infiltrating tumor cells. This could also enhance delivery of large 
molecules such as antibodies and proteins, across the BBB.  
 
2.3.1.1      BBB DISRUPTION VIA OSMOTIC MECHANISMS OR ULTRASOUND 
Osmotic BBB disruption is a mechanism-based technique that has been investigated for 
transiently disrupting the BBB to increase permeability to drug molecules. This method 
relies on administration of hypertonic solutions that lead to shrinkage of the endothelial 
cells, and disruption of the tight junction complexes creating gaps that allow for 
paracellular diffusion of molecules (Rapoport, 1970).  In 1972, Rapoport and colleagues 
reported that osmotic opening of the BBB by hypertonic arabinose led to staining of the 
brain tissue by Evans blue in mouse models (Rapoport et al., 1972) Similar hyperosmolar 
solutions that have been used preclinically include mannitol, contrast agents and 
lactamide (Kroll and Neuwelt, 1998; Kemper et al., 2004). Neuwelt and his group 
pioneered the clinical application of this concept of using hypertonic solutions to 
osmotically open the BBB to enhance drug delivery of chemotherapeutics (Kroll and 
Neuwelt, 1998). The group reported promising results with carboplatin (intra-arterially) 
and etoposide (intravenously) administered in conjunction with mannitol (infusion into 
the internal carotid artery) to osmotically disrupt the tight junctions in the treatment of 
malignant astrocytomas, neuroectodermal tumors and CNS lymphoma (Williams et al., 
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1995). In another study consisting of 41 malignant glioma patients (21 GBM patients and 
20 anaplastic astrocytoma patients), the authors compared the effect of blood-brain 
barrier disruption (BBBD) with mannitol in patients treated with intra-arterial 
chemotherapy alone vs. chemotherapy administered in conjunction with BBBD. The 
authors reported enhanced median survival with BBBD therapy (~90 weeks) compared to 
chemotherapy alone group (~40 weeks) (Kraemer et al., 2002). Since BBBD is 
performed using arterial infusion, this process leads to rapid equilibration of the drug 
even into the contralateral hemisphere, thus providing a uniform drug delivery throughout 
the brain.  
 
The ultrasound-based BBB disruption method is a focal, selective and non-invasive 
targeted approach to enhance delivery of drugs into the brain through thermal or 
mechanical mechanisms. Focused ultrasound (FUS) relies on transcranial delivery of 
low-frequency ultrasound waves that result in opening of the tight junctions between the 
endothelial cells (Hynynen et al., 2006). Typically, the ultrasonic exposures last for 20-30 
seconds and are given at a frequency of 1 Hz (Hynynen, 2008). This technique was first 
successfully applied to enhance delivery of BBB impermeable liposome-encapsulated 
doxorubicin in rats with glioma (Etame et al., 2012). Recently, the microbubble (MB) 
enhanced focused ultrasound (FUS) approach has shown to temporarily and reversibly 
disrupt the tight junctions in the brain endothelial cells to increase permeability of drugs 
across the BBB. The microbubbles act as drug carrier vehicles that can enhance 
penetration of BBB impermeable drugs and also protect them from degradation.. In 
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combination with ultrasound, MB can collapse the tight junctions and vessel stability at 
high acoustic pressures (Sheikov et al., 2004; Aryal et al., 2014). Using this approach, 
Ting and colleagues reported enhanced brain penetration of carmustine (BCNU) into the 
brain by using multifunctional microbubbles whose transport into the local brain 
environment was increased due to the presence of focused ultrasound (Ting et al., 2012). 
In a similar study, Liu et al. reported increased brain delivery of BCNU into both tumor 
and surrounding normal brain using a 400-kHz focused external ultrasound generator 
(Liu et al., 2010).  
 
 
2.3.1.2       PHARMACOLOGICAL APPROACHES TO MODULATE TIGHT   
JUNCTION PERMEABILITY  
The BBB is a protective physical and biochemical barrier that not only maintains neural 
homeostasis but also limits passage of molecules across the endothelium into the brain 
parenchyma by interfering with paracellular diffusion of solutes through a network of 
tight junctional complexes and supportive glia cells. Recently, Alvarez et al. reported that 
glia cells, such as astrocytes, secrete Sonic hedgehog (Shh, a glycoprotein), which binds 
to and inactivates the Patched-1 receptor. This hypothesized mechanism would allow 
activation of the Smoothened (SMO) pathway and subsequent induction of Gli 
transcription factors thus providing stability to BBB integrity by affecting expression of 
gene targets that control tight junction formation (Alvarez et al., 2011).  It is further 
posited that SMO inhibitors act by destabilizing vessel integrity thus opening tight 
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junctions between the endothelial cells. This postulate would suggest that co-
administration of a SMO inhibitor could increase brain delivery of concomitantly 
administered drugs. Currently, 3 SMO inhibitors are in clinical trials for use in 
medullablastoma, a pediatric brain tumor that in some cases is uniquely driven by 
hyperactivation of SMO (Romer et al., 2004). Although SMO inhibitors have shown 
promising results in preclinical models of medullablastoma, their application as adjuvant 
therapy for chemotherapeutics to improve drug delivery to the brain requires further 
investigation.   
 
Bradykinin-like compounds (histamine, leukotrienes and bradykinin) act by disrupting 
the tight junctions by stimulating B2 receptors preferentially expressed on tumor cells and 
in the process induce second messenger systems that transiently increases cytosolic Ca2+, 
resulting in opening of the tight junctions (Kemper et al., 2004). There are reports that 
have indicated the role of nitric oxide in selectively increasing the brain tumor 
permeability after administration of bradykinin (Nakano et al., 1996). A low dose of 
bradykinin selectively increased blood tumor barrier permeability in intracerebral tumor 
when administered as an infusion through the ipsilateral internal carotid artery (Inamura 
and Black, 1994). These finding led to the development of Cereport (RMP-7), a 100-fold 
more potent bradykinin analog and a selective agonist for B2 receptors.  RMP-7 is 
resistant to degradation by bradykinin-metabolizing enzymes (Doctrow et al., 1994)and 
has enhanced delivery of a hydrophilic compound, carboplatin, to tumor cells in a RG2 
rat-glioma model by 30-80% (Elliott et al., 1996; Borlongan and Emerich, 2003). 
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However, the combination showed disappointing results when tested in a randomized, 
double-blind, placebo controlled, phase 2 trial in recurrent malignant glioma patients 
(Prados et al., 2003). The end point, determined as the median time to tumor progression, 
was not significantly different between the group treated with RMP-7 and chemotherapy 
alone group. Kroll and colleagues conducted a direct comparison of BBBD by osmotic 
methods to bradykinin treatment in nude rats with 6-day intracerebral human small cell 
lung carcinoma tumors. The group reported that use of hypertonic mannitol resulted in 
global delivery of variety of agents whereas bradykinin treatment was not effective in 
increasing delivery of drugs in this human brain tumor xenograft model. These data 
indicate that the goal of using an adjuvant therapy to open tight junctions remains elusive.   
 
2.3.2             OVERCOMING ACTIVE EFFLUX at the BBB 
While the BBB is primarily formed of capillary endothelial cells that are interconnected 
by tight intercellular junctions, , the BBB is also an efficient functional barrier to several 
solutes by the presence of active efflux transporters such as P-gp and Bcrp (Agarwal et al., 
2011a).  In order to effectively deliver drugs across the BBB and evade active efflux, 
several approaches have been investigated. These include modification of the drug 
structure to diminish affinity to efflux transporters or co-administration of transport 
inhibitors to enhance delivery of anti-cancer drugs.  Table 2.1 lists molecularly-targeted 
agents that have demonstrated substrate liability for P-gp and Bcrp.   Given the number of 
targeted agents, exemplified by table 2.1, approved or in development that are substrates 
for active efflux at the BBB, the treatment options to effectively administer these 
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compounds for GBM will require methods to engineer the transporter liability out of the 
molecule, or use other means to overcome active efflux. 
 
Table 2.1: List of molecularly targeted agents that have been examined for treatment of 
glioblastoma and their P-gp/Bcrp substrate status 
a- Steady state conc ratios 
b- AUC ratios 
c- With dual inhibitor (GF120918) 
d- Pbrain 
e- B/P ratios not available  
f- Using in-situ brain perfusion to determine fold increase 
g- Determined at a single time point post oral dose 
h- Determined at 2 time points; here we reported 1 hr after oral dose 
i- Determined at 2 time points; here we reported 1 hr after oral dose; B/P ratio in 
absence of P-gp and Bcrp was not reported 
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 Drug Target Wild-type Substrate Status References 
P-gp P-gp 
B/P ratio 
BCRP BCRP 
B/P ratio 
Combined 
P-gp/BCRP 
B/P ratio 
Erlotinibb EGFR 0.14 ✓ 0.41 ✓ 0.14 0.58 (de Vries et al., 
2012) 
Tandutinibb PDGFR, 
FLT3 
 ✓ ~3.2 fold ✓ ~0.9 fold ~13.5 fold (Yang et al., 2010) 
Gefitiniba EGFR 0.07 ±0.02 ✓  ✓  7.3 ±0.5 (Agarwal et al., 
2010) 
Cediraniba VEGFR 0.25 ± 0.10 ✓ 5.2± 1.1 ✓ 0.27± 
0.01 
6.3 ± 1.2 (Wang et al., 2012) 
Sorafeniba1, d2 RAF-
kinase, 
VEGFR, 
PDGFR 
a10.094 
±0.007, 
d25.3 ± 2.7 
✓ a10.11 
±0.02, 
d25.8 ± 2.2 
✓ a10.36 
±0.06, 
d222.6 ± 
5.0 
a10.91 ±0.29, 
d249.4 ± 5.2 
a1(Agarwal et al., 
2011c) 
d2(Lagas et al., 2010) 
vandetanibc VEGFR, 
EGFR 
0.21 ✓  ✓  0.64 (Minocha et al., 
2012a) 
Pazopanibc VEGFR, 
PDGFR, 
c-KIT 
0.015 ✓  ✓  0.041 (Minocha et al., 
2012b) 
dasatinibd1, b2  16.39 ± 
1.39 
b20.12 
✓ 122.7 ± 5.41 ✓ 15.11±0.7 
 
184.3±13.3, 
b20.93 
1(Lagas et al., 2009) 
2(Agarwal et al., 
2012) 
sunitinibd1, a2 VEGFR, 
PDGFR, 
c-KIT 
1.6 ± 1.0 
a2 0.51 ± 
0.26 
✓ 2.8 ±0.8, 
a2 2.33 ± 
0.56 
✓ 2.4 ± 0.9, 
a2 0.73 ± 
0.44 
42.4±10.7, 
a2 17.44 ± 5.08 
d1(Tang et al., 2012) 
a2(Oberoi et al., 
2013) 
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Table 2.1 Continued… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Target Wild-type Substrate Status References 
P-gp P-gp 
B/P ratio 
BCRP BCRP 
B/P ratio 
Combined 
P-gp/BCRP 
B/P ratio 
imatinibe1, g2, f3 BCR-
ABL, 
PDGFR, 
c-KIT 
 ✓ ~2.73 folde1, 
~3.6 foldg2, 
~5.5 foldf3 
 ~2.5 folde2  e1(Dai et al., 
2003) 
g2(Breedveld et 
al., 2005) 
f3(Bihorel et al., 
2007) 
Lapatiniba EGFR 0.03±0.01 ✓ 0.09 ± 0.02 ✓ 0.04±0.01 1.2  ±0.42 (Polli et al., 
2009) 
Everolimusb mTOR  ✓ ~1.3 fold    (Chu et al., 
2009) 
GNE-317i Dual 
PI3K/ 
mTOR 
1.01 ± 0.05 x x x   (Salphati et al., 
2012a) 
GDC-0980h Dual 
PI3K/ 
mTOR 
0.082 ± 
0.008 
✓  ✓  1.0 ± 0.20 (Salphati et al., 
2012b) 
GDC-0941G PI3K  ✓ ~2.24 fold x ~1.05 fold ~29.42 fold (Salphati et al., 
2010) 
PALOMID 
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Dual 
PI3K/ 
mTOR 
x x  x   (Lin et al., 2013) 
Axitinibd VEGFR-
1,2-3 
94.8 ± 27 ✓ 643.6 ±183.2 ✓ 47.7 ± 
12.7 
1315 ± 375 (Poller et al., 
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2.3.2.1        STRUCTURAL REFINEMENT TO ALLOW PASSIVE DIFFUSION 
OF DRUGS 
An emerging understanding of the molecular aberrations in GBM, the propensity of the 
disease to invade well beyond the tumor core and the delivery challenges presented by 
active efflux and tight junctions at the BBB, have stimulated several researchers and 
pharmaceutical companies to attempt to discover drug candidates that have favorable 
BBB penetrating properties. For instance, Genentech has synthesized molecularly-
targeted dual PI3K/mTOR inhibitors, GNE-317 and GDC-0084, which have been 
structurally modified using appropriate structural-activity relationships (SAR) such that 
they show less affinity to active efflux by P-gp and BCRP at the BBB (Heffron et al., 
2012).  Similarly, BKM120, a Novartis pan-PI3K inhibitor with good BBB penetrating 
activity has shown promising results in several GBM cell lines in vivo. (Wen et al., 2012). 
The use of computational models to alter the physicochemical properties of the drug has 
allowed development of compounds that pass BBB by passive diffusion. 
 
2.3.2.2              USE OF PHARMACOLOGICAL INHIBITION 
Two important and widely investigated active efflux transporters at the BBB are P-
glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Several molecularly-
targeted agents and anti-cancer drugs have demonstrated substrate affinity to both P-gp 
and Bcrp at the BBB (Table 2.1). The expression of efflux transporters has also been 
reported in glioma cells (Demeule et al., 2001; Fattori et al., 2007). This is critical to 
understand as the presence of active efflux transporters not only presents a functional 
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barrier on the BBB but also on the brain-tumor cell. Earlier Agarwal et al. have reviewed 
the role of the BBB and brain-tumor cell barrier in restricting brain penetration of 
molecularly targeted agents (Agarwal et al., 2011b). These two sequential barriers restrict 
delivery of chemotherapeutics into the intracellular space of the glioma cell.  
 
One approach to modulate active efflux is by administration of pharmacological 
inhibitors of P-gp and Bcrp.   Elacridar is a commonly used dual P-gp and Bcrp inhibitor 
investigated both preclinically and clinically. Several researchers have reported higher 
brain concentrations of molecularly-targeted agents, e.g., including gefitinib (Agarwal et 
al., 2010), vandetanib (Minocha et al., 2012a) and sunitinib (Tang et al., 2012; Oberoi et 
al., 2013) on co-administration of elacridar in non-tumor bearing wild-type mice (see 
Table 2.1). In addition, Agarwal et al. reported higher brain concentrations on 
administration of erlotinib with elacridar in a U87 orthotopic rat xenograft model of 
glioma (Agarwal et al., 2013).  
 
Earlier reports of clinical experience with efflux transport inhibitors have shown 
interesting results. In 2005, Sasongko et al. observed enhanced brain penetration of 11C-
verapamil on co-administration of a P-gp inhibitor, cyclosporine A in healthy volunteers 
(Sasongko et al., 2005; Hsiao et al., 2006). Wagner and colleagues reported similar 
results using another inhibitor of P-gp, tariquidar, in healthy volunteers (Wagner et al., 
2009). Although administration of specific or dual efflux modulators is a strategy worth 
exploring to enhance the brain accumulation of drugs, this approach has one major 
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limitation. It is important to consider that concurrent administration of P-gp and Bcrp 
inhibitors could lead to changes in systemic pharmacokinetics of the drug which could  
result in increased systemic toxicity.  
 
 
2.3.3                LOCAL DELIVERY STRATEGIES 
2.3.3.1             CONVECTION-ENHANCED DELIVERY (CED) 
CED is an invasive local delivery method where the distribution of large and small 
molecular weight compounds into the brain tissue is driven by positive hydrostatic 
pressure from a prolonged slow infusion in the brain parenchyma (Groothuis et al., 
1999). First developed in 1994 (Bobo et al., 1994), CED directly delivers the drug into 
the intracerebral tumor tissue, which results in drug distribution into the peritumoral 
tissue by bulk flow, thereby achieving a relatively constant drug concentration over a 
somewhat predictable distance from the site of infusion; and sparing regions of the brain 
far from the infusion source (Dickinson et al., 2008; Ding et al., 2010; Serwer and James, 
2012).  
 
This method has been extensively evaluated for delivery of therapeutic proteins, 
oligonucleotides, liposomes and viral-mediated therapies. Notably, delivery of high 
molecular weight therapeutic proteins such as Pseudomonas aeruginosa exotoxin (PE) 
such as IL4-PE (PRX321) and IL13-PE38QQR (cintredekin besudotox) have been 
extensively evaluated in phase I and II trials, with acceptable safety profiles, but did not 
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reach efficacy standards to obtain FDA approval (Serwer and James, 2012). Cintredekin 
besudotox was evaluated in a phase III trial (the PRECISE trial, 2011) but failed to show 
superiority compared to use of Gliadel wafers. Trabedersen (AP-12009), an antisense-
oligonucleotide that targets TGFβ-2, showed significant benefit for the 14-month tumor 
control rate in an anaplastic astrocytoma subgroup compared to chemotherapy alone 
(temozolomide or procarbazine/lomustine/vincristine) in phase II studies but no 
significant difference in median survival was observed compared to chemotherapy group 
(Bogdahn et al., 2011). Combination strategies of PE fusion proteins (MR1-1) with anti- 
EGFR fragment antibodies showed promising results in preclinical studies, but 
comparisons with existing therapies need to be established (Ding et al.).  
 
The technique is highly dependent on catheter placement, which can influence 
geographic distribution of the drug and can also influence induction of adverse effects 
such as chemical meningitis (Serwer and James, 2012). Moreover, lack of proper drug 
distribution and efficacy can result due to leakage of infusate into subarachnoid (pressure 
drives infusate up the needle track) and intravascular space (Sampson et al., 2007). Other 
factors that can influence drug distribution by CED include parameters such as pH, 
osmolarity and ionic composition, and the solubility of the drug.  These factors can limit 
the use of convection-enhanced strategy (Groothuis, 2000). Furthermore, there is 
heterogeneity in spatial distribution of the drug in the brain. Bobo et al. studied the 
distribution of small molecule [14C]-sucrose and large molecule [111In]-transferrin in cat 
brain using CED (Bobo et al., 1994). The authors observed that even though sucrose 
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diffused farther than transferrin, both molecules showed differences in distribution 
wherein higher drug concentrations were observed closer to the site of catheter tip. This 
is critical for the treatment of an invasive tumor such as GBM. Such a targeted regional 
delivery could spare the infiltrated growing edge of the tumor and the invasive glioma 
cells at distant sites, such as the contralateral hemisphere. Nonetheless, for large 
molecules that are unable to cross BBB, CED may provide a therapeutically useful 
delivery tool. 
 
2.3.3.2              OTHER LOCAL DELIVERY STRATEGIES 
Other invasive local delivery methods include bolus injection of chemotherapeutics by 
intracranial (IC) delivery, intracerebro-ventricular (ICV) delivery and intrathecal 
delivery. Drug administration by these methods bypasses the BBB by locally introducing 
the drug into the brain parenchyma, ventricles or lumbar puncture into the subarachnoid 
space of the spinal cord. Other methods make use of biodegradable, cytotoxic drug 
impregnated wafers (such as Gliadel® wafers (carmustine)) which are placed locally after 
surgical resection in the tumor cavity (Duntze et al., 2013) and intrathecally placed 
implantable pumps such as SynchroMed® (Medtronic) and Codman® 3000 (Codman) 
(Bhatia et al., 2013). Although the major advantage of these methods is that they are not 
limited by the size of drug molecule (small and large molecules), the main 
pharmacological limitation lies in that the drug concentration decreases exponentially as 
the diffusion distance increases due to the sink effect of the brain vasculature. Moreover, 
the constant flow and drainage of the brain interstitial fluid can have implications on local 
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drug concentration, which is cleared from the brain parenchyma through this route. This 
process can limits CNS accumulation of many drugs (Abbott, 2004).  
 
Intranasal delivery is another approach that is being extensively investigated as it 
provides a noninvasive alternative approach to bypass BBB. The olfactory receptor cells 
are present at the boundary of both the nasal cavity and the CNS (Uraih and Maronpot, 
1990) and this neuronal pathway constitutes a direct connection to the brain parenchyma 
through paracellular route (Mathison et al., 1998). The major advantage of this route is 
that it not only circumvents the BBB, but drugs administered through this route also 
bypass the hepatic first-pass effect and degradation by enzymes such as peptidases in the 
blood (Dufes et al., 2003; Zhu et al., 2012). This method has been employed to study 
brain delivery of several peptides and proteins, which are prone to degradation (e.g., 
insulin, vasoactive intestinal peptide, insulin-like growth factor-1). Factors such as pH 
and osmolality of the drug are important determinants for effective brain delivery of 
peptides and proteins. Despite low brain uptake reported due to changes in pH, the nasal 
route of brain drug delivery provides an interesting alternative to deliver peptides to the 
CNS.   
 
2.3.4              NANOPARTICLE DRUG CARRIERS 
Recent advances in nanotechnology allow delivery of drugs as nanoparticles which are 
otherwise poorly distributed to the tissues such as the brain. Conventionally, nanocarriers 
and nanovectors are polymer-based systems that can carry multiple drugs. These carrier 
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systems enhance delivery of drugs by entrapping or encapsulating the drug in the core, or 
chemically conjugating or grafting a targeting peptide/ligand on its surface, thus 
increasing drug solubility and stability. These systems include dendrimers, polymeric 
micelles, nanoparticles and solid-lipid nanoparticles (SLNs). These carrier systems cross 
the BBB by utilizing transcellular pathways such as receptor-mediated endocytosis at the 
BBB (Herve et al., 2008).  
 
A major advantage of SLNs is that their high lipid solubility physically stabilizes the 
nanoparticle, thereby increasing drug loading capacity and resulting in a controlled rate 
of drug release (Blasi et al., 2007).  Two cytotoxic drugs, doxorubicin and camptothecin, 
encapsulated in pegylated SLNs exhibited efficient transport across the brain capillary 
endothelial cells when formulated as pegylated SLNs (Yang et al., 1999; Zara et al., 
1999).  
 
Although nanoparticles and lipid-based formulations have shown to increase systemic 
circulation times and increased tumor retention by enhanced permeation and retention 
(EPR) effect, their major limiting factor is the rapid clearance from the blood circulation 
by the reticuloendothelial system (RES). They are mostly limited to regions adjacent to 
the blood vessels, such that the areas far from the tumor core which constitute the 
aggressive, infiltrated tumor cells are spared from drug therapy. Moreover, presence of 
multi-drug resistant proteins on the tumor cells reduces the therapeutic benefit from drugs 
released from these carrier systems in the vicinity of the tumor (Chavanpatil et al., 2006). 
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NPs carrying both an efflux transporter inhibitor and an anticancer drug (Song et al., 
2010) have been tried in the past and were found to efficiently overcome resistance 
mediated by active efflux transporters. However, combination strategy has not been very 
successful due to adverse effects resulting from altered distribution of the drug 
systemically (Li and Huang, 2008). Furthermore, presence of an intact BBB on the 
invasive glioma cells and high interstitial fluid pressure, may limit passive targeting of 
nanoparticles (Boucher et al., 1997; Rich and Bigner, 2004).  
 
 
2.3.5               PEPTIDE-BASED DRUG DELIVERY 
Peptide-like macromolecules are transported into the cells via adsorption- or receptor-
based transcytosis processes (Scherrmann, 2002).  In this method, the drug is chemically 
conjugated by a linker to a targeting moiety, which is then taken up by a specific receptor 
and undergoes endocytosis. These vector-based methods can improve delivery for drugs 
that are otherwise relatively low or not penetrant into the brain. Small peptides such as 
AngioPep-2, have been shown to enhance delivery of small molecules into the BBB 
parenchyma via low-density lipoprotein receptor-related protein (LRP1) (Vlieghe and 
Khrestchatisky, 2013). ANG1005/GER1005, designed using AngioChem’s novel 
platform technology, consists of three molecules of paclitaxel and one molecule of 
AngioPep-2 vector (a 19-amino acid vector) was shown to increase brain penetration of 
paclitaxel in rat brain via in-situ brain perfusion (Takasato et al., 1984). Currently 
ANG1005 has shown promising results in two Phase I trials for recurrent glioma and 
metastatic brain tumors (Gabathuler, 2010). Wu and colleagues have engineered a 58  
peptide by phage display, with a sequence of VTWTPQAWFQWV (VTW). They 
showed that this peptide had higher binding affinity to human glioma cell lines in-vitro 
and weaker binding affinity to human astrocytes and other cell lines (Wu et al., 2008). 
Using this peptide sequence, Wang and colleagues developed a PEI/DNA nanoparticles 
conjugated with VTW and demonstrated selective targeting to tumor cells using U87 
human glioblastoma cell line (Wang et al., 2013).  
 
 
2.3.6              PRODRUG/INFLUX TRANSPORT MODIFICATIONS 
The BBB not only is formed by tight junctions and active efflux transporters, but it also 
expresses a number of influx carrier systems such as amino acid carriers and nutrient 
transporters that actively play a role in translocating nutrients from the blood to the brain. 
 
A prodrug approach is an important strategy that has been explored to increase brain 
penetration of drugs across the BBB. A prodrug is essentially a bioreversible derivative 
of a drug molecule, which undergoes enzymatic or biochemical transformation in the 
systemic circulation to release the drug (Ettmayer et al., 2004; Rautio et al., 2008; 
Vlieghe and Khrestchatisky, 2013). Derivatization of the drug molecule could include 
addition of a lipophilic group to a more polar functional group of the drug or addition of a 
carrier to the drug. Modification of drug properties by attaching moieties such as amino 
acids, fatty acids, glycerides or phospholipids, not only alters pharmaceutical properties 
but also pharmacokinetics and biodistribution of the drug (Patel et al., 2009). Depending 
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upon structural modifications, translocation of prodrug occurs by processes such as 
receptor mediated endocytosis, large neutral amino acid transporter (LNAT) and glucose 
transporter (GLUT) thereby achieving higher drug concentrations in the brain (Stenehjem 
et al., 2009). Large amino acid transport system, member 1 (LAT1) is the major LNAT 
transporter and transports drugs that include α-methyldopa, melphalan and gabapentin 
(Cornford et al., 1992; Gynther et al., 2008). Other similar transport systems at the BBB 
include cationic amino acid transporter for basic amino acids and monocarboxylate 
transporter, which transports drugs such as probenecid (Patel et al., 2009). Presence of 
organic anion transporting polypeptides (OATPs) has been reported in several tissues 
including the BBB, although the exact localization on the brain endothelial cells is still 
not confirmed.  
The prodrug strategy is a potential option to increase penetration of drug molecules 
across the BBB by altering the drug design and delivery process.  
  
 
2.4               CONCLUSIONS AND FUTURE PERSPECTIVES  
The BBB influences delivery of several drugs to the brain. This review describes 
anatomical and functional factors that restrict brain penetration of chemotherapeutics for 
the treatment of gliomas. In addition, we have also described the influence of glioma 
microenvironment and heterogeneity in BBB disruption on brain distribution of anti-
cancer drugs. Understanding these factors related to the location of the tumor and the 
tumor characteristics will help guide the development of techniques and approaches for 
effective drug delivery to the tumors.  60  
 This review discusses the current strategies for enhancing brain penetration of drugs for 
the treatment of GBM. One of the major challenges to effective treatment of gliomas is 
obtaining sufficient concentrations of these agents in brain beyond the tumor core. 
During the past decade, several strategies have been employed to improve brain drug 
delivery, which include techniques to chemically or physically disrupt the tight junctions, 
use pharmacological inhibitors to overcome multi-drug efflux at the brain capillary 
endothelial cell and to use drug conjugates, nanoparticles, lipid-based formulations or 
peptide based delivery methods to enhance transit of drugs across the BBB. In addition, 
efforts are in progress to develop molecules with optimized brain penetration (such as 
GNE-317) and no liability to P-gp and Bcrp at the BBB. Most of these strategies have 
shown promising results in the preclinical setting, however, the results in the clinical 
trials are disappointing. This may be, in part, due to the invasive nature of glioma where 
the tumor cells infiltrate into the normal brain. Hence, delivery of therapeutic agents to all 
regions of the brain is the key to achieve success in the clinical trials. This will be key in 
refining therapies for GBM, where the reason for failure can be either the lack of 
adequate delivery of an effective drug, or insufficient activity of the drug at the target, or 
a lack of both delivery and efficacy. 
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SUNITINIB LC-MS/MS ASSAY IN MOUSE PLASMA 
AND BRAIN TISSUE: APPLICATION IN CNS 
DISTRIBUTION STUDIES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published as a manuscript in Chromatographia. 2013 Dec 
1;76(23-24).  
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Sunitinib malate is a multi-targeted tyrosine kinase inhibitor, currently in clinical trials 
for glioma. Previously developed methods for preclinical studies in species such as mice 
have either employed HPLC or did not describe a detailed analytical method, which 
could be employed by other preclinical laboratories. In this paper, we have developed and 
validated a simple, sensitive high-performance liquid chromatography tandem mass-
spectrometric method (LC-MS/MS) for the determination of sunitinib concentration in 
mouse plasma and brain tissue homogenate using dasatinib free base as the internal 
standard. A single step liquid-liquid extraction method was used for both the matrices. 
Since sunitinib exhibits light-induced E/Z isomerism, all sample preparation was done in 
light-protected conditions. Separation was performed on a ZORBAX Eclipse XDB C18 
column 4.6 x 50 mm, 1.8 µm. The mobile phase consisted of 20mM ammonium formate 
(with 0.1% formic acid): acetonitrile (70:30, v/v) pumped isocratically at a flow rate of 
0.25 mL/min with a total run time of 13 minutes. The retention times of sunitinib and 
dasatinib were 7.8 and 5.5 minutes, respectively. The calibration curve was linear over 
the range from 1.95 ng/mL to 500 ng/mL in both plasma and brain tissue homogenate 
with 1.95 ng/mL as the LLOQ for both the matrices. Inter- and intra-day accuracy and 
precision was <15% for low QC, med QC and high QC and <20% for LLOQ. The 
method was applied to a pharmacokinetic study in FVB-wild-type mice to determine the 
plasma and brain concentrations after a single oral sunitinib malate dose of 20 mg/kg.  
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3.1     INTRODUCTION: 
Glioma is a solid neoplasm that originates in the glial cells of the brain. However, drug 
therapy for diseases of the brain is limited by the presence of the blood brain barrier 
(BBB) (Mellinghoff et al., 2011). The first step in defining the distribution of a drug to 
any target organ is via pharmacokinetic studies done in preclinical species. Though the 
FDA requires preclinical studies to be done in a variety of rodent and non-rodent species, 
the mouse remains one of the most studied species. 
 
Sunitinib malate (N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-
ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, SU011248) is an orally active 
multi-targeted tyrosine-kinase inhibitor (TKI) with potent anti-angiogenic and antitumor 
activity. In addition, it also inhibits other tumor growth pathway receptors such as 
PDGFR-α and -β, stem cell factor receptor (c-KIT), basic fibroblast-growth factor 
receptor (bFGF), FMS-related tyrosine kinase 3 (FLT-3), a proto-oncogene RET and 
colony stimulating factor receptor (CSF 1-R) (Faivre et al., 2007). Its potent antitumor 
activity has been reported both in-vitro and in-vivo in several tumor cell lines and 
preclinical xenograft models, including brain tumor models (Faivre et al., 2007; Zhou and 
Gallo, 2009). The FDA approved sunitinib malate for the treatment of metastatic renal 
cell carcinoma and gastrointestinal stromal tumors in May 2006 (Goodman et al., 2007). 
Currently, there are many ongoing clinical trials to test the efficacy of sunitinib in glioma, 
a primary brain tumor, as a single agent and as a combination with other anti-cancer 
drugs. However, due to the anatomical structure of the blood brain barrier, the brain 
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delivery of sunitinib is limited and this could potentially impact its pharmacological 
action in glioma patients.  
 
Sunitinib is an analog of SU5416 (semaxinib) and exhibits light-induced isomerization 
due to the presence of a double bond between 2-oxindol and the pyrrole ring. Rotation 
around this double bond leads to the existence of two isomers, the E-isomer and Z-isomer 
[9]. The powder form exists as the Z-isomer, which is also the thermodynamically stable 
form of the drug. However, when put into solution in light, it isomerizes and forms the E-
isomer, which is an inactive form of sunitinib (de Bruijn et al., 2010). Furthermore, the E-
isomer is not available as an analytical standard, and therefore a method for quantifying it 
cannot be developed. The amount of conversion of Z- to E-isomer depends upon how 
long the sample solution has been exposed to the light. Sunitinib is an extensively studied 
drug with regard to development of an assay method but most of these methods are 
deficient in some respect related to light-sensitivity, the type of method employed (HPLC 
vs LC-MS/MS) or information with regard to its stability under laboratory conditions or 
the effect of matrix employed. Gotze et al. reported that the formation ratio of E:Z was 
1:4 (Gotze et al., 2012) and used the second peak (Z-isomer) for quantitation while 
Haouala et al. reported ratio of 1:2 (Haouala et al., 2009) and used summation of both the 
peak areas for calibration purposes. Such variability in results suggests that the isomer 
ratio is dependent on many factors in addition to the duration of time the samples have 
been exposed to light. Several papers have been published on the LC-MS/MS method 
validation of sunitinib in human plasma (Haouala et al., 2009; Honeywell et al., 2010; de 
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Bruijn et al., 2010; Rodamer et al., 2011; Bouchet et al., 2011; Gotze et al.; Lankheet et 
al., 2013), but have failed to mention the light-sensitive phenomenon (Minkin et al., 
2008). Baratte et al. reported an analytical method for sunitinib and its metabolite in 
several tissues, including the brain. However, this method employed monkey tissues, 
which is not a routinely used laboratory animal (Baratte et al., 2004). Earlier attempts 
have been made to develop a LC-MS/MS assay for sunitinib where samples have been 
prepared under light-protected conditions. Zhou et al reported a LC-MS/MS method for 
determination of sunitinib in mouse plasma and normal and tumor brain tissue (Zhou and 
Gallo). However, their report did not discuss the stability of sunitinib under laboratory 
conditions such as sample preparation time stability (bench top) or long term stability for 
samples frozen from pharmacokinetic studies. In addition, their report also lacked any 
mention of the effect of matrix on the extraction of sunitinib.  Considering these 
deficiencies in published literature, there is a need to develop a stable and a reliable 
analytical method for preclinical purposes in an animal that is routinely used for brain 
distribution studies. Thus, the main purpose of the current study was to develop and 
validate an LC-MS/MS method in mouse plasma and brain homogenate, which could 
effectively describe preclinical systemic disposition and brain distribution of sunitinib. 
To minimize the E-to-Z isomerism, all the experiments in this study were performed in 
strict light-protected conditions. 
 
3.2        MATERIALS AND METHODS 
3.2.1     CHEMICALS 
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Sunitinib malate salt (Figure 3.1A) and internal standard dasatinib (Figure 3.1B; IS) 
were purchased from LC laboratories (Woburn, MA, USA).  Acetonitrile (ACN), 
methanol (MeOH), ethyl acetate and dimethyl sulfoxide (DMSO) were procured from 
Fisher Scientific (Fair Lawn, NJ, USA). Ammonium formate, formic acid, bovine serum 
albumin (BSA; > 96% pure from agarose gel electrophoresis) was obtained from Sigma 
Aldrich (St. Louis, MO, USA). Drug-free mouse plasma was obtained from Valley 
Biomedicals (Catalog # AP3054, Winchester, VA, USA). The mobile phase was vacuum-
filtered through a 0.45um filter (Millipore, Milford, MA, USA). 
 
 
3.2.2     PREPARATION OF STOCK SOLUTION, CALIBRATION STANDARDS  
AND QUALITY CONTROLS  
All preparation was done in light-protected conditions. Individual stock solutions of 
sunitinib malate (in black polypropylene tubes) and the IS were prepared at a 
concentration of 1 mg/mL in DMSO.  
 
Dilutions from the stock solutions were made in methanol to yield a working stock 
solution of 100 µg/mL to then generate two 10 µg/mL working solutions of sunitinib 
malate and one 10 µg/mL working solution of the IS. One 10 µg/mL working solution of 
sunitinib malate was used to prepare a series of eight non-zero calibration standards 
ranging from 1.95 ng/mL to 500 ng/mL in amber-colored glass vials. 10 µg/mL working 
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solution of IS was diluted to get a final working concentration of 2 µg/mL. The stock 
solution, sub-stocks, and the calibration standards were stored in the dark at -80°C.  
 
A separate 10 µg/mL working solution of sunitinib was used to obtain 1 µg/mL sub-stock 
solution. Quality control samples were prepared independently from this sub-stock 
solution which to obtain 250 ng/mL (High QC; HQC), 62.5 ng/mL (Medium QC; MQC), 
3.9 ng/mL (Low QC; LQC) and 1.95 ng/mL (lower limit of quantification; LLOQ). The 
QC samples were stored in the dark at -80°C.  
 
3.2.3     SAMPLE PREPARATION 
The blank brain homogenate was prepared by homogenizing drug-free mouse brains 
using a tissue homogenizer (PowerGen 125, Fisher Scientific, Pittsburgh, PA) and 
diluting it with 3 volumes of ice-cold 5% (w/v) BSA in phosphate-buffer saline (PBS) 
solution. Drug-free plasma was commercially obtained (see Materials).  
 
Microcentrifuge tubes containing 100 µL of the IS and 100 µL of each calibration 
standard prepared in triplicate or the QC samples prepared in six replicates were dried 
under a gentle stream of nitrogen. Then, 100 µL of drug-free plasma or 200 µL of blank 
brain homogenate was added. This was followed by a single step liquid-liquid extraction, 
by adding 1 mL of ice-cold ethyl acetate and the tubes were vigorously shaken on a 
vortex-mixer for 10 minutes, followed by centrifugation at 7500 rpm for 15 minutes at 4 
°C (SORVALL LEGEND RT, Kendro). Eight hundred microliters of the supernatant 
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consisting of the organic solvent was transferred to a fresh set of polypropylene micro 
centrifuge tubes and dried under nitrogen.  
 
The dried samples were reconstituted in 100 µL of the mobile phase (30:70:0.1, 
ammonium formate:acetonitrile:formic acid, %v/v) and transferred to the autosampler 
inserts in amber-colored glass vials for injection.  A volume of 5 µL of each sample was 
injected for analysis by LC-MS/MS.  
 
 
3.2.4     INSTRUMENTATION AND MASS-SPECTROMETRIC CONDITIONS 
The LC system consisted of an Agilent 1200 series binary pump (Santa Clara, CA, USA) 
and analytical separation was achieved using a ZORBAX Eclipse XDB C18 column 4.6 x 
50 mm, 1.8 μm (Agilent Technologies, Santa Clara). The mobile phase consisted of 20 
mM ammonium formate buffer (containing 0.1% formic acid) and acetonitrile (70:30; 
v/v) and was delivered at a flow rate of 0.25 ml/min and the total run time was 13 
minutes. 
 
A TSQ Quantum triple quadrupole mass spectrometer (Thermo Finnigan, San Jose, CA, 
USA) using Selected-Reaction-Monitoring (SRM) mode and an electrospray ionization 
source (ESI) in positive ion mode was utilized to obtain mass spectra at a voltage of 
4500V. The sheath gas pressure and auxillary gas pressure was maintained at 50 and 20 
arbitrary units, respectively. The capillary temperature was maintained at 300°C 
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throughout the run. The collision energy for the analyte and IS was 28eV and 16eV, 
respectively. Data acquisition and analysis were performed using Xcalibur software, 
Version 2.0.7. The precursor to product ion transition (Q1  Q3) for quantitation (m/z) 
of sunitinib and dasatinib were programmed in the spectrometer at (399.26  282.98) 
and (488.00  401.03), respectively, to obtain the optimum parameters.   
 
 
3.2.5          CALIBRATION CURVE 
The linear calibration curve of sunitinib was estimated by using the peak area ratio of the 
analyte to the IS, employing a weighting factor of 1/y2 (where, y= peak area ratio). 
Parameters obtained from the calibration curve were used to determine the concentration 
of the unknown samples by back-calculation. 
 
3.3           METHOD VALIDATION: ASSAY CHARACTERISTICS 
The developed method was validated for accuracy, precision, stability, linearity, matrix 
effect, and extraction recovery. 
 
3.3.1     INTER-ASSAY AND INTRA-ASSAY VARIABILITY.  Method validation 
for accuracy and precision in the mouse plasma and brain was performed on three 
separate days as three batches. Each batch comprised of three replicates of eight non-zero 
calibration standards and six replicates of each QC sample, including the LLOQ. Inter- 
and intra-day accuracy and precision was determined by obtaining the plasma and brain 
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concentrations of sunitinib malate and calculating the relative standard error (%RSE) and 
percentage coefficient of variation (%CV).  
 
3.3.2     LIMIT OF QUANTIFICATION. According to the FDA guidance for 
bioanalytical method validation (FDA, 2001; www.fda.org, 2001), the LLOQ is the 
lowest calibration standard and is selected on the basis that the variability in the accuracy 
and precision should be less than 20% and the signal-to-noise ratio greater than 5. The 
signal-to-noise ratio is obtained from the peak area ratio of the LLOQ and the 
background noise obtained from drug-free plasma and brain homogenate run in the same 
time window.  
 
3.3.3     MATRIX EFFECTS (IONIZATION EFFICIENCY). The effect of matrix 
interference caused by endogenously present substances in plasma and brain homogenate 
on the ionization efficiency was evaluated by determining the ratio as ((ratio of absolute 
peak area of post-extracted spiked sample/absolute peak area of non-extracted samples 
reconstituted in the mobile phase)-1)*100. Matrix effect on the ionization efficiency of 
the IS was also determined in a similar way (Wang et al., 2011). 
 
The post-extracted spiked samples were prepared as follows: three replicates (n=3 each 
matrix) of 100 µL of the drug-free plasma and 200 µL of drug-free brain homogenate 
were extracted by liquid-liquid extraction using 1 mL of ice-cold ethyl acetate.  Eight 
hundred microliters of the supernatant was transferred to a microcentrifuge tube and dried 
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under nitrogen. To the dried residue, 100 µL of the analyte at three concentration levels 
(HQC, MQC and LQC) and 100 µL of the IS were added and dried again under nitrogen. 
The dried samples were reconstituted in 100 µL of the mobile phase and were injected 
into the LC-MS/MS for analysis. 
 
3.3.4     EXTRACTION RECOVERY.  A liquid-liquid extraction method was 
employed to efficiently extract the drug from the biological matrices, plasma and brain. 
Three replicates (n=3) at three concentration levels (HQC, MQC and LQC) for the 
analyte and the working concentration of the IS were studied. Extraction recovery was 
evaluated by comparing the absolute peak areas of the extracted and post-extracted 
spiked samples reconstituted in mobile phase. The processed samples consist of samples 
extracted from plasma and brain as mentioned earlier. 
 
Extraction recovery was determined by (ratio of processed samples/ post-extracted spiked 
samples in mobile phase)*100.   
 
3.3.5     STABILITY. Stability of sunitinib malate was evaluated in five replicates at 
three concentration levels (HQC, MQC and LQC) in both plasma and brain homogenate. 
Analysis was performed for short-term, long-term, freeze-thaw, auto-sampler and stock-
solution stability. 
 
For short-term or bench-top stability, samples were kept for 5 h at ambient temperature 
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(room temperature) in light-protected conditions. The time period was chosen on the 
basis of the maximum time the samples will be exposed to room temperature during 
sample preparation. 
 
Three freeze-thaw cycles were performed to assess stability. Samples were prepared and 
thawed unassisted at the bench on day one, then frozen again at -80 °C. This cycle was 
repeated three times and then the samples were extracted on day three.  
 
Long-term stability was assessed by storing the samples at -80 °C for two months (60 
days) followed by extraction on day 61. 
 
Auto-sampler stability of the samples was determined for the extracted and re-constituted 
QC samples by re-injecting the third day validation run samples, which were additionally 
stored at 4 °C for 48 h and compared to freshly prepared QC samples.  
 
Since we had prepared the stock solution of all calibration standards and QC’s, and stored 
them at -80 °C, we also determined the stock solution stability by preparing fresh QC’s 
on the day of the experiment and analyzing them with the QC’s stored in -80 °C for 6 
months. Stock solution stability was determined only in non-extracted neat samples. 
 
All stability studies were determined by comparing the peak area of freshly prepared 
samples and stability samples expressed as percent recovery.  
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 3.4     METHOD APPLICATION 
The LC-MS/MS assay was applied to an oral pharmacokinetic study of sunitinib malate 
in FVB wild-type mice. Plasma and brain concentration profiles were determined 
following an oral dose of sunitinib at 20 mg/kg administered as a 1% CMC 
(carboxymethyl cellulose) suspension via oral gavage in 24 mice. All mice were between 
8-10 weeks old at the time of the experiment and the average weight was ~30 grams.  The 
experiment was conducted in accordance with the University of Minnesota (UMN) 
Institutional Animal Care and Use Committee (IACUC).  Animals were euthanized at 
various time points 0.5, 1, 2, 4, 6, 11 and 16 h post-dose (n=4 at each time point). Blood 
was collected via cardiac puncture (~500 µL) and immediately transferred into 
microcentrifuge tubes containing 20 µL (100 units/mL) of heparinized saline. Plasma was 
separated by centrifuging the blood at 7500 rpm at 4 °C for 15 min. Whole brain was 
immediately removed and rinsed with ice-cold saline to remove extraneous blood and 
blot-dried. Brain was snap-frozen in liquid nitrogen and stored in pre-weighted and 
labeled vials at -80 °C until analysis. On the day of analysis, all brain samples were 
thawed and weighed to obtain the brain weight expressed as the difference between the 
pre- and post-vial weights. The brains were homogenized with 3 volumes of 5% BSA 
using a tissue homogenizer. Pharmacokinetic parameters were calculated using non-
compartmental analysis by Phoenix WinNonlin Version 6.3. (Pharsight, CA). 
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3.5           RESULTS AND DISCUSSION 
3.5.1        CHROMATOGRAPHY AND MASS-SPECTROMETRIC CONDITIONS 
Dasatinib belongs to the same class of tyrosine-kinase inhibitors as sunitinib and was 
chosen as the IS due to its similar chromatographic behavior. We chose not to use 
deuterated sunitinib malate as the IS in part because we did not want to have the 
complication of interfering peaks due to isomerism for the IS. Moreover, at the time we 
began our experiments; deuterated sunitinib was not readily available and was very 
expensive. Therefore, we wanted to use an IS, which is readily available for laboratory 
purposes. Even though all experiments were done in light-protected conditions, still we 
could not totally avoid the Z-to-E isomerism of sunitinib. The Z-isomer is the stable form 
of sunitinib and the E-isomer formed is too small in peak area to account for any 
significant effect. However, we have determined that after a light exposure time of 5 to 6 
hours, equal peak areas of E- and Z-isomer were obtained (1:1 ratio; data not shown). 
Optimal resolution for analyte and IS was achieved with 70 volumes of aqueous buffer 
and 30 volumes of acetonitrile, when run isocratically at 0.25 mL/min.  
 
Mass spectrometric conditions were optimized to obtain the maximum stable response of 
the parent analyte and the product ion. Three product ions were obtained for sunitinib 
with m/z of 326, 283 and 238. We have chosen the product ion with m/z of 283 as it gave 
the highest percentage fragmented. The use of Selected Reaction Monitoring (SRM) over 
Selected Ion Monitoring (SIM), afforded a better advantage in reducing interference and 
increasing sensitivity. The retention time achieved for E-isomer and Z-isomer of sunitinib 
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and dasatinib was 2,7 minutes, 7.8 minutes and 5.5 minutes, respectively. Low 
background noise from the biological matrix showed good selectivity of the method. 
Typical chromatograms of HQC, LLOQ and IS in both plasma (Figure 3.2) and brain 
(Figure 3.3) are shown.   
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Figure 3.1: Chemical structures of (A) sunitinib and (B), internal standard, dasatinib 
 (A)  Chemical structure of sunitinib malate 
 
 
 
 
 
 
 
 
 
 
 
(B) Chemical structure of dasatinib (IS) 
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 Figure 3.2: Representative HPLC-MS/MS chromatograms of high QC (250 ng/mL), 
LLOQ (1.95 ng/mL) and  IS (dasatinib, 2 µg/mL) in plasma extracts. Two peaks 
observed for sunitinib in the high QC sample indicate E-isomer (2.7 minutes) and Z-
isomer (7.8 minutes). 
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 Figure 3.3: Representative HPLC-MS/MS chromatograms of high QC (250 ng/mL), 
LLOQ (1.95 ng/mL) and IS (dasatinib, 2µg/mL)  in brain tissue homogenate extracts.  
Two peaks observed for sunitinib in the high QC sample indicate E-isomer (2.7 
minutes) and Z-isomer (7.8 minutes). 
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3.5.2     LINEARITY, ACCURACY, PRECISION AND LLOQ. The assay was found 
to be linear over the calibration range from 1.95 ng/mL to 500 ng/mL for both plasma 
and brain homogenate using a weighting scheme of 1/y2 (y= peak area ratio). Selection of 
the weighting scale was based on the best estimation of coefficient of determination (r2) 
and deviation of back-calculated concentrations from calibrators expressed as % 
difference. The calibration curves for sunitinib in plasma and brain had coefficients of 
determination (r2) of about 0.99 and 0.97 for plasma and brain, respectively (n=3 in each 
run) (Table 3.1). 
 
 
 
 
Table 3.1: Precision and accuracy of calibration standards of sunitinib in mouse 
plasma and brain tissue homogenate 
 
 
Conc 
(ng/mL) 
Brain Plasma 
RE% CV% RE% CV% 
1.95 12.9 6.15 -0.076 3.08 
3.9 -12 3.5 1.4 3.6 
15.6 -1.72 1.92 0.572 1.21 
31.25 1.870 3.980 8.365 3.083 
62.5 6.54 8.67 -0.858 2.53 
125 -4.52 1.50 -1.78 0.640 
250 1.09 3.49 -13.2 12.2 
500 -1.07 2.38 -0.867 1.94 
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Inter- and intra-assay variability at four different concentrations, HQC (250 ng/mL), 
MQC (62.5 ng/mL), LQC (3.9 ng/mL) and LLOQ (1.95 ng/mL) was determined in 
plasma and brain with six replicates on each day for three separate days. Inter- and intra-
assay bias (%CV) and precision (%RE) were within ±15% for all QC’s, except at LLOQ 
(±20%), which is in agreement with FDA guidelines. This indicates that this assay is 
suitable in terms of accuracy and precision. The detailed results for inter-assay accuracy 
and precision in plasma and brain and intra-assay accuracy and precision in plasma and in 
brain are summarized (Table 3.2). 
 
 
 
 
Table 3.2: Inter-assay and intra-assay accuracy and precision of sunitinib in mouse 
plasma and brain tissue homogenate 
 
Matrix Conc (ng/ml) Intra-day (N=6) Inter-day (N=18) 
  RE% CV% RE% CV% 
 
 
Plasma 
LLOQ_1.953 ng/ml -4.38 4.15 -4.83 4.94 
Low QC_3.906 ng/ml 1.41 2.88 -0.12 8.63 
Med QC_62.5 ng/ml -5.92 5.17 -3.87 5.84 
High QC_250 ng/ml -8.72 7.86 -8.97 1.33 
 
 
Brain 
     
LLOQ_1.953 ng/ml 11.81 10.73 9.05 5.91 
Low QC_3.906 ng/ml -12.85 5.39 -7.66 7.45 
Med QC_62.5 ng/ml -1.43 3.27 3.53 5.44 
High QC_250 ng/ml -6.46 4.35 0.05 5.82 
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 3.5.3     RECOVERY. Recovery was calculated by comparing the absolute peak area of 
the processed samples at 3.9, 62.5 and 250 ng/mL, using the extraction method described 
earlier, with those of post-extracted samples at the same concentrations in mobile phase, 
expressed as a percentage. Extraction recovery of the IS was also determined at 2 µg/mL 
using the same procedure. Average recovery for sunitinib in plasma and brain was 
112.3% and 94.3%, respectively. The recovery results are summarized in Table 3.3. 
 
3.5.4     MATRIX EFFECTS. Effect of endogenous substances in the biological matrix 
was evaluated at three different concentrations, 3.9, 62.5 and 250 ng/mL for sunitinib and 
at a single concentration of 2 µg/mL for the IS. The suppression of ionization in both 
plasma and brain homogenate was highest in medium QC (approx. -44%) and lowest for 
the high QC (approx. -34%). Plasma extracts enhanced the ionization of the IS by ~ 
0.04%, but was decreased by -1.7% in the brain homogenate extracts. These results 
suggest that plasma and brain homogenate interfered with the ionization of the analyte 
(Table 3.3). 
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 Table 3.3: Matrix effect of plasma and brain homogenate on the ionization efficiency 
of sunitinib and IS and extraction recovery of sunitinib and IS in mouse plasma and 
brain homogenate. 
 
 
 
 Conc (ng/mL) Matrix Effect, 
Mean (%)±SD (%) 
N=3 
Extraction 
Efficiency, 
Mean (%)±SD (%) 
N=3 
 
 
                   Plasma 
 
Low QC_3.9 -38.1 ± 5.4 126 ± 0.1 
Med QC_62.5 -43.8 ± 4.3 119 ± 0.1 
High QC_250 -33.5 ± 3.5 92 ± 0.1 
Dasatinib (IS)_2000 0.04 ± 0.03 79 ± 0.02 
 
 
 
Brain 
 
Low QC_3.9 -43 ± 2.4 113 ± 0.1 
Med QC_62.5 -45 ± 2.6 102 ± 0.1 
High QC_250 -34.1 ± 3.1 68 ± 0.04 
Dasatinib (IS)_2000 -1.7 ± 0.9 72 ± 0.02 
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3.5.5     STABILITY. Five replicates of HQC, MQC and LQC were used to assess the 
stability of sunitinib under various conditions. The results are summarized in Table 3.4. 
Results from bench-top stability suggest that the sample preparation time of 5 h did not 
lead to significant degradation of sunitinib in both the plasma and the brain samples (< 
±15%). Results from auto-sampler, freeze-thaw and long-term stability indicate that the 
degradation of sunitinib might occur under these conditions and therefore determining 
reliable concentrations from such samples must take this into consideration. Storing the 
samples after an experiment for long-term (>= 60 days) under frozen conditions (-80C) 
can lead to deterioration of the drug. It is thus advisable to analyze the samples as soon as 
possible. Furthermore, results from auto-sampler stability suggest that it is not ideal to 
use re-constituted samples for determination of sunitinib concentrations if they are kept 
for more than 48 h in the auto-sampler. With the given run-time in this assay, we were 
able to analyze up to 120 samples overnight without observing degradation of the analyte. 
The standard stock solution was found to be stable over the time period of storage (6 
months). This is important as it avoids the need to make fresh standards everyday. (Table 
3.5). 
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Table 3.4: Stability of analyte and IS under various conditions examined 
 
 
Matrix Concentration 
(ng/mL) 
Bench-Top# 
(% recovery) 
N=5 
Freeze-thaw## 
(% recovery) 
N=5 
Auto-sampler### 
(% recovery) 
N=5 
Long-Term#### 
(% recovery) 
N=6 
  Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
 3.9 94.79 ± 4.04* 84.37 ± 7.38 98.4 ± 6.05* 112 ± 21.64 
Plasma 62.5 91.8 ± 9.74 85.6 ± 9.69 68.66 ± 8.92 67.42 ± 13.80 
 250 82.74 ± 20.08 100.73 ± 5.16 100.5 ± 6.13 70.19 ± 5.91 
      
 3.9 95.26 ± 9.84 71.68 ± 5.73 121.08 ± 8.88 122.26 ± 12.14 
Brain 62.5 96.35 ± 3.16 82.42 ± 9.88 119.08 ± 8.44 111.62 ± 11.47 
 250 98.79 ± 5.05 92.62 ± 4.15 102.18 ± 9.02 107.59 ± 16.11 
*no. of replicates = 4  
#At least 5 h at room temperature 
##At least three freeze-thaw cycles 
###At least 48 h at 4°C 
####At least 2 months (60 days) at -80 ± 5°C 
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Table 3.5: Stock solution stability of the analyte 
 
 
Nominal Conc 
(ng/mL) 
% recovery 
Mean ± SD 
Low QC_3.9 102.3 ± 0.61 
Medium QC_62.5 103.51 ± 0.22 
High QC_250 99.54 ± 3.57 
 
 
 
3.6     METHOD APPLICATION 
The established method was successfully used to determine pharmacokinetic parameters 
in plasma and brain following a single oral dose of 20 mg/kg sunitinib administered as a 
1% CMC suspension in FVB wild-type mice. Plasma and brain samples were collected at 
predetermined time points and analyzed using this assay. The assay was found to be 
sensitive in determining sunitinib concentrations in both plasma and brain. A non-
compartmental analysis approach yielded a terminal half-life of 1.8 h in plasma and 2 h in 
brain. All measured concentrations were above the LLOQ. The plasma and brain area 
under the curve from time zero to infinity (AUC0-∞) was 1.85 hr-µg/mL and 0.77 hr-
µg/mL, respectively, and AUC brain-to-plasma ratio was 0.42, i.e., 42% of the drug in 
plasma reaches the brain, suggesting limited delivery of sunitinib into the brain 
(measured as the total sunitinib concentrations, Figure 3.4). The peak concentration, 
Cmax, was 320 ng/mL and 127 ng/mL in both plasma and brain, respectively.  
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Figure 3.4: Plasma and brain sunitinib concentration-time profiles in FVB-wild type 
mice after a single oral dose of 20 mg/kg. 
 
 
 
 
 
 
3.7     CONCLUSION 
In conclusion, we have developed and validated a robust, sensitive and reproducible LC-
MS/MS method for analysis of sunitinib in mouse plasma and brain tissue homogenate. 
This study reports a validated method for sunitinib analysis in mouse plasma and brain 
considering its light-sensitive nature and has been successfully employed for pre-clinical 
pharmacokinetic investigations in mice. High extraction efficiency using a liquid-liquid 
extraction method in this assay is simple to apply and does not involve the need for an 
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additional protein precipitation step. The described method was found to be linear over a 
wide range, from 1.95 ng/mL to 500 ng/mL. This method requires only small amount of 
sample (100 µL for plasma and 200 µL for brain homogenate), therefore it is also feasible 
for analysis of sunitinib from in-vitro cell culture studies and using this assay we have 
determined sunitinib from cellular accumulation studies in our lab.  
 
3.8     FOOTNOTES 
We would like to thank Dr. Tianli Wang and Dr. Sagar Agarwal for their valuable 
discussions. This work was supported by grants, CA 138437, NS 077921 and CA 
108961. 
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CHAPTER  IV 
 
 
PHARMACOKINETIC ASSESSMENT OF EFFLUX 
TRANSPORT IN SUNITINIB DISTRIBUTION TO 
THE BRAIN 
 
 
 
 
 
 
 
This chapter has been published as a manuscript in Journal of Pharmacology and 
Experimental Therapeutics, Dec 2013;347(3):755-64. 
Reprinted with permission of the American Society for Pharmacology 
and Experimental Therapeutics. All rights reserved. 
Copyright © 2013 by The American Society for Pharmacology and Experimental 
Therapeutics 
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This study quantitatively assessed transport mechanisms that limit the brain distribution 
of sunitinib, and investigated adjuvant strategies to improve its brain delivery for the 
treatment of glioblastoma multiforme (GBM). Sunitinib has not shown significant 
activity in GBM clinical trials, despite positive results seen in preclinical xenograft 
studies. We performed in vivo studies in transgenic FVB mice: wild-type, Mdr1a/b(-/-), 
Bcrp1(-/-) and Mdr1a/b(-/-)Bcrp1(-/-) genotypes were examined. The brain-to-plasma 
AUC ratio after an oral dose (20 mg/kg) was similar to steady-state tissue distribution 
coefficient (Kp), indicating linear distribution kinetics in mice over this concentration 
range. Furthermore, the distribution of sunitinib to the brain increased after 
administration of selective P-glycoprotein (P-gp) or breast cancer resistance protein 
(Bcrp) pharmacological inhibitors, and a dual inhibitor, elacridar, comparable to that of 
the corresponding transgenic genotype. The brain-to-plasma ratio after co-administration 
of elacridar in wild-type was ~12, compared to ~17.3 in Mdr1a/b(-/-)Bcrp1(-/-) mice. 
Overall, these findings indicate that there is a co-operation at the BBB in restricting the 
brain penetration of sunitinib and brain delivery can be enhanced by administration of a 
dual inhibitor. These data indicate that the presence of cooperative efflux transporters, P-
gp and Bcrp, in an intact BBB, can protect invasive glioma cells from chemotherapy. 
Thus, one may consider the use transporter inhibition as a powerful adjuvant in the 
design of future clinical trials for the targeted delivery of sunitinib to GBM.  
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4.1      INTRODUCTION 
Glioblastoma multiforme (GBM) is an aggressive tumor with a median survival of 12.6 
months with treatment (Louis et al., 2007). Progression of glioma is dependent on a rich 
blood supply accomplished by angiogenesis (Brem et al., 1992; Tuettenberg et al., 2006), 
a process mediated by vascular endothelial growth factor receptor (VEGFR), platelet-
derived growth factor receptor (PDGFR), basic fibroblast growth factor (bFGF) and 
epidermal-derived growth factor receptor (EGFR) (Tuettenberg et al., 2006; Wong et al., 
2009).  Anti-angiogenic therapy is an important treatment option for GBM, in addition to 
cytotoxic therapy with temozolomide. Bevacizumab (Avastin®), an anti-VEGF 
monoclonal antibody, was approved in May 2009 for GBM (Cohen et al., 2009). Since 
then, several targeted agents such as tyrosine-kinase inhibitors (TKIs) have been tested in 
clinical trials, alone and in combination with other anti-cancer therapies. None of these 
treatment regimens have shown significant efficacy in GBM patients (di Tomaso et al., 
2011; Wick et al., 2011), leaving several unresolved questions remaining; such as 
whether or not the drugs themselves are ineffective, or if the delivery of a possibly 
effective drug is inadequate, or both. 
 
Effective delivery of drugs for the treatment of brain disorders has always been a 
challenging task due to the presence of the blood-brain barrier (BBB). The BBB is 
comprised of endothelial cells annealed by tight-junctions, which is further complicated 
by the presence of active efflux transporters. The ATP-Binding Cassette (ABC) family of 
transporters, include P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein 
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(BCRP, ABCG2), two major efflux transporters present in the luminal side of the BBB. 
These transporters work in tandem to restrict delivery of several therapeutics into the 
brain (Gottesman et al., 2002; Fletcher et al., 2010)  .  
 
The microvasculature within a brain tumor is heterogeneous. The tumor core has 
some degree of necrosis and is highly permeable (Horowitz et al., 1983), while the brain 
adjacent to the core may have a slightly higher permeability than normal brain (Levin et 
al., 1975). The core, visualized by MRI, is often removed during resection; however the 
tumor cells adjacent to the core, are found in regions with a relatively intact BBB, and are 
capable of causing the tumor recurrence. Furthermore, some tumor cells infiltrate into 
distant sites of the brain to form a sanctuary of tumor cells, thus making GBM, in 
essence, a “whole brain” disease (Agarwal et al., 2011a). The tumor and BBB 
characteristics work in tandem to present a real challenge in achieving adequate drug 
delivery throughout the brain, which would yield a treatment that will be most likely to 
result in a longer progression-free survival in GBM (Agarwal et al., 2011a).  
 
Sunitinib (N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-
ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide); SU112468; Sutent, MW: 
532.561223 g/mol MF: C26H33FN4O7) is an orally active TKI with activity against 
VEGFR1-3 and PDGFR-α/β receptors, which are over-expressed in gliomas (Faivre et 
al., 2007). Preclinical studies have shown significant anti-tumor and anti-angiogenic 
activity of sunitinib (Zhou et al., 2008; Zhou and Gallo, 2009). However, recent clinical 
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trials have been disappointing (Neyns et al., 2011; Pan et al., 2012). One possibility for 
these conflicting results could be due to the lack of adequate drug delivery, mediated by 
the efflux transporters at the BBB. Sunitinib is known to interact with P-gp and Bcrp at 
the BBB (Dai et al., 2009; Hu et al., 2009; Shukla et al., 2009).  
 
Recently, Tang et al. reported that sunitinib is transported in-vitro by human 
ABCB1 (MDR1) and ABCG2 (BCRP) and murine ABCG2 (Bcrp), but not by human 
ABCC2 (MRP2) (Tang et al., 2012). They showed that single knockout of efflux 
transporters, P-gp or Bcrp, did not result in a profound increase in the brain accumulation 
of sunitinib when given as a single oral dose of 10 mg/kg; however, absence of both the 
transport systems (Abcb1a/1b/Abcg2-/-) resulted in a 23-fold increase in brain penetration. 
Furthermore, administration of a high dose of an inhibitor of both P-gp and Bcrp, 
elacridar, resulted in 12-fold increase in brain accumulation of sunitinib, comparable to 
the levels observed in Abcb1a/1b/Abcg2-/- mice, when examined at a single time point 
(Tang et al., 2012).  
 
Therefore, the primary aim of this investigation was to study the interaction of 
sunitinib with P-gp and Bcrp at the BBB and quantitatively assess using pharmacokinetic 
principles, the true brain partitioning. We further proposed strategies to improve the brain 
distribution of sunitinib. We determined how assessment of brain partitioning at any 
single time point can lead to misinterpretation of the influence of efflux mechanisms; 
however, this assessment can be achieved at transient steady state. A novel aspect of this 
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study is the inhibition of remaining P-gp and Bcrp in Bcrp knockout and P-gp knockout 
mice, respectively. This is important, especially for a tumor such as glioma, which is 
highly invasive in nature and has a greater tendency to infiltrate into the normal regions 
of the brain. Thus sub-therapeutic concentrations in the regions where BBB has intact 
tight junctions, in conjunction with efflux transporters, can lead to decreased delivery, 
and hence efficacy of the targeted therapeutic agent.  
 
4.2        MATERIALS  
4.2.1     CHEMICALS AND REAGENTS 
Sunitinib malate and dasatinib free base were purchased from LC Labs (Woburn, MA). 
Elacridar [GF120918; N-(4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-5-
methoxy-9-oxo-10H-acridine-4-carboxamide] and Ko143 [(3S,6S,12aS)-
1,2,3,4,6,7,12,12aoctahydro- 
9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino(1',2':1,6) pyrido(3,4-b)indole-3- 
propanoic acid 1,1-dimethylethyl ester] were purchased from Toronto Research 
Chemicals, Inc. (North York, ON, Canada). Zosuquidar [LY335979; (R)-4-
((1aR,6R,10bS)-1,2-difluoro-1,1a,6,10btetrahydrodibenzo-
(a,e)cyclopropa(c)cycloheptan-6-yl)-α-((5-quinoloyloxy) methyl)-1-piperazine ethanol, 
trihydrochloride] was a gift from Eli Lilly & Co. (Indianapolis, IN). All other reagents 
and chemicals were of HPLC grade and were purchased from Sigma (St. Louis, MO). 
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4.2.2     ANIMALS 
In-vivo studies were performed in the FVB mouse strain of either sex, wild-type and 
transgenic mice that have the gene for P-gp knocked out (Mdr1a/b(-/-) knockout mice), 
Bcrp (Bcrp1(-/-) knockout mice) and both P-gp and Bcrp (Mdr1a/b(-/-)Bcrp1(-/-) or 
“triple-knockout” mice) obtained from Taconic Farms (Germantown, NY). All mice were 
8-10 weeks old and were maintained under temperature-controlled conditions with 12-hr 
dark/12-hr light cycle. Mice were handled according to the guidelines set by the National 
Institute for Health (NIH) and all experiments were conducted in accordance with the 
Institutional Animal care and Use Committee (IACUC) of the University of Minnesota.  
 
4.2.3  PLASMA AND BRAIN PHARMACOKINETICS AFTER ORAL 
ADMINISTRATION 
The sunitinib dosing solutions for all in-vivo studies were prepared as a stable suspension 
in 1% carboxymethylcellulose on the day of the experiment. All mice were administered 
20 mg/kg by oral gavage were euthanized using a carbon-dioxide chamber at the desired 
time point. Since sunitinib exhibits light-sensitive diastereoisomerism (de Bruijn et al., 
2010), all experiments and sample analyses were performed in light-protected conditions.  
In the oral dosing study, wild-type, Mdr1 a/b (-/-), Bcrp1(-/-) and Mdr1 a/b (-/-), Bcrp1(-
/-) mice were administered 20 mg/kg sunitinib suspension via oral gavage. Blood and 
brain were harvested at pre-determined time points, i.e., 0.5, 1, 2, 4, 6, 11, 16 and 22 97  
    
hours post-dose (n=3 to 4 at each time point). Following euthanasia, blood was collected 
via cardiac puncture and immediately transferred to tubes containing 20 µL of 100 
units/mL heparinized saline. Plasma was obtained by centrifugation at 40C at 3500 rpm 
for 15 minutes. Whole brain was rapidly removed, rinsed with ice-cold buffer and blotted 
with tissue paper to remove superficial blood vessels, followed by flash freezing in liquid 
nitrogen. Brains were transferred to pre-weighed tubes and plasma and brain samples 
were stored at -800C until analysis. 
On the day of the analysis, brain samples were thawed at room temperature and brain 
weights were determined. Brains were homogenized using 3 volumes of ice-cold 5% 
bovine serum albumin (BSA) prepared in phosphate-buffered saline (pH= 7.4) using a 
tissue homogenizer (PowerGen 125, Fisher Scientific, Pittsburgh, PA)  
Previously, we have determined that the brain vascular space in FVB mice is 1.4% of the 
whole brain volume (Dai et al., 2003), therefore we used this value to correct all brain 
concentrations for the residual drug in the brain vasculature.  
 
4.2.4       STEADY-STATE BRAIN DISTRIBUTION OF SUNITINIB 
The steady-state brain-to-plasma ratio or the “tissue partition coefficient” (Kp) was 
determined for sunitinib by measuring the plasma and brain concentrations in wild-type, 
Mdr1(-/-), Bcrp1(-/-) and Mdr1a/b(-/-)Bcrp1(-/-) mice using Alzet osmotic minipumps 
(Durect Corporation, Cupertino, CA) as described previously for sunitinib (Dudek et al., 98  
    
2013). In brief, 30 mg of sunitinib was dissolved in 1 mL of DMSO and osmotic 
minipumps (model 1003D) were loaded with 100 µL. The pumps were equilibrated by 
immersing them overnight in saline at 370C in light-protected conditions. On the day of 
the experiment, mice were anesthetized with isoflurane (Boynton Health Service 
Pharmacy, University of Minnesota, Minneapolis, MN) and the primed pumps were 
surgically implanted in the peritoneal cavity of the mice, after which the mice were 
allowed to recover on a heated pad. Each minipump is designed to operate at a flow rate 
of 1 µL/hr, which, in this case, yields a constant intraperitoneal infusion rate of 30 µg/hr. 
After 48 h (approximately 24 half-lives), animals were euthanized and brain and blood 
were harvested as described earlier. A 48 hr infusion was sufficient to achieve steady 
state as both the plasma and brain half-lives were approximately 2 hrs. Plasma and brain 
samples were stored in -800C until the day of analysis. On the day of the analysis, brains 
were prepared for analysis as described above. 
 
4.2.5     INHIBITION OF P-gp AND/OR Bcrp1 
The influence of selective or dual pharmacological inhibition of P-gp and Bcrp on the 
brain distribution of sunitinib was examined by pre-treating FVB wild-type mice with 
selective inhibitors of P-gp (zosuquidar, LY335979) (Dantzig et al., 2001), Bcrp (Ko-
143) (Allen et al., 2002) and a dual inhibitor of P-gp/Bcrp (elacridar, GF120918) 
(Maliepaard et al., 2001; Hubensack et al., 2008). Zosuquidar was administered at a dose 
of 25 mg/kg and both Ko-143 and elacridar were administered at doses of 10 mg/kg 99  
    
(vehicle: 40% DMSO, 40% propylene glycol, 20% saline). All inhibitors were 
administered via intravenous route, 30 minutes prior to sunitinib dosing (20 mg/kg) via 
oral gavage. Mice were sacrificed 1 hour post sunitinib dosing, and blood and brain 
specimens were collected and prepared for analysis as described above.  To further 
delineate the role of P-gp and Bcrp in regulating the brain distribution of sunitinib at the 
mouse BBB, we studied the effect of selective pharmacological inhibitors in transgenic 
mice, therefore, P-gp knockout mice (Mdr1a/b(-/-)) were administered a Bcrp-selective 
inhibitor, Ko-143 (10mg/kg) and Bcrp knockout mice (Bcrp1(-/-)) were administered a P-
gp selective inhibitor, zosuquidar (25 mg/kg) and FVB wild-type mice were administered 
both zosuquidar and Ko-143 intravenously 30 minutes prior to the sunitinib oral dose (20 
mg/kg). Mice were sacrificed 1 hour after sunitinib dosing and blood and brain specimens 
were collected and stored at -800C until analysis. 
Further, we compared the brain concentrations and brain-to-plasma concentration ratios 
at the 1-hour time point following pharmacological inhibition with those obtained at 1-
hour time point in genetically altered mice, i.e., the Mdr1a/b(-/-), Bcrp1(-/-) and 
Mdr1a/b(-/-)Bcrp1(-/-) mice after oral administration.  Moreover, given that these brain 
distribution data are often reported in the literature at a single time-point post dose, these 
experiments allow us to compare single time point brain distribution (brain-to-plasma 
concentration ratios at a single time point) with the steady-state concentration ratios and 
the AUC ratios from time zero to infinity.   
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4.2.6     DATA ANALYSIS 
Estimation of pharmacokinetic parameters and metrics was accomplished using Phoenix 
WinNonlin version 6.3 employing non-compartmental estimation methods (Pharsight, 
Mountain View, CA). Cmax and Tmax were direct measurements obtained as the maximum 
observed concentration and the time to reach Cmax, respectively.  The area under the 
concentration time profile (AUC) was calculated up to the last measured concentration 
using log-linear trapezoidal approximation (AUC0-tlast), with an area extrapolation to time 
infinity in the terminal phase by adding Clast/λz, where λz is the terminal rate constant of 
the drug from plasma or brain, that was calculated from the last three to five data points 
of the respective concentration-time profiles. An extension of Nedelman and Jia’s method 
was employed to analyze data using a sparse sampling method, and to estimate variance 
on area under the concentration time profile from time 0 to the last measurable time point 
(Nedelman and Jia, 1998). The percentage of extrapolated AUC was less than 2% for all 
the four groups for both plasma and brain. In addition, we assessed the transient steady-
state kinetics of sunitinib. A transient steady state occurs when the brain concentration is 
at maximum, Cmax, brain. At that time, the rate of change of drug concentration in the brain 
is zero. That is, a transient steady state is determined by the ratio of maximum observed 
brain concentration (Cmax) to the corresponding plasma concentration at that time point. 
The ‘AUC’ brain-to-plasma ratio and the ‘transient’ steady-state ratio were compared to 
the ‘steady-state’ brain-to-plasma ratio obtained after a continuous intraperitoneal 
infusion lasting 48 hours. We also determined brain-to-plasma concentration ratios at all 
measured time points in all genotypes. Furthermore, a drug-targeting index (DTI) of 101  
    
sunitinib was determined for both the efflux transporters as AUC brain-to-plasma ratios 
of the “treatment” groups (Pgp knockout, Bcrp knockout or triple knockout) divided by 
the AUC brain-to-plasma ratios of the control group, in this case the AUC brain-to-
plasma ratio in FVB wild-type mice, written as 
DTI = [AUCbrain/AUCplasma], knockout / [AUCbrain/AUCplasma], wild-type 
 
4.2.7     LC-MS/MS ANALYSIS 
Quantitative determination of sunitinib concentrations in mouse plasma and brain tissue 
homogenate was done using high performance liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) according to the method previously described (Oberoi RK, 
2013). In brief, on the day of the analysis, samples were thawed at room temperature, 
protected from light. Brain samples were homogenized with 3 volumes of 5% ice-cold 
bovine serum albumin in phosphate buffered saline (pH=7.4). 100 µL of plasma and 200 
µL of brain homogenate were transferred to micro centrifuge tubes containing 100 µL of 
internal standard, dasatinib (2000 ng/mL). Samples were extracted by adding 1 mL of 
ice-cold ethyl acetate and vigorously shaken for 5 minutes, followed by centrifugation at 
40C at 7500 rpm for 10 minutes. 750µL of the supernatant was transferred to 
microcentrifuge tubes and dried under a gentle stream of nitrogen. Dried samples were 
re-constituted in 100 µL of mobile phase (70:30:0.1, v/v %, 20 mM ammonium formate, 
pH 3.5: acetonitrile: formic acid) and transferred to amber colored glass vials. 5 µL of the 
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sample was injected into LC-MS/MS. The chromatographic system consisted of Agilent 
Technologies model 1200 separation system. Separation of the analyte was achieved on 
ZORBAX XDB Eclipse C18 column (4.6 x 50 mm, 1.8um, Agilent Technologies). The 
LC-system was interfaced with TSQ Quantum triple quadrupole mass spectrometer 
(Thermo Finnigan, San Jose, CA) equipped with selected reaction monitoring (SRM) 
mode by electrospray ionization source (ESI) operated in positive ion mode at a spray 
voltage of 4000V. The mobile phase flow rate was 0.25 mL/min and the total run time 
was 13 min. Data acquisition and analysis was performed using the Xcalibur software, 
version 2.0.7. The mass-to-charge transitions programmed in the spectrometer were 
(399→283) and (488→401) for analyte sunitinib and internal standard, dasatinib, 
respectively. 
 
4.2.8     STATISTICAL ANALYSIS 
Unpaired two-sample t-tests were used to test for statistical significance between two 
groups. One-way ANOVA, followed by Bonferroni’s test, was employed to test for 
significance among multiple groups. Significance was declared at p < 0.05 for all tests. 
(GraphPad Prism 5.01, San Diego, CA, USA). 
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4.3        RESULTS 
4.3.1   SUNITINIB PHARMACOKINETICS IN PLASMA AND BRAIN AFTER 
ORAL ADMINISTRATION  
Sunitinib plasma and brain concentration-time profiles were determined in wild-type, 
Mdr1a/b(-/-), Bcrp1(-/-) and Mdr1a/b(-/-)Bcrp1(-/-) mice after a single oral dose of 20 
mg/kg sunitinib. The plasma and brain concentrations in the wild-type mice at the 22 hr 
time-point were below the limit of quantification (LLOQ, 1.95 ng/mL) and therefore 
were not considered in the pharmacokinetic analyses.  
Plasma concentrations (and hence the AUCs in plasma) were not statistically different 
among the four genotypes. This suggests that absence of P-gp and/or Bcrp does not 
influence the systemic pharmacokinetics of sunitinib. The apparent oral clearances 
(CL/F) observed amongst the genotypes were similar. The apparent oral clearance of 
sunitinib in wild-type, Mdr1a/b(-/-), Bcrp1(-/-) and Mdr1a/b(-/-)Bcrp1(-/-) was 4.6 
mL/min, 4.1 mL/min, 5.1 mL/min and 6.5 mL/min, respectively. This is reflected in 
similar areas under the plasma concentration-time profiles among each group (AUC 
plasma) (Figure 4.1 (a), Table 4.1). However, the brain concentrations varied greatly 
amongst the genotype groups. In the wild-type mice, the brain concentrations were lower 
than the plasma concentrations at all the measured time points, indicating limited delivery 
of sunitinib into the brain. Brain concentration-time profiles in Bcrp knockout mice and 
P-gp knockout mice closely followed concentrations corresponding in the plasma. This 
indicates that Bcrp or P-gp alone do not dramatically affect the brain distribution of 
sunitinib. However, the brain concentrations in the triple knockout mice were 104  
    
significantly greater than the plasma concentrations at all measured time points (p <0.05), 
indicating that like many other TKIs, sunitinib brain distribution is influenced by both P-
gp and Bcrp acting in concert at the BBB (Figure 4.1 (b)) (Chen et al., 2009; Lagas et al., 
2009; Polli et al., 2009; Poller et al., 2011). Non-compartmental analysis of all four 
concentration-time profiles indicated that the terminal half-life in plasma was similar to 
the terminal half-life in the brain within each group. The half-life in plasma ranged from 
1.8 hrs to 3.0 hrs while the half-life in the brain ranged from 2.0 hr to 3.2 hrs (Table 4.1). 
Although the AUC in plasma was not different between groups, significant differences, 
however, were observed in the brain AUCs (AUC0-tlast) in all knockout mice compared to 
the wild-type mice. This indicates that the efflux transporters influence sunitinib brain 
distribution between groups; a slight difference in the P-gp and BCRP knockout animals, 
but with a much more pronounced effect in the triple-knockout animals. The maximum 
observed concentration in the brain (Cmax brain) was also significantly different between all 
groups of mice. The Cmax brain in the wild-type (0.13 ±0.04 µg/gm) was lower than that 
observed in Bcrp1 (-/-) mice (0.20 ± 0.02 µg/gm), Mdr1a/b(-/-) mice (0.52 ± 0.14 µg/gm) 
and Mdr1a/b(-/-)Bcrp1(-/-) (4.9 ± 0.7 µg/gm) mice. The area under the brain 
concentration time profile (AUC 0-∞, brain) was 37.4-fold higher in Mdr1a/b(-/-)Bcrp1(-
/-) mice compared to wild-type mice, whereas the AUC brain in Mdr1a/b(-/-) mice was 
4.75-fold higher and in Bcrp1(-/-) mice was 2.08-fold higher, compared to the wild-type 
mice (Table 4.1).  
The resulting AUC brain-to-plasma ratio, also known as tissue Kp (brain-to-plasma 
partition coefficient), was 0.42 in the wild-type mice, suggesting that sunitinib has, 105  
    
compared to many other TKIs (Agarwal et al., 2011b; Minocha et al., 2012b; Minocha et 
al., 2012a), a greater partitioning into the brain. However, in the absence of both P-gp and 
Bcrp (Mdr1a/b(-/-)Bcrp1(-/-)) mice, the AUC brain-to-plasma ratio is 20.5, whereas in 
Mdr1a/b(-/-) and Bcrp1(-/-) mice, the AUC brain-to-plasma ratio was 1.61 and 0.88, 
respectively. These results indicate that the both P-gp and Bcrp work in cooperation to 
efflux sunitinib out of the brain. This could impact the drug levels in the brain for 
treatment of brain tumors, both primary and metastatic. The drug-targeting index (DTI) 
of sunitinib was calculated as the ratio of AUC brain-to-plasma ratios, in the transgenic 
mice divided by the same ratio in the control group, which in this case are the wild-type 
mice. Based on the mean AUC0-∞ values, the observed DTI values were 3.8 for 
Mdr1a/b(-/-), 2.4 for Bcrp1(-/-) and 55.5 for Mdr1a/b(-/-)Bcrp1(-/-). This indicates a 
great influence of the efflux transporters in limiting the brain targeting of sunitinib 
(Table 4.1). These results closely follow the pattern previously observed for several 
TKIs, where a greater than additive effect of P-gp and Bcrp is observed (Lagas et al., 
2009; Polli et al., 2009). Our results indicate that the efflux activity with Mdr1a/b(-/-) 
mice and Bcrp1(-/-) mice is a combined effect since we determined that P-gp efflux 
activity (DTI for Mdr1a/b(-/-) mice) was 3.8-fold and Bcrp efflux activity (DTI for 
Bcrp1(-/-) mice) was 2.4-fold. Therefore, it is hard to conclusively say whether either P-
gp or Bcrp has a greater contribution to the in vivo efflux clearance of sunitinib from the 
brain. Nevertheless, it is clear that both transporters work in tandem at the BBB to efflux 
sunitinib from the brain, and the action of both transporters must be inhibited to 
significantly improve the distribution of sunitinib to the brain.  
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The brain-to-plasma concentration ratios vs. time of all genotypes are shown in Figure 
4.1 (c). In all the mouse genotypes, these ratios showed an increase before reaching a 
plateau, when a pseudo-distributional equilibrium had been attained. 
Table 4.1: Plasma and brain pharmacokinetic parameters determined by non-
compartmental analysis after the administration of a single oral dose of sunitinib (20 
mg/kg) in wild-type, Mdr1a/b(−/−), Bcrp1(−/−), and Mdr1a/b(−/−)Bcrp1(−/−) mice.  
Results are expressed as mean ± S.D. n = 3 - 4. 
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Cmax,  maximum observed concentration; half-life (hr),  time taken to reach one-half of 
its steady-state value; AUC, area under the concentration-time profile curve; DTI,  drug 
targeting index 
PLASMA 
Parameter 
(units) 
FVB-wild 
type 
Mdr1a/b(-/-) Bcrp1(-/-) Mdr1a/b(-/-
)Bcrp1(-/-) 
Cmax 
(ug/mL) 
0.32 ± 0.08 
 
0.42 ± 0.13 0.225 ± 0.09 0.38 ± 0.04 
Half-life (hr) 1.8 2.1 3.0 2.8 
Tmax (hr) 1 0.5 2 2 
CL/F 
(mL/min) 
4.6 4.1 5.1 6.5 
AUC (0-tlast) 
(hr-ug/mL) 
1.85 ± 0.36 2.26 ± 0.26 1.81 ± 0.20 1.39 ± 0.12 
AUC (0-inf) 
(hr-ug/mL) 
1.85 2.27 1.83 1.40 
BRAIN 
Cmax (ug/mL) 0.13 ± 0.04 0.52 ± 0.14 0.20 ± 0.02 4.92 ± 0.74 
Half-life (hr) 2.0 2.5 3.2 3.0 
Tmax (hr) 4 4 6 2 
AUC (0-tlast) 
(hr-ug/mL) 
0.76 ± 0.11 3.63 ± 0.15 1.58 ± 0.15 28.43 ±  3.10 
AUC (0-inf) 
(hr-ug/mL) 
0.77 3.65 1.61 28.8 
                                               BRAIN/PLASMA RATIO 
AUCBrain/ 
AUCPlasma 
0.42 1.61 0.88 20.53 
DTI  3.9 2.1 48.9 
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Figure 4.1 (a): Plasma concentration-time profiles of sunitinib after a single oral dose 
(20 mg/kg) in FVB wild-type, Mdr1a/b(-/-), Bcrp1(-/-) and Mdr1a/b(-/-)Bcrp1(-/-) mice 
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Figure 4.1 (b): corresponding brain concentration-time profiles of sunitinib after  
a single oral dose (20 mg/kg) in FVB wild-type, Mdr1a/b(-/-), Bcrp1(-/-)   
and Mdr1a/b(-/-)Bcrp1(-/-) mice 
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Figure 4.1 (c): Brain-to-plasma ratios with time in wild-type, Mdr1a/b(-/-), Bcrp1(-/-)  
and Mdr1a/b(-/-)Bcrp1(-/-) mice 
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4.3.2     STEADY STATE PLASMA AND BRAIN DISTRIBUTION OF SUNITINIB 
An intraperitoneal infusion was employed to clearly elucidate the influence of active 
efflux by P-glycoprotein and Bcrp on the BBB penetration of sunitinib at steady state. In 
a system that exhibits linear distribution characteristics, the steady-state tissue-to-plasma 
concentration ratio should be equivalent to the tissue-to-plasma AUC ratio. The infusion 
was administered at a constant rate of 30 µg/hr and the plasma and brain concentrations 
were determined 48 hours (15-20 half-lives) after the start of infusion in wild-type, 
Mdr1a/b(-/-) mice, Bcrp1(-/-) mice and Mdr1a/b(-/-)Bcrp1(-/-) mice. The steady-state 
plasma concentrations were not significantly different from each other in the four 
genotypes, and ranged from 0.195 ± 0.186 µg/mL to 0.264 ± 0.086 µg/mL; another 
indication that P-gp and Bcrp do not influence the apparent clearance of sunitinib from 
plasma (Figure 4.2 (a)). This is in agreement with the single oral dose study where the 
apparent clearance of sunitinib is also not altered by active efflux. However, the steady-
state brain concentration in the wild-type mice was significantly lower (0.09 ± 0.07 
µg/gm) than that observed in the triple knockout mice (4.46 ± 1.66 µg/gm) (p < 0.05). 
When compared to wild-type mice, the brain steady-state concentrations were not 
different in the Bcrp1(-/-) mice (0.09 ± 0.04 µg/gm), but were 4.3-fold higher in 
Mdr1a/b(-/-) mice (0.39 ± 0.36 µg/gm, p < 0.05) (table 4.2, Figure 4.2 (b)). The steady-
state brain-to-plasma ratio was 2.33 ± 0.56 in Mdr1a/b(-/-) mice and 0.73 ± 0.44 in 
Bcrp1(-/-) mice, whereas, in the Mdr1a/b(-/-)Bcrp1(-/-) mice it was 17.44 ± 5.08, a 34-
fold increase in sunitinib brain distribution when both of the transporters are absent. 
These steady-state data indicate that a single deletion of either P-gp or Bcrp does not 112  
    
impact sunitinib brain distribution to a great extent, however deletion of both transporters 
result in a significant increase in sunitinib brain distribution (figure 4.2 (c)).  
 
 
Table 4.2:  Steady state plasma and brain concentrations of sunitinib in wild-type, 
Mdr1a/b(−/−), Bcrp1(−/−), and Mdr1a/b(−/−)Bcrp1(−/−) mice after a constant 
intraperitoneal infusion of sunitinib at a rate of 30 µg/hr for 48 hrs (n =4 each group). 
*Data presented as mean ± S.D., #P < 0.005 compared to wild-type.  
 
Genotype *Plasma Css (µg/ml) *Brain Css 
(µg/gm) 
Brain-to-plasma ratio 
FVB-wild type 0.19 ± 0.16 0.09 ± 0.06 0.51 ± 0.26 
Mdr1a/b(-/-) 0.18 ± 0.15 0.39 ± 0.36 2.33 ± 0.56# 
Bcrp1(-/-) 0.19 ± 0.19 0.09 ± 0.04 0.73 ± 0.44 
Mdr1a/b(-/-)Bcrp1(-/-) 0.26 ± 0.09 4.46 ± 1.66# 17.44 ± 5.08# 
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Figure 4.2: (a) steady-state plasma concentrations of sunitinib after a continuous 
intraperitoneal infusion at 30 µg/hr for 48 hrs in wild-type, Mdr1a/b(-/-), Bcrp1(-/-)  
and Mdr1a/b(-/-)Bcrp1(-/-) mice; (b) corresponding steady-state brain concentrations 
of sunitinib in wild-type, Mdr1a/b(-/-), Bcrp1(-/-) and Mdr1a/b(-/-)Bcrp1(-/-) mice; (c) 
steady-state brain-to-plasma ratios of sunitinib 
  Data represented as Mean ± S.D. 
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These results are in agreement with the previous report by Tang et al. (Tang et al., 2012). 
The authors reported sunitinib brain distribution across the same genotypes of mice at a 
single time point (6 hr post oral dose). Since the efflux clearance from brain depends on 
the relevant efflux transporters available [i.e., present (WT) vs. absent (transgenic 
knockout mice)], determination of brain-to-plasma ratio at a single time point may lead to 
significant errors, depending on the time point and the distribution kinetics of the drug 
(Wang, 2011). Further, if the chosen time point does not represent a steady state, then the 
brain-to-plasma ratio will change with time until pseudo-distributional equilibrium is 
achieved in the terminal phase (see Figure 4.1 (c)). However, it is important to note that, 
after a single dose or intermittent multiple dosing, the steady-state condition for brain 
distribution can be approximated by a transient steady state in the brain, which will occur 
at a specific time that corresponds to the maximum concentration in the brain (peak brain 
concentration) relative to the plasma concentration at that same time (Tmax of drug in 
brain). Determination of tissue distribution at a single time point can however, be done at 
transient steady-state, that is, when the drug concentration in the target tissue is at 
maximum (Cmax, tissue). At this point, the rate of change of drug concentration in the target 
tissue, which in this case, is the brain, is equal to zero, implying that the rate into the 
brain is at pseudo-distributional equilibrium with the rate out of the brain. In our results, 
we observed that the steady-state brain-to-plasma concentration ratio (Css brain/Css plasma) in 
all four genotypes was similar to the corresponding brain-to-plasma partition coefficient 
(Kp) observed after oral dose (AUCbrain/AUCplasma), which in turn was comparable to that 
obtained at transient steady-state (Cbrain, max/Cplasma), and at 1 hr post oral dose (Cbrain, 1 hr  
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po/Cplasma, 1 hr po) in all genotypes. (Table 4.3).   
 
 
Table 4.3: Brain-to-plasma ratios of sunitinib in all genotypes after a single oral dose 
(20 mg/kg), steady state concentration ratios after a continuous intraperitoneal 
infusion (rate equal to 30 µg/hr), at transient steady state (calculated as the maximum 
brain concentration to the corresponding plasma concentration in each genotype) and 
concentration ratios determined at 1 hr post oral dose (20 mg/kg)  in each genotype. 
Data presented as mean ± S.D.  
 
Genotype AUC0∞ 
p.o. 
Css steady-
state i.p. 
Transient 
steady-state 
Ratio at 1 hr 
FVB-wild type 0.42 0.51 ± 0.26 0.66 ± 0.17 0.42 ± 0.09 
Mdr1a/b(-/-) 1.61 2.33 ± 0.56 2.42 ± 1.42 1.76 ± 0.65 
Bcrp1(-/-) 0.88 0.73 ± 0.44 1.09 ± 0.38 0.24 ± 0.20 
Mdr1a/b(-/-)Bcrp1(-/-) 20.53 17.44 ± 5.08 12.83 ± 1.26 8.14 ± 3.47 
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4.3.3    INHIBITION OF P-GP AND BCRP INFLUENCES THE BRAIN 
DISTRIBUTION OF SUNITINIB 
In the past, many research groups have employed two approaches to delineate the 
contribution of efflux transporters in drug delivery to the CNS: 1) a genetic approach 
with the use of genetically knockout transgenic mice, and 2) pharmacological inhibition 
of P-gp and Bcrp at blood-brain barrier (Wang et al., 2012).  
In this study, we have compared the above approaches by comparing the brain-to-plasma 
concentration ratio at 1 hr (plasma Tmax in wild-type, Table 4.1) after an oral dose of 20 
mg/kg sunitinib in genetically knockout mice (Mdr1a/b(-/-), Bcrp1(-/-) and Mdr1a/b(-/-
)Bcrp1(-/-)) to the wild-type mice that were administered pharmacological inhibitors of 
these two efflux transporters. Genetic deletion of transporters resulted in a drug targeting 
index at a single time point, 1 hr of 0.5 in Bcrp knockout mice, 3.7-fold in P-gp knockout 
mice and 17.3-fold in triple knockout mice. Administration of pharmacological inhibitors 
did not influence the plasma concentration of sunitinib at this time point (Figure 4.3 (a)), 
however significant differences were observed in the brain concentrations (Figure 4.3 
(b)). A specific Bcrp inhibitor (Ko-143, 10 mg/kg) and a specific P-gp inhibitor 
(zosuquidar, LY335979, 25 mg/kg) resulted in brain targeting of 0.9-fold and 3.5-fold, 
respectively. In addition, a 12-fold increase in brain targeting of sunitinib was observed 
on administration of the dual P-gp/Bcrp inhibitor (elacridar, GF120918, 10 mg/kg). The 
brain targeting of sunitinib using these pharmacological inhibitors was comparable to that 
observed with the transgenic mice (Figure 4.3 (c)).  
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Figure 4.3 (a): plasma concentrations of sunitinib at 1 hr post oral dose (20 mg/kg) in 
wild-type mice after administration of selective P-gp inhibitor (LY335979 (25 mg/kg)), 
selective Bcrp inhibitor (Ko-143 (10 mg/kg)), both LY335979 and Ko143, and dual P-
gp/Bcrp inhibitor (elacridar (10 mg/kg)), selective P-gp inhibitor in Bcrp1(-/-) and 
selective Bcrp inhibitor in Mdr1a/b(-/-)  mice. The plasma concentrations with 
pharmacological inhibition are compared at 1 hr in transgenic transporter-deficient 
mice 
 
 
 
 
118  
    
Figure 4.3 (b): Corresponding brain concentrations of sunitinib in the treatment group 
at 1 hr post oral dose (20 mg/kg) in wild-type mice after administration of selective P-
gp inhibitor (LY335979 (25 mg/kg)), selective Bcrp inhibitor (Ko-143 (10 mg/kg)), both 
LY335979 and Ko143, and dual P-gp/Bcrp inhibitor (elacridar (10 mg/kg)), selective P-
gp inhibitor in Bcrp1(-/-) and selective Bcrp inhibitor in Mdr1a/b(-/-)  mice. The brain 
concentrations with pharmacological inhibition are compared at 1 hr in transgenic 
transporter-deficient mice 
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Figure 4.3 (c) corresponding brain-to-plasma ratios of sunitinib at 1 hr post oral dose 
(20 mg/kg) in wild-type mice after administration of selective P-gp inhibitor (LY335979 
(25 mg/kg)), selective Bcrp inhibitor (Ko-143 (10 mg/kg)), both LY335979 and Ko143, 
and dual P-gp/Bcrp inhibitor (elacridar (10 mg/kg)), selective P-gp inhibitor in Bcrp1(-
/-) and selective Bcrp inhibitor in Mdr1a/b(-/-)  mice.  
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Importantly, the current study examines the effect of the specific P-gp inhibitor, 
zosuquidar, in Bcrp1(-/-) mice, and the specific Bcrp inhibitor, Ko-143, in Mdr1a/b(-/-) 
mice on sunitinib brain distribution. Further, simultaneous inhibition of P-gp and BCRP 
was achieved by administration of both zosuquidar and Ko-143 to the FVB wild-type 
mice. The plasma and brain concentrations from these mice were determined at 1 hr post 
oral dose of 20 mg/kg sunitinib. The brain-to-plasma ratio was 1.8 in Mdr1a/b(-/-) mice 
who received Ko-143, while the brain-to-plasma ratio in Bcrp1(-/-) mice who received 
zosuquidar was 3.6. However, the cohort of wild-type mice that received both zosuquidar 
and Ko-143 had a brain-to-plasma ratio of 3.7, where the group that received elacridar 
and Mdr1a/b(-/-)Bcrp1(-/-) mice, had a brain-to-plasma ratio of 5.6 and 8.1, respectively 
(Figure 4.3, table 4.4).  
These results show the correlation between the use of selective and non-selective 
pharmacological transport inhibitors and specific genetic deletion of transporters in the 
brain distribution of sunitinib. This agreement between the two approaches also indicates 
that, for sunitinib, it is likely that Ko143 and LY335979 are truly selective for the 
inhibition of Bcrp and P-gp, respectively. Moreover, in this regard, we have previously 
determined (Agarwal et al., 2012) via quantitative proteomics approach that genetic 
deletion of P-gp and Bcrp does not influence the expression of several transport systems 
at the BBB and P-gp or Bcrp do not compensate for the loss of one another by up-
regulation of the other’s expression in the BBB.  
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Table 4.4: Comparison of brain-to-plasma ratio of sunitinib in transgenic transporter 
deficient mice and in FVB-wild type treated with specific P-gp and/or Bcrp inhibitors. 
 
Pharmacological Inhibition Genetic Deletion 
 Mean ± SD  Mean ± SD 
Wild-type 0.47 ± 0.18 Wild-type 0.47 ± 0.18 
Wild-type+ LY335979 1.64 ± 0.57 Mdr1a/b(-/-)  1.76 ± 0.65 
Wild-type + Ko-143 0.42 ± 0.24 Bcrp1(-/-)  0.24 ± 0.20 
Wild-type + elacridar 
Wild-type + LY335979 + 
Ko143 
Mdr1a/b(-/-) + Ko143 
Bcrp1(-/-) + LY335979 
5.63 ± 2.33 
 
3.71 ± 2.37 
1.81 ± 0.59 
3.56 ± 2.08 
 
 
Mdr1a/b(-/-)Bcrp1(-/-) 
 
 
8.14 ± 3.47 
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4.4       DISCUSSION 
The objective of this study was to investigate and pharmacokinetically assess 
mechanisms that limit brain distribution of sunitinib for the treatment of glioblastoma 
multiforme (GBM). Gliomas are fatal brain tumors characterized by high degree of 
microvascular proliferation with endothelial cell migration. A highly invasive tumor, the 
cells have a strong tendency to migrate in other parts of the brain and hide beneath an 
intact BBB (Agarwal et al., 2011a). It is therefore important to achieve adequate drug 
concentrations across the BBB, in the brain parenchyma, to target the tumor cells that 
reside in the growing edge of the tumor as well as in the distant sites of the brain. 
Previous preclinical investigations have suggested that efflux transporters, P-gp and Bcrp, 
limit the delivery of several anti-cancer agents into the brain. In the current study, we 
have examined the influence of P-gp and Bcrp, in restricting the brain distribution of 
sunitinib in the FVB strain; wild type, Mdr1a/b(-/-), Bcrp1(-/-)and Mdr1a/b(-/-)Bcrp1(-/-) 
mice using novel pharmacokinetic tissue distribution assessment methods, and proposed 
strategies to improve its delivery across BBB based on efflux transport inhibition. 
 
Sunitinib is a multi-targeted tyrosine kinase inhibitor with activity against VEGFR 1-3 
and PDGFR-α/β, in addition to other regulators of tumor growth and angiogenesis 
(Christensen, 2007). As a pan-inhibitor of VEGFR, particularly VEGFR2, sunitinib 
represents an attractive treatment option as an anti-angiogenic drug in the therapy of 
glioma. However, clinical trials using sunitinib (Neyns et al., 2011; Pan et al., 2012) and 
several molecularly targeted agents (e.g., cediranib, pazopanib, vandetanib) have shown 
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to be unsuccessful in GBM therapy (Batchelor et al., 2010; Iwamoto et al., 2010; Kreisl 
et al., 2012). This may be due in part to the limited delivery of these agents across BBB 
(Minocha et al., 2012a; Wang et al., 2012). 
 
To quantify the influence of efflux transporters, P-gp and Bcrp, on the brain distribution 
of sunitinib, we performed oral pharmacokinetic studies in FVB mice, wild-type, 
Mdr1a/b(-/-), Bcrp1(-/-) and Mdr1a/b(-/-), Bcrp1(-/-). Plasma and brain concentration-
time profiles were determined in all the four groups. AUC 0-∞, plasma were not different 
amongst all four genotypes; however, AUC 0-∞, brain were different amongst all groups. 
Although sunitinib showed substantial partitioning into the brain (Kp = 0.42), deletion of 
both P-gp and Bcrp resulted in an AUC brain-to-plasma ratio of 20.5. Single deletion of 
P-gp or Bcrp had a little influence on the brain distribution of sunitinib; however, a 
notable difference was observed in the absence of both these transporters. This suggest 
that both P-gp and Bcrp act in a concerted fashion to limit the brain distribution of 
sunitinib (Table 4.1, Figure 4.1). The drug targeting index (DTI) of sunitinib for the 
brain was 3.9 in Mdr1a/b(-/-) mice and 2.1 in Bcrp1(-/-) mice. The DTI in Mdr1a/b(-/-
)Bcrp1(-/-) mice was 48.9, indicating a significant role of both P-gp and Bcrp on 
sunitinib’s brain distribution. 
 
Further, to examine the penetration of sunitinib across the BBB, we determined the 
steady state brain-to-plasma ratios (Css, brain/Css, plasma) in wild type and transgenic 
transporter-deficient mice using a continuous intraperitoneal infusion lasting 48 hours. 
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Although, the plasma concentrations at steady state were not different among all groups, 
suggesting that the systemic distribution of sunitinib is not influenced by active efflux via 
P-gp and Bcrp, the steady-state brain concentrations were significantly greater in the 
group that lacked both P-gp and Bcrp (p < 0.05) (Figure 4.2, Table 4.2). The steady state 
brain-to-plasma ratios in wild type, Mdr1a/b(-/-), Bcrp1(-/-) and Mdr1a/b(-/-)Bcrp1(-/-) 
mice were 0.51 ± 0.26, 2.33 ± 0.56, 0.73 ± 0.44 and 17.44 ± 5.08, respectively. These 
ratios are comparable to the corresponding AUC brain-to-plasma ratios determined after 
a single oral dose (Table 4.3).  
 
Earlier, Tang et al. reported the influence of P-gp and Bcrp on the brain distribution of 
sunitinib (Tang et al., 2012) across the transporter-deleted genotypes of mice, at 6 hr post 
single oral dose. Estimation of true drug partitioning into a tissue at a single time point 
can misguide interpretation of the effect of efflux transport on tissue distribution, 
depending on the chosen time point and the differences in the distributional kinetics of 
the drug under investigation. Characterization of brain distribution at a transient steady 
state can be considered to be an estimate of the steady-state tissue partitioning since it is 
at that point in time when the rate of drug entry into the brain is equal to the rate out of 
the brain (Table 4.3). Estimation of the brain-to-plasma distribution using a single time 
point before or after attainment of Cmax brain can lead to an under- or over-estimation of the 
true tissue (brain) partition coefficient.  Therefore, determining brain distribution at only 
one time point may be misleading depending on when the brain/plasma concentration 
ratio is determined, which is dependent on when the brain is sampled. Riad et al. have 
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earlier studied this “transient steady state” approach for carbamazepine metabolites in 
humans (Riad et al., 1993). In our study, we found that the AUC brain-to-plasma ratio 
after single oral dose was similar to both the steady-state brain-to-plasma ratio and the 
brain-to-plasma ratio at a transient steady state (Table 4.3).   
 
Besides using transporter knockout mice, we also studied the effect of administering 
specific P-gp or Bcrp inhibitors and a dual inhibitor of P-gp and Bcrp on the plasma and 
brain concentration of sunitinib at 1 hr post oral dose of sunitinib. Results from this study 
indicated that plasma concentrations were not different at 1 hr in all treatment groups 
(Figure 4.3 (a)) and brain concentrations were not different in the cohorts that received 
specific P-gp inhibitor, zosuquidar, and specific Bcrp inhibitor, Ko-143. However, a ~12 
fold increase in the brain-to-plasma ratio was observed in the group of mice that received 
dual P-gp and Bcrp inhibitor, elacridar. These findings were comparable to that observed 
with the knockout mice (Figure 4.3 (b) and (c), Table 4.4).  
 
The results from this study warranted further investigation on the potential role of P-gp 
and Bcrp in mediating the active efflux of sunitinib from brain. To examine this, we 
administered specific P-gp inhibitor to Bcrp1(-/-) mice and specific Bcrp inhibitor to 
Mdr1a/b(-/-) mice. Additionally, we also administered both zosuquidar and Ko-143 to 
wild type mice and determined plasma and brain concentrations of sunitinib at 1 hr. To 
the best of our knowledge, this is the first time that such an approach has been employed 
to understand the role of P-gp and Bcrp in the distribution of sunitinib. The results from 
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this study confirmed our results from the single oral dose study and steady-state 
distributional kinetics, i.e., that sunitinib is actively effluxed by both P-gp and Bcrp at the 
BBB. It is important to note here that the brain-to-plasma concentration ratio of sunitinib 
in the groups of mice receiving pharmacological inhibitors for both P-gp and Bcrp were 
not significantly different from the single knockout mice receiving specific P-gp or Bcrp 
inhibitor and the corresponding transgenic mice (Figure 4.3 (c)). The concordance 
between these approaches (use of transgenic mice vs. pharmacological inhibitors) to 
determine the impact of efflux transport via P-gp and Bcrp on the brain distribution of 
sunitinib suggests that pharmacological inhibition can be used as an effective tool to 
improve the brain distribution of sunitinib for the treatment of glioma. Recently, 
Kunimatsu and colleagues reported a similar phenomenon on greater accumulation in the 
brain on dual inhibition of efflux transport in rats (Kunimatsu et al., 2013). This is 
important since tailored-chemotherapy with sunitinib in an anaplastic meningioma patient 
expressing PDGFR-β failed to show desirable efficacy (Yoshikawa et al., 2012). It is 
therefore important to understand that in addition to the intended molecular target, issues 
related to effective drug delivery are pertinent in treatment of brain tumor.  
 
In conclusion, we have shown that sunitinib has limited penetration into the brain due to 
the presence of active efflux mediated by both P-gp and Bcrp at the BBB. Single deletion 
of P-gp or Bcrp does not play a significant role as compared to dual P-gp and Bcrp 
deletion, indicating a simple functional compensation between these two transporters at 
the BBB in restricting the brain distribution of sunitinib. We also showed here that the 
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tissue partition coefficient obtained after single oral dose calculated by the AUC brain-to-
plasma ratio is similar to the brain-to-plasma steady-state concentration ratios, which 
would be expected for non-saturable, linear distributional kinetics. Furthermore, 
determination of the extent of brain distribution of sunitinib can be determined at a single 
time point, provided that at the chosen time point, is the time in which a transient steady 
state is attained between the plasma and the brain. This will occur at a time when the 
brain concentration reaches a maximum following a single dose. Relying on a single time 
point not at this transient steady state to determine the brain partition coefficient can lead 
to significant errors, and complicate the comparison of several studies. Moreover, 
administration of selective inhibitors of active efflux as well as dual inhibitor of efflux 
transporters resulted in enhanced brain penetration of sunitinib; in concordance with that 
observed in transgenic mice. These results can be of clinical significance to improve the 
brain delivery of sunitinib to areas of tumor cells that lie hidden beneath an intact BBB 
that has active P-gp and Bcrp transport systems. 
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CHAPTER  V 
 
 
 
NON-LINEAR MIXED EFFECT MODELING OF 
SERIAL SACRIFICE DATA: SENSITIVITY 
ANALYSIS OF SAMPLE SIZE AND BETWEEN 
SUBJECT VARIABILITY FOR BRAIN 
DISTRIBUTION STUDIES  
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Preclinical pharmacokinetic studies in rodents are often limited by the number of samples 
that can be withdrawn to one sample (plasma and corresponding tissue) per subject. In 
this one point per animal design, a naïve-pooled approach is often used to estimate AUCs 
in tissue and plasma and the AUC ratio is used to estimate distribution coefficients (Kp). 
Such ratios ignore within-animal correlations; in addition, they are not associated with 
any statistical certainty. The goals of this study were: (1) to determine the uncertainty 
associated with ratios of exposure, Kp; (2) examine bias and precision in evaluating the 
influence of between- subject variability (BSV) and sample size at each time point on 
estimation of Kp. We used a model drug, sunitinib, to study this approach. 
 
Model: NONMEM VII was used for estimations. Sunitinib has restricted delivery into the 
brain via efflux mechanisms mediated by P-glycoprotein (P-gp) and breast cancer 
resistance protein (Bcrp). However, uncertainty in Kp values was not obtained using 
conventional trapezoidal method for estimation of area under the concentration-time 
curve from time 0 to infinity (AUC0-∞). Datasets consisted of plasma (Cpl) and brain 
(Cbr) concentrations after single oral dose (20 mg/kg) and steady-state concentrations 
(obtained after a continuous intraperitoneal infusion at a rate of 30 µg/hr) of sunitinib. A 
one-compartment model described Cpl which was used as forcing function to describe 
Cbr. BSV was fixed to 20% for all parameters. Simulations: PsN was used for all 
simulations. Influence of sample size at each time point (n = 2, 3, 4, 8, 12) and BSV 
(10%, 20%, 40%) on bias and precision of Kp was evaluated.  
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The predicted plasma and brain concentrations from the model adequately described the 
observed values. The Kp ratios were found to be comparable to naïve-pooled method. 
The values of Kp were relatively insensitive to assumptions regarding BSV. Bias was 
<1% for levels of BSV and sample size tested. Precision improved with sample size. 
  
Population-based approach for serial-sacrifice data provides variability on AUC-based 
parameters for statistical evaluation. Assumptions’ regarding magnitude of BSV and 
sample size does not influence parameter estimates but affects precision.  
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5.1 INTRODUCTION 
Preclinical pharmacokinetic and toxicokinetic studies are an essential part of the early 
drug discovery stage and are usually conducted with a set of guidelines in a homogenous 
population of animals, both rodent and non-rodent species.  The goal is to investigate the 
disposition of the drug with the primary motive being able to determine its exposure. In 
large non-rodent species (e.g., monkeys and dogs), serial sampling allows for collection 
of more than one sample per subject. However, this is not the case in rodents (e.g., rats 
and mice). Usually, the number of samples that can be obtained is limited to one sample 
per time point per subject. This kind of sampling procedure is called as a serial-sacrifice 
design or ‘quantic’ design (Ette et al., 1995a). A major disadvantage of this procedure is 
that intra-individual concentration-time course data are not available; hence, estimation 
of inter-animal variability is a challenge. Conventionally, to determine exposure as the 
area under the concentration time curve (AUC), concentrations are averaged at each time 
point and an AUC is calculated using the trapezoidal rule. This is called the naïve data 
averaging approach and is commonly conducted using a non-compartmental analysis 
(NCA).  
 
In a tissue distribution study, the primary goal is to determine the tissue distribution 
coefficient (commonly referred to as Kp, tissue).  Kp is determined by obtaining the ratio of 
AUC0-inf in tissue and the plasma AUC0-inf. In a serial sacrifice design, one set of paired 
plasma and tissue concentrations are contributed from each animal. The analysis of this 
type of data becomes statistically complicated because the within-animal correlation in 
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the data is ignored when data are averaged in the naïve data pooling approach. Another 
shortcoming of this method is that a measure of uncertainty associated with the tissue 
distribution coefficient is not readily calculated. This leads to an inability to statistically 
compare treatments or groups of animals. A third drawback of this method is that we are 
unable to estimate inter-animal variability, as we do not obtain intra-individual 
concentration-time profiles.  
 
Non-linear mixed effect modeling (NLME) approaches have gained wide acceptance as a 
useful tool to determine population pharmacokinetic (PopPK) and pharmacodynamic 
(PD) parameters for sparse data. In the past, attempts have been made to analyze 
‘quantic’ data using these approaches (Hing et al., 2001) and comparisons have been 
made with the noncompartmental analysis approach. It has been reported and shown 
through simulations that the NLME approach offers a more robust method for estimation 
of population PK parameters (eg., CL and V) (Ette et al., 1995b). Most of the earlier 
analyses focused on modeling the plasma concentration-time profile data, with exception 
of a few that considered analysis of both plasma and tissue, although separately. In 
NLME, variability or randomness in parameter estimates is partitioned into between-
subject variability (BSV, or inter-animal variability) and residual-unexplained variability 
(RUV, a pooled measure of remaining variability, e.g., analytical variability and model 
misspecification error). In a serial-sacrifice design, it is not possible to distinguish both 
types of variability because deviation between an observed and predicted concentration 
could be due to either BSV or RUV and probably both. Hence, the value of one type is 
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assumed known and fixed, allowing estimation of the other (Hing et al., 2001). It is of 
concern to understand the sensitivity of NLME when variability of one type is assumed 
known vs. the other type. In previous attempts, RUV has often been assumed constant to 
a value (10% (Hing et al., 2001) or 15% (Ette et al., 1995a)) often close to the lowest 
limit of quantification of the analytical assay method or slightly higher, implying that 
RUV is primarily determined by assay error, while BSV was estimated. While this 
approach does have merit, the situation becomes more complicated with two types of 
outputs (e.g., drug and metabolite or plasma and brain concentrations, or concentration 
and effect) being measured.  While it is obvious that each type of measurement might 
have different analytical errors associated with it, it is not clear how to ascribe RUV 
when the two types of measurements also includes different extents of model 
misspecification.  The limitations of currently employed analysis methods (e.g., NCA) 
and assumptions from previous methods (e.g., fixing RUV while estimating BSV in 
NLME) led us to seek answers to key questions pertaining to the need for and 
implications of obtaining variability around a point estimate.  
 
The current investigation was motivated by the results obtained from the brain 
distribution study of sunitinib in FVB-wild type, Mdr1a/b(-/-) (P-gp knockout), Bcrp1(-/-
) (Bcrp knockout) and Mdr1a/b(-/-)Bcrp1(-/-) (triple knockout) (Oberoi et al., 2013). 
Previously we have conducted this study to evaluate the influence of efflux transporters 
on the brain distribution of sunitinib by estimation of the brain-tissue distribution 
coefficient for each genotype. In our model, between-subject variability (inter-animal 
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variability) was assumed constant and residual unexplained variability was estimated. 
Further, we examined the influence of the assumed magnitude of BSV at three levels 
(low, medium, high) and the sample size at each time point (small to large) on the 
estimation of the tissue distribution coefficient for each genotype by stochastic 
simulations and estimations (see methods section).  
 
 
5.2     METHODS 
Model development was performed by nonlinear mixed effects modeling using 
NONMEM® software (version 7.2, Icon Development Solutions, Ellicott City, MD, 
USA) in conjunction with Visual Fortran compiler (Professional Edition for Windows 
11.1, Intel®) and PdxPop (Version 5.1, ICON Development Solutions). Additionally, 
stochastic simulations and estimations were performed using Perl speaks NONMEM® 
(version 3.5.3, http://psn.sourceforge.net/) and Pirana® (version 2.5.0, 
http://www.pirana-software.com/). R-Studio® (version 2.15.0, http://r-project.org/) was 
used for graphical presentation.  
 
 
5.2.1        MOTIVATING EXAMPLE 
The objective of this study was to determine uncertainty associated with the tissue 
partition coefficient (in this case, the tissue is the brain; hence, the brain partition 
coefficient) in a serial sacrifice design and compare our proposed method to the approach 
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traditionally employed, that is, naïve-data averaging approach or noncompartmental 
analysis (NCA).   
 
Briefly, the data set consisted of plasma and brain concentrations of sunitinib from two 
separate studies conducted in FVB-wild type, Mdr1(-/-), Bcrp1(-/-) and Mdr1a/b(-/-
)Bcrp1(-/-) mice.  
 
Study 1 consisted of plasma and brain concentrations obtained after a single oral dose of 
20 mg/kg.  Mice were sacrificed at pre-determined time intervals 0.5, 1, 2, 4, 6, 11, 16 
and 22 hours (n=3 or 4 at each time point).  Study 2 consisted of plasma and brain 
concentrations obtained after a continuous intraperitoneal infusion at a rate of 30 μg/hr 
for 48 hours (n=4 in each group). Therefore, each animal contributed one plasma and 
corresponding brain concentration. Brain distribution coefficient, Kp, was incorporated as 
a parameter into the model. 
 
From the given data set, plasma and brain concentrations at each time point were 
averaged to obtain a mean value. Using trapezoidal rule, area under the concentration 
time profile from time 0 to time infinity (AUC0-inf) was obtained. This method resulted in 
a single value of AUC plasma and AUC brain. Kp, the distribution coefficient, was 
obtained as the ratio of AUC0-inf brain-to-plasma. This approach is also called as naïve 
data-averaging approach and results in a single estimate of Kp, without an estimate of 
variability. 
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Non compartmental analysis of these data have been reported previously (Oberoi et al., 
2013) and the results are summarized in Table 5.1. 
 
 
5.2.2        PHARMACOKINETIC AND STATISTICAL MODEL 
A pharmacokinetic model (Figure 5.1) with first order rate of absorption was specified to 
simultaneously explain the plasma and brain concentration-time course data.  The PK 
model consisted of two inputs, one as a single oral dose and another as a continuous 
intraperitoneal infusion. The brain concentration-time course was modeled using the 
plasma concentrations as a forcing function, thus maintaining within-animal correlations.  
 
The plasma concentration time course after a single oral dose and intraperitoneal infusion 
was explained by a set of differential equations (see appendix). Here, C(p) = plasma 
concentration and C(br)= brain concentrations. CL/F and V/F are apparent oral clearance 
and apparent oral volume of distribution and follows normal distribution with variance 
σ2, ~Ν(CL/F, σ2 CL/F) and ~Ν(V/F, σ2 V/F).  F is the relative oral bioavailability determined 
relative to i.p. infusion. A common absorption rate constant, Ka, was assumed for the 
model. Since our goal was to determine the brain distribution coefficient, we incorporated 
Kp as a parameter in our model where Kp followed normal distribution with variance σ2, 
~Ν(Kp, σ2 Kp).  CLout was parameterized in terms of Kp and CLin.  The PK model was 
built using NONMEM subroutine ADVAN6 and differential equations were written to 
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simultaneously model plasma and brain concentrations. A complete schematic of the 
model is provided in Figure 5.1. 
 
A first order conditional estimation method (FOCE) was utilized to obtain population 
parameter estimates.  Between-subject variability (BSV) in parameters (ØI) was modeled 
using exponential error model following normal distribution with mean zero and variance 
σ2 as shown below: 
                           
                                  ØI = TVØ*exp(eta);   eta~ Ν(0, ω2 theta),  
 
where TVØ is the typical value of the parameter in the population. The variance (ω2) was 
fixed to 20% for all the parameters in the current model.  
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Figure 5.1:  Schematic representation of the hybrid-population pharmacokinetic model 
with first order rate of absorption from the gut and peritoneum to simulatenously 
describe plasma and brain concentration-time profile. Plasma concentrations were 
defined as a one-compartment model and were used as a forcing function to explain 
the brain concentrations. The brain distribution coefficient (Kp) is defined as 
CLin/CLout. 
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Error model: 
Plasma and brain concentrations were modeled separately using proportional error model 
for each tissue such that observed concentration Cobs is given by 
 
                             Cobs = Cpred*exp (ε) 
 Where ε is assumed to follow normal distribution with mean zero and variance σ2.  
 
 
5.2.3        DATA ANALYSIS USING NONMEM 
We had 127 each plasma and brain concentrations. Non-linear mixed effects modeling 
approach was implemented in NONMEM (ADVAN6, TRANS1, TOL5, FOCE-
estimation method) to simultaneously model sunitinib plasma and brain concentrations. A 
one-compartment model with a common first order rate of absorption from gut and 
peritoneum with first order rate of elimination from the central compartment was 
employed to model plasma concentrations. Brain concentrations were defined by a CLin 
and a CLout of the brain compartment. The plasma concentration was the driving force for 
the rate into the brain compartment. The model was parameterized in terms of apparent 
oral clearance (CL/Fabs), apparent volume of distribution (V/Fabs), a clearance in (CLin), 
relative bioavailability (Frel) and brain-partition coefficient (Kp). Variability in the PK 
parameters was modeled as  
                                                             Θ = TVΘ * exp(ηΘ), 
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 where TVΘ is the typical value of the parameter and η ~ N(0, ω2). 
 
We investigated the effect of genotype on Kp, by performing a step-wise covariate 
analysis where the covariate was the genotype. With prior knowledge that plasma and 
brain concentrations were obtained from four genotypes, wild-type, Mdr1(-/-), Bcrp1(-/-) 
and Mdr1(-/-)Bcrp1(-/-), we performed our analysis by removing each group one at a 
time with wild-type as reference and observing the increase in OFV (> 10.83 at p-value < 
0.001). (a) In the first step, the OFV of the final model (four genotypes as covariates on 
Kp) was estimated. Subsequently, the effect of genotype was analyzed using following 
procedure: (b) all the knockout animals (Mdr1(-/-)Bcrp1(-/-), Bcrp1(-/-) and Mdr1a/b(-/-
)) were combined into one group and estimated as a single Kp vs. the wild-type, (c) in the 
third step, Kp values for Mdr1a/b(-/-) and wild-type were estimated while (Mdr1(-/-
)Bcrp1(-/-) and Bcrp1(-/-) were combined into one group, (d) then Kp values for  Bcrp1(-
/-) and wild type were estimated while (Mdr1(-/-)Bcrp1(-/-) and Mdr1a/b(-/-) were 
combined into one group,  (e) in the last step, a single Kp was estimated for wild-type, 
Bcrp1(-/-) and Mdr1a/b(-/-) vs. the Kp of Mdr1a/b(-/-)Bcrp1(-/-).  
 
Our final model consisted of genotype added as a covariate on Kp. One of the 
assumptions we made was that all the animals are from the same homogenous population, 
therefore, inter-animal variability (BSV) is likely to be less than 50%. The residual 
unexplained variability (RUV) included not only different analytical errors for plasma 
and brain concentrations, but also differences in the extent of model misspecification. 
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Therefore, in this model, BSV was fixed to 20% and RUV was estimated for both plasma 
and brain concentrations. In order to assess our assumption on fixing BSV = 20%, we 
performed a sensitivity analysis for BSV from 2.5% to 40%. The effect of BSV on 
parameter estimates (accuracy and precision given by the point estimate and confidence 
interval, respectively) was determined. The results of Kp estimation obtained using 
NONMEM were compared to the values obtained using non-compartmental analysis 
method (Oberoi et al.). 
 
 
5.2.4         MODEL EVALUATION 
Model evaluation was performed using goodness of fit plots (prediction-based 
diagnostics and residual-based diagnostics) and simulation-based diagnostics (visual 
predictive check (VPC)). VPC was implemented within PsN. 500 new datasets were 
generated through simulations of the final model that described the central tendency and 
the variability in the observed data obtained through 10th and 90th percentile range.  
Furthermore, VPC plots were stratified according to genotype and compartment, plasma 
or brain.   
 
 
5.3          SIMULATIONS  
The purpose of the simulations was to answer two key questions; one, how does the 
magnitude of assumed between-subject variability influence estimation of brain partition 
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coefficient (Kp), and second, how does the sample size, that is, number of animals 
sacrificed at each time point influence estimation of Kp. In the current study, the model 
used was a one-compartment open model based on the PK model described above. 
 
Individual parameter values for CL, V, CLin and Kp were randomly generated by 
sampling from the population distribution for eta~ Ν(0, ω2 theta). The simulation study 
consisted of a data simulation model and a data analysis model. For the data simulation 
model, sample size at each time point (n= 2, 3, 4, 8, 12) was evaluated assuming BSV 
fixed at 20%.  The data analysis model was evaluated for 3 levels of  BSV (10%, 20%, 
40%), that is, the simulated data was estimated as 3 levels of BSV.    
 
The simulations were performed in Pirana using PsN employing stochastic simulations 
and estimations mode (SSE). SSE is a method that is employed for model comparison 
and hypothesis testing and gives insight to our models and model performance. In this 
study, we used SSE as a tool to evaluate model performance and our assumptions for 
BSV. We performed simulations on the input PK model with BSV fixed at 20% and then 
estimated all the simulated data sets for each sample size by varying the model 
paramaters for BSV to 10%, 20% or 40%.  
 
Varying sample size at each time point 
The simulated data set was generated at BSV=20% and each animal supplied one plasma 
and corresponding tissue observation. The number of animals studied at each time point 
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varied from low to high (n=2, 3, 4, 8, 12). The simulated data set was re-estimated for 
parameters at BSV=10%, 20% and 40%, thus making total of 15 scenarios that were 
investigated. The effect of sample size and inter-animal variability on estimation of bias 
(accuracy) and precision was investigated. 
 
5.4             ANALYSIS 
Since the value of the ‘true’ parameter was known in the simulations, bias and a metric of 
precision were estimated relative to the known true value. 
Bias was calculated as the mean prediction error (MPE) given as the relative difference 
between the known ‘true’ value and the ‘predicted’ value obtained from re-estimation of 
the simulated data for each scenario. Bias was reported as 
                         MPE = (predicted – true)/true 
 
A metric for precision was defined as a measure of error that could be tolerated in 
estimation of the parameter. We determined this metric of precision as the number of 
times the bias values were within ±5%, ±10% and ±20% of the known ‘true’ value and 
plotted for different sample sizes and BSV for each genotype. 
 
5.5             RESULTS 
5.5.1          CASE STUDY 
We have previously applied NCA approach to assess the brain distribution of sunitinib to 
the brain (Oberoi et al., 2013). To determine whether P-gp and/or Bcrp play a significant 
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role in the brain disposition of sunitinib, statistical evaluation between these Kp values 
needed to be evaluated. The objective of the current investigation was to determine the 
uncertainty associated with AUC-derived parameters such as the brain partition 
coefficient (Kp) in a serial sacrifice design. To achieve this goal, we employed a non-
linear mixed effect modeling approach to destructively sampled data. A hybrid 
pharmacokinetic model was applied to simultaneously explain plasma and brain 
concentration-time profile in all four genotypes. This method ensured that within-animal 
correlations were maintained. Table 5.1 displays the AUC brain-to-plasma ratios 
obtained from NCA and population analysis method. No measures of uncertainty around 
the estimates of Kp were obtained from NCA whereas the estimates of Kp from the 
population analysis method had associated estimates of precision. All parameter 
estimates obtained using NONMEM had relative standard error (RSE) % less than 20% 
and the values of point estimates were similar to those determined using NCA. These 
model-based results also suggest that both P-gp and Bcrp play a significant role in 
influencing the brain distribution of sunitinib. 
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Table 5.1:  Final parameter estimates of the brain distribution coefficient determined 
by noncompartmental analysis (NCA) and population based approach. RSE% = 
percent relative standard error, C.I.= 95% confidence interval = estimate ± 
1.96*(standard error of estimate ) (Oberoi et al., 2013). 
 
Model 
parameters 
Population estimate 
(%RSE) 
95% C.I. Parameter 
estimate (NCA) 
Kp wild type 0.402 (17) 0.27, 0.53                 0.42 
Kp Mdr1a/b(-/-) 2.02 (17) 1.36, 2.68        1.61 
Kp Bcrp1(-/-) 0.88 (16) 0.604, 1.15 0.88 
Kp Mdr1a/b(-/-) 
Bcrp1(-/-) 
17.6 (12) 13.3, 21.9 20.53 
Residual variability 
Proportional 
error- plasma 
73.8%  NA 
Proportional 
error- brain 
59.6%                    NA 
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We also evaluated our assumption of fixing the BSV to 20% in the model for evaluation 
of Kp using sensitivity analysis, wherein the BSV was tested across range from 2.5 % to 
40%. Table 5.2 displays the results from sensitivity analysis of varying BSV on the point 
estimate of Kp. The values obtained for Kp were similar across the range of BSV values 
tested with no clear trend in values as BSV increased. These results suggest that BSV has 
little impact on estimation of Kp in a serial sacrifice design.  
 
 
Table 5.2:  Sensitivity analysis of varying between-subject variability on point estimate 
of brain distribution coefficient, Kp determined by population-based approach. The 
estimates were compared to the values obtained by noncompartmental analysis (NCA). 
(Oberoi et al., 2013). 
  NCA 2.5% 5% 20% 30% 40% 
Kp- Wild type 0.42 0.394 0.394 0.402 0.382 0.35 
Kp- P-gp Knockout 1.61 2.1 2.11 2.02 1.87 1.56 
Kp- Bcrp Knockout 0.88 0.853 0.852 0.878 0.874 0.831 
Kp- Bcrp/P-gp 
knockout 
20.53 16.9 17 17.6 17.4 16.5 
Proportional error- 
plasma (%)  
84.3 82.4 73.8 67.5 41 
Proportional error- 
brain (%)  
74.5 73.1 59.6 49 40 
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5.5.2         MODEL EVALUATION 
The goodness of fit plots are shown in Figure 5.2. The model predicted plasma and brain 
concentrations in all four genotypes reasonably fit the observed data. Figure 5.2 (a) 
shows observed concentrations vs. model predicted concentrations. The individually 
observed plasma and brain concentrations, stratified by genotype indicated by color, do 
not deviate substantially from model predicted individual and population predicted 
concentrations (Figure 5.2 (b) and (c)).  
 
The conditional weighted residuals (CWRES) vs. time which is a weighted difference 
between observed and predicted suntinib concentrations, were randomly distributed 
around zero and were within 2 units from the zero-ordinate, indicating that the structural 
model plausibily fits the observed data.  
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Figure 5.2 (a):  Shows model predicted and observed concentrations in the plasma and 
brain of all four genotypes, wild-type, Mdr1a/b(-/-), Bcrp1(-/-) and Mdr1a/b(-/-)Bcrp1(-
/-).   
The black and red dots represent observed plasma and brain concentrations and the solid 
black and red lines indicate model predicted plasma and brain concentration-time profile. 
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Figure 5.2 (b):  Goodness-of-fit plots for the final hybrid pharmacokinetic model for 
plasma stratified (color-coded) by genotypes 
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Figure 5.2 (c):  Goodness-of-fit plots for the final hybrid pharmacokinetic model for 
brain stratified (color-coded) by genotypes 
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For the VPC, the observed data for all genotypes was simulated to form 500 new datasets 
using the same experimental design and parameter estimates. The 10th and 90th percentile 
of the simulated data were calculated and plotted against the observed concentrations. 
The 50th percentile of the median of the observed data and simulated data were plotted 
and compared as shown in figure 5.3. 
  
The visual predictive checks were stratified by tissue and genotypes. The lower bound 
predictions for the wild-type plasma showed a negative trend indicating that the lower tail 
of normal distribution predict concentrations that are below the lowest limit of 
quantification of the analytical method. Log-transformation of plasma data, use of 
exponential error model or restricting the predicted plasma concentrations to the lowest 
standard value are alternatives that have been suggested previously. However, we think 
such a modification could introduce bias in interpretation. The estimate of residual 
proportional error for plasma and brain are ~74% and 60%, respectively. Negative 
predictions of concentrations could also have been caused by high estimates of RUV. 
Since we fixed BSV to 20%, the remaining error not explained by the model was pooled 
into RUV, which could attribute to the high estimates of RUV for both plasma and brain.  
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Figure 5.3  (a-d) Concentration-time profile of sunitinib in plasma and brain stratified 
by genotypes. Observed concentrations (grey dots), median of observed concentrations 
(solid red line), population predicted concentrations by simulations (median = black 
solid line), 10th and 90th percentile (black dotted line) are depicted for each genotype. 
 
(a) Wild-type 
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(b)  Mdr1a/b(-/-)  (P-gp knockout) 
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(c)  Bcrp1(-/-) (Bcrp-knockout) 
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(d)  Mdr1a/b(-/-)Bcrp1(-/-)  (P-gp/Bcrp- knockout or ‘triple’ knockout) 
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5.5.3     EVALUATION OF STUDY DESIGN ELEMENTS USING SIMULATIONS 
 
We assessed model performance and sensitivity of brain distribution coefficient, Kp, 
using simulations wherein the sample size at each time point was varied and the resulting 
simulated datasets were estimated at 3 levels of BSV (10%, 20% or 40%). 
 
Briefly, 1000 new data sets were simulated for each sample size (n= 2, 3, 4, 8 and 12) 
using the parameter estimates from the PK-model with BSV fixed at 20%. Each of the 
simulated data set was estimated at 3 levels of  BSV (10%, 20% or 40%). Since the ‘true’ 
value of the parameter estimates was known in the simulation, we were able to determine 
bias and a measure of precision in the study.   
 
Table 5.3 summarizes the results from the estimation of bias as the number of animals at 
each time point increase. Irrespective of the number of animals used at each time point, 
bias was < 2-3% for all simulation scenarios tested. BSV had no influence over 
estimation of bias in a serial sacrifice deisgn. Earlier, Wang et al. reported similar 
findings on the effect of BSV using a bayesian approach to NCA (Wang et al., 2014). 
 
Precision was evaluated for each sample size using a novel approach by estimating the 
fraction of Kp-estimates within 5%, 10% and 20% of the estimate of bias obtained using 
the known parameter values. As the number of animals at each time point increased, 
estimates of Kp became closer to the true value. Overall, these estimates were not 
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substantially affected by the magnitude of between animal variability. At BSV= 10%, 
20% and 40%, similar trends were observed for precision in estimation of Kp as shown in 
figure 5.4. 
 
Table 5.3:  median (25th and 75th quantile) of estimate of bias determined as 
((predicted-true)/true) from 1000 simulations and re-estimations for brain distribution 
coefficient, Kp.  
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Inter-
animal 
variability 
Sample 
size 
Bcrp-knockout P-gp Knockout P-gp/Bcrp Knockout Wild-type 
10% 2 -0.001 (-0.15, 0.17) -0.016 (-0.16, 0.17) -0.037 (-0.18, 0.14) -0.028 (-0.15, 0.14) 
3 -0.02 (-0.15, 0.14) -0.014 (-0.14, 0.14) -0.015 (-0.15, 0.14) -0.008 (-0.13, 0.13) 
4 -0.001 (-0.15, 0.12) -0.003 (-0.12, 0.14) -0.005 (-0.12, 0.12) -0.006 (-0.11, 0.13) 
8 -0.002 (-0.15, 0.09) -0.010 (-0.10, 0.09) 0.006 (-0.08, 0.10) 0.007 (-0.08, 0.10) 
12 0.007 (-0.15, 0.09) -0.0004 (-0.08, 0.08) 0.014 (-0.05, 0.10) 0.009 (-0.06, 0.07) 
20% 2 -0.004 (-0.15, 0.16) -0.010 (-0.16, 0.18) -0.03 (-0.18, 0.15) -0.023 (-0.15, 0.15) 
3 -0.011 (-0.15, 0.14) -0.012 (-0.14, 0.14) -0.02 (-0.15, 0.13) -0.002 (-0.14, 0.14) 
4 -0.008 (-0.12, 0.11) -0.006 (-0.13, 0.13) -0.02 (-0.13, 0.10) -0.006 (-0.11, 0.14) 
8 -0.008 (-0.09, 0.09) -0.014 (-0.10, 0.08) -0.01 (-0.09, 0.08) -0.003 (-0.08, 0.09) 
12 -0.001 (-0.07, 0.08) -0.003 (-0.08, 0.07) -0.008 (-0.07, 0.06) -0.002 (-0.07, 0.07) 
40% 2 -0.001 (-0.15, 0.17) -0.006 (-0.15, 0.17) -0.025 (-0.17, 0.14) -0.012 (-0.15, 0.15) 
3 -0.016 (-0.14, 0.12) -0.009 (-0.13, 0.13) -0.02 (-0.14, 0.12) -0.005 (-0.13, 0.13) 
4 -0.018 (-0.11, 0.11) -0.002 (-0.11, 0.10) -0.022 (-0.12, 0.09) -0.002 (-0.11, 0.11) 
8 -0.013 (-0.09, 0.08) -0.014 (-0.09, 0.07) -0.011 (-0.09, 0.07) -0.006 (-0.08, 0.07) 
12 -0.012 (-0.07, 0.06) -0.012 (-0.07, 0.06) -0.010 (-0.07, 0.54) -0.008 (-0.07, 0.06) 159  
    
 
 
Figure  5.4: Fraction of 1000 replicate simulations giving an estimate of Kp within 5%, 
10% and 20% of the true value. The analysis evaluated the influence of sample size at 
each time point and between-subject variability in precisely estimating Kp under the 
given model.  
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5.6              DISCUSSION 
Rodents such as mice and rats are among the most commonly used animals for 
pharmacokinetic and toxicokinetic studies. The size of the animals limits the number of 
samples that can be withdrawn in a time-course study, therefore, often groups of animals 
are sacrificed at specified time points to obtain plasma and tissues. This design is called a 
‘serial sacrifice design’ or destructively sampled design. However, in tissue distribution 
studies the goal is to determine the tissue partition coefficient. This is traditionally done 
by averaging concentrations at each time point to obtain a mean value. This approach, 
however, has its disadvantages. First, we lose correlation in the structure of the data by 
averaging the concentrations at each time point for both plasma and tissue. This also 
results in loss of information for each animal because each animal supplies two 
concentrations, plasma and tissue (Ette et al., 1995a). Second, we do not obtain 
variability around the partition coefficient so it is difficult to ascertain any statistical 
significance of genotype (in this case) or treatment or group effect.  
 
The objective of this study was to statistically assess variability in the brain distribution 
coefficient in a serial sacrifice design. We have proposed a mixed effect modeling 
(MEM) approach over the commonly used naïve-data averaging method for estimating 
population parameters and uncertainty associated with brain distribution coefficient, Kp. 
In the past, the MEM method has been investigated for determination of plasma PK 
parameters such as Cl and Vd for quantic data (Hing et al., 2001). Ette et al. compared 
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the traditional NCA approach to resampling based approaches - random sampling (RS) 
and pseudo-profile based bootstrap (PpbB) methods to estimate tissue/plasma AUC 
ratios. The authors also evaluated the effect of correlation between plasma and tissue 
concentrations using paired and unpaired data in estimating tissue/plasma AUC ratios 
(Chu and Ette, 2005). The authors observed that the RS approach was more robust than 
the PpbB method.  
 
Our approach is an alternative approach to random sampling and does not rely on any 
resampling assumptions and multi-step approach to determine the tissue distribution 
coefficient. In this study, plasma and brain concentrations were simulatenously modeled 
using a hybrid pharmacokinetic model wherein the plasma concentrations were modeled 
as a forcing function for the corresponding brain concentrations. This approach ensured 
that within animal correlations in the data were maintained. In the MEM method, the 
variability in parameter estimates is influenced by BSV and RUV.  In our analysis, we 
assumed that all animals belong to the same homogenous population and therefore we 
fixed the between subject variability fixed at 20% and estimated RUV. Our approach was 
motivated by the results obtained from the brain distribution of sunitinib (Oberoi et al., 
2013).  
 
Results from the case study show that the point estimates of Kp obtained from NCA were 
comparable to the Kp ratios obtained using MEM method. In addition, we also obtained 
uncertainty around the point estimates of AUC brain/plasma ratio for all genotypes. 
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Based on these results and the uncertainty associated with the Kp ratios, we found that 
both P-gp and Bcrp significantly limit the brain distribution of sunitinib. We also found 
that the model predicted plasma and brain concentrations described the observed 
concentrations reasonably well. Furthermore, we also performed a sensitivity analysis to 
test the assumptions on fixing BSV to 20% in the model. We found that varying the BSV 
from 2.5% to 40% did not influence estimates of Kp for all genotypes. Therefore, BSV 
did not appear as a sensitive parameter in the model. 
 
The second objective of this investigation was to examine the influence of BSV (10%, 
20% and 40%) and sample size (low to high) at each time point on tissue partition 
coefficient in a serial sacrifice design. We studied the effect of study design features 
using stochastic simulation and estimation (SSE) method using PsN. 1000 simulated data 
sets were generated using known parameter estimates and BSV =20% for each sample 
size (n=2, 3, 4, 8, 12). Each of the simulated data sets were then estimated assuming BSV 
=10% or 20% or 40%.  Bias and precision were determined. Under the conditions 
studied, the model parameters were estimated irrespective of the value of between subject 
variability. The accuracy of parameter estimates was unaffected by varying either BSV or 
sample size at each time point.  Bias was less than 2-3% in all scenarios studied. 
Precision was determined by the fraction of estimates of Kp that were within 5%, 10% or 
20% of the known ‘true’ value.  We observed that as the number of animals at each time 
point increased from low to high, higher fraction of estimates were within 20% of the true 
value. 5% and 10% difference in bias (difference of estimated Kp value from simulations 
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and given parameter values for simulation) were stringent conditions as only 40% and 
70% of the time the estimates were within 5% and 10%, respectively, of true value when 
the number of animals per time point was 12. More commonly, 3-4 animals are grouped 
at each time point in a destructively sampled design. When 20% difference in bias was 
acceptable, 80%-85% of the time, the parameter estimates were precisely estimated. 
Therefore, as the number of animals sampled at each time point increases, precision in 
estimation of Kp increases while accuracy remains unaffected. However, assumptions 
regarding the magnitude of between subject variability in a serial sacrifice design are 
relatively unimportant.  
 
The results obtained in this study are comparable to those obtained by Ette et al. (Ette et 
al., 1995b). The authors reported that with BSV between 15% and 30%, CL and V were 
precisely estimated with 4 - 15 animals/time point. The authors assumed that a substantial 
fraction of RUV was due to assay error and fixed intraindividual variability (RUV) to 
15%, an approach previously employed by several researchers previously (Ette et al., 
1995b). They observed that varying RUV significantly increased the magnitude in bias. 
Other groups have also assumed that errors in measurement of concentration contribute 
significantly to error associated with structural model parameters. Our approach differs 
from this in that we estimated RUV as a measure of model misspecification error or error 
in data collection that would appear as random and unexplainable with little emphasis on 
analytical assay error.  
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One criticism for using the NLME based approach is that assumptions regarding the 
magnitude of between subject variability and residual unexplained variability are 
subjective. However, under the assumtpions of the current model, we have shown that 
varying the magnitude of BSV does not influence the estimates of tissue distribution 
coefficient. Obtaining a duplicate assay for each sample would provide more information 
to adequately define the analytical component of RUV.  In the simulation studies, we 
obtained plasma concentrations that were below the limit of quantification. The 
concentrations in the tail of a normal-distributed data are plausible when one type of 
variability is fixed (in this case, BSV) as all the remaining error in the model is lumped 
into another type (RUV, in this case).  
 
In summary, we have demonstrated that an NLME based approach provides estimates of 
precision and standad error associated with derived pharmacokinetic parameters (for 
example, tissue distribution coefficient) following destructive sampling under certain 
conditions. This approach is an alternative to noncompartmental based approaches such 
as random sampling, pseudo-profile based bootstrap approach and bayesian approach that 
have been investigated previously to determine variability with PK parameters.    
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CHAPTER   VI 
 
 
INFLUENCE OF ACTIVE EFFLUX AT THE BLOOD 
BRAIN BARRIER ON THE PHARMACOKINETIC-
PHARMACODYNAMIC ANALYSIS OF DUAL 
PI3K/mTOR INHIBITORS 
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6.1     INTRODUCTION 
Glioblastoma multiforme (GBM) is an invasive and the most malignant form of primary 
brain tumor with an average median survival of 14.6 months with the current standard of 
care, surgery, radiation and chemotherapy (Grossman et al., 2010; Stupp et al., 2005). 
Despite multimodal treatment options comprising of surgery, radiotherapy and 
chemotherapy, GBM remains incurable and recurrence of the disease is inevitable 
resulting in death. Several molecularly targeted agents have been evaluated in clinical 
trials but the results have been disappointing (Agarwal et al., 2011b; Akhavan et al., 
2010; Huang et al., 2009). 
 
Often the failure in clinical trials is attributed to resistance mechanisms such as the up-
regulation of alternative tumor growth pathways via redundancy, drug efflux 
mechanisms, decrease in sensitivity of pro-apoptotic ligands to their cell surface 
receptors, an ineffective drug or an ineffective target (Haar et al., 2012; Schmalz et al., 
2011). Unfortunately, there is little emphasis on drug delivery issues. The brain is 
surrounded by a complex anatomical and functional barrier, the blood brain barrier 
(BBB) that restricts the penetration of xenobiotics from the peripheral circulation into the 
brain parenchyma. This limited penetrance is mediated by a combination of the 
endothelial tight junctions and active efflux (Pardridge, 2005). ATP-binding cassette 
(ABC) transporters such as P-glycoprotein (P-gp) and breast cancer resistance protein 
(BCRP) are the two of the most important active efflux transporters expressed on the 
luminal side of the BBB (Schinkel and Jonker, 2003). These transporters have been 
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regarded as the ‘gatekeepers’ that have restricted brain penetration of several anticancer 
drugs (Agarwal et al., 2011a). Previous studies have shown that many molecularly 
targeted agents are substrates for both P-gp and BCRP (Tamaki et al., 2011). Some 
researchers have argued that the BBB is leaky in the tumor core; hence drug delivery is 
not an issue for GBM treatment (Hofer and Frei, 2007). Recent studies have also shown 
high drug concentrations in the tumor core compared to the areas surrounding the core 
(Agarwal et al., 2013; Michaud et al., 2010). Although the core is surgically removed, 
there is mounting evidence that recurrence of GBM can be attributed to the residual cells 
that migrate centimeters away from the tumor core forming a niche of tumor cells 
(Berens and Giese, 1999). Recent imaging techniques have been enabled researchers to 
identify this population of cells.  Bulk tumor cells are visible on T1- contrast enhanced 
MRI and to a larger extent on 18-F-DOPA PET images while invasive cells become more 
readily apparent on T2-FLAIR images (Pafundi et al., 2013). This highly infiltrative 
nature of the tumor further complicates the treatment of GBM. Presence of intact BBB in 
these regions can significantly limit brain distribution of chemotherapeutics (Agarwal et 
al., 2011b). Therefore, restricted delivery of drugs to the invasive glioma cells could be 
one of the reasons for failure in GBM clinical trials. 
 
Researchers have experimentally investigated and shown that BBB disruption is not 
homogenous within the tumor mass as the core is heterogeneously disrupted than the rim 
and the contralateral hemisphere (Choucair et al., 1986); (Levin et al., 1975). In order to 
fully assess the brain distribution and efficacy in preclinical models, the ideal animal 
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model should not only represent GBM in tumor biology and histopathology but should 
also mimic the invasiveness and angiogenic potential of GBM progression (Newcomb 
and Zagzag, 2009). Use of an inappropriate preclinical GBM model to investigate drug 
delivery could also be one of the reasons for inefficacy observed in clinical trials for 
several anti cancer drugs. Previously investigators have employed flank models or more 
traditional models such as U87MG glioma cell line model. The flank models fail to 
mimic the glioma microenvironment and the BBB characteristics in limiting brain 
penetration. On the other hand, the U87 human glioma cell line model fails to recapitulate 
the true nature of human GBM invasiveness and heterogeneity in BBB disruption. The 
U87 model was derived from a patient in 1968 but current neurooncological and 
neurosurgical standards would not classify the U87 tumor as a GBM today (Ponten and 
Macintyre, 1968). Despite these dissimilarities to glioblastoma, this model has been used 
in more than 1,700 publications (Clark et al., 2010). The tumor cells grow as a ball of 
cells with a sharply defined tumor boundary, much unlike the human counterpart 
(Newcomb and Zagzag, 2009). Preclinical results based on such models can lead to 
misleading interpretations, as one would believe that the BBB is not an impediment in 
drug delivery. Use of green fluorescent protein (GFP) enhanced tumors can help 
differentiate the brain regions into the core, the brain around the core and the 
contralateral hemisphere. Previously our lab has demonstrated the importance of BBB in 
limiting brain penetration of erlotinib and dasatinib using spontaneous and xenograft 
models, respectively (Agarwal et al., 2013; Agarwal et al., 2012). These studies showed 
that the brain concentrations in the core were significantly higher than in the rim and the 
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contralateral hemisphere and provided a plausible explanation that inadequate drug 
delivery to the normal and tumor brain could be the likely mechanism for failure of 
molecularly targeted agents in clinical trials. 
 
PI3K (phosphatidylinositol-3-kinase)/Akt/mTOR (mammalian target of rapamycin) 
pathway (PI3K/AKT/mTOR) is one of the most deregulated pathways in GBM (Akhavan 
et al., 2010). It is the downstream signaling pathway for several receptor tyrosine kinases 
such as epidermal derived growth factor receptor (EGFR), vascular endothelial growth 
factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and insulin-
growth factor receptor (IGFR) (Knobbe and Reifenberger, 2003). PI3K deregulation has 
been detected in more than 86% GBM samples and is known to play an important role in 
gliomagenesis (2008; Jiang and Liu, 2009; Karar and Maity, 2011). Therefore, inhibition 
of PI3K pathway represents an attractive target for therapeutic intervention in GBM. 
mTOR, the downstream target of this pathway is critical to GBM progression by 
regulating cell proliferation, survival, migration and angiogenesis via two multi-protein 
complexes, mTORC1 and mTORC2 (Guertin and Sabatini, 2007; Gulati et al., 2009). 
Activation of mTORC1 results in phosphorylation and activation of translation (S6) and 
initiation factor that control cell growth (Kim et al., 2002) while mTORC2 activates AKT 
in a PI3K-independent manner resulting in cell survival, proliferation and metabolism 
(Sarbassov et al., 2005). First generation mTOR inhibitors such as rapamycin and 
rapamycin analogs (Rapalogs such as temsirolimus and everolimus) predominantly and 
selectively inhibit mTORC1 and have been extensively studied in GBM clinical trials. 
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Unfortunately, these compounds have failed to show any therapeutic efficacy, potentially 
due to limited drug targeting of mTORC1 or compensatory upregulation of alternative 
signaling pathways such as MAP-kinase pathway (Carracedo et al., 2008; Galanis et al., 
2005; Rodon et al., 2013). Second generation mTOR inhibitors such as dual mTORC1/2 
complex inhibitors or dual PI3K/mTOR inhibitors are being currently investigated in 
several cancers including GBM (Rodon et al., 2013; Sabbah et al., 2011).  
 
In this study, we have investigated the role of blood-brain barrier in limiting brain 
distribution and efficacy of PI3K/mTOR inhibitors in three GBM models: GL261 
syngeneic model, GBM10 patient-derived xenograft model and U87 human glioma cell 
line derived model. GNE-317 and GDC-0980 are dual PI3K/mTOR inhibitors with potent 
activity against PI3K and both mTORC1 and mTORC2 (Figure 6.1). GNE-317 was 
custom synthesized to penetrate the BBB (Salphati et al., 2012a) while GDC-0980 is 
liable to active efflux at the BBB (Salphati et al., 2012b). The objective of this study was 
to investigate (a) heterogeneity in BBB disruption in preclinical glioma models, (b) the 
role of intact BBB in the area around the tumor core in restricting delivery of molecularly 
targeted agents intracellularly and (c) whether there is a need of not only effective 
delivery but also an effective drug to target the tumor cells.  
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Figure 6.1: Structures of (a) GDC-0980 and (b) GNE-317. Both are dual PI3K/mTOR 
inhibitors with a similar backbone except for difference in the side chain (highlighted 
here in the figure). 
 
 
 172  
    
6.2                MATERIALS AND METHODS 
6.2.1             CHEMICALS AND REAGENTS   
GNE-317 and GDC-0980 were obtained from Genentech (San Francisco, CA).  
Ammonium formate and acetonitrile were HPLC grade and were procured from Sigma-
Aldrich (St. Louis, MO). Texas Red Dextran 3000 MW (TRD) was purchased from 
Molecular Probes (Invitrogen). 
  
6.2.2            GLIOBLASTOMA ANIMAL MODELS 
Three glioma models were used for in-vivo tumor studies: GL261 mouse model (a 
syngeneic murine model), GBM10 (a patient-derived glioblastoma multiforme xenograft 
model obtained from Mayo Clinic, Rochester, MN) and U87 (a patient-derived 
glioblastoma multiforme cell line purchased from American Type Culture Collection, 
Manasass, VA, USA). Studies in GL261 model were conducted in collaboration with Dr. 
David Largaespada, Department of Neuroscience, University of Minnesota, MN, USA 
and studies with GBM10 and U87 were conducted in collaboration with Dr. Jann 
Sarkaria, Mayo Clinic, Rochester, MN, USA.  
 
6.2.2.1          GL261  ORTHOTOPIC SYNGENEIC MODEL OF GLIOMA 
GL261 cells transfected with luciferase and GFP (green fluorescent enhanced protein) 
were obtained from Dr. David Largaespada lab at the University of Minnesota. Cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum albumin, penicillin (100 U/ml), streptomycin (100 μg/ml), G418 
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(4mg/mL) and Puromycin (4 mg/mL). All supplements were obtained from Sigma-
Aldrich. Cells were maintained in 5% oxygen conditions. For inoculations, cells were 
harvested using TrypLE (Life Technologies, NY, USA) and suspended in PBS at a 
concentration of 30,000 cells/μl. Female C57BL/6 mice (6-8 weeks) were obtained from 
Jackson Laboratories (Wilmington, MA). Mice were anesthetized with 
ketamine/xylazine cocktail solution (53.7 mg/ml ketamine, 9.26 mg/ml xylazine) 
delivered at 1 ml/kg. 1 μl of the cell solution containing 3 x 104 GL261-luc-GFP 
(enhanced green fluorescent protein) labeled cells were injected intracranially and 
stereotactically into the right ventral striatum (0.5 mm anterior, 2.5 mm lateral, 3.0 mm 
depth from the surface). The tumor was allowed to grow for 1 week before further 
studies.  
 
6.2.2.2     GBM10 PATIENT-DERIVED AND U87 CELL-LINE XENOGRAFT 
MODEL 
GBM10 is a serially passaged glioblastoma cell line derived from the tumor of a patient. 
Molecular genetic aberrations and histopathology of the tumor has already been 
described previously (Yang et al., 2008). The cells were grown as flank tumors in 
immunocompromised mice and harvested and grown in short-term cell cultures (5-14 
days) as described previously (Carlson et al., 2011) in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum albumin, penicillin (100 U/ml) and 
streptomycin (100 μg/ml). U87 is a glioma cell line maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum albumin and 10mM HEPES, 
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penicillin (100 U/ml) and streptomycin (100 μg/ml).  
Briefly, the following procedure was followed for both GBM10 and U87 models. Female 
athymic nude mice (Ncr-nu/nu, National Cancer Institute) (5-6 weeks old) were 
maintained as flank tumor passages. The flank tumor cells obtained from these animals 
was mechanically disaggregated to form a cell suspension and maintained in DMEM with 
2.5% fetal calf serum. Following trypsinization, the cells were re-suspended in phosphate 
buffered saline (PBS) at 105 cells/μL. Using a stereotaxic frame (ASI Instruments, 
Houston, TX) GBM10 cells and U87 cells were suspended at a concentration of 3 x 105 
cells and injected into the right basal ganglia (3 μL)  (1mm right lateral and 2mm anterior 
to the bregma). For in-vivo brain distribution studies, GFP-labeled GBM10 and GFP-
labeled U87 cells were used. 
 
 
6.2.3         REGIONAL BREAKDOWN OF THE BBB 
6.2.3.1     GL261 SYNGENEIC MODEL 
Cohorts of GL261-luc-GFP labeled tumor-bearing C57BL/6 mice were injected with 
Texas Red dextran (1.5 mg/animal body weight, molecular weight= 3000 Da) via tail 
vein. To investigate the degree of BBB disruption during tumor progression, the animals 
were grouped into four categories according to their signal strength as determined by 
luciferase imaging (5x10-5, 5x10-6, 5x10-7, 5x10-8 p/sec/cm2/sr). After 10 minutes, the 
animals were perfused with a brief cardiac washout for 30 seconds at a rate of 10 
mL/minute. Following perfusion, brains were harvested and flash frozen in isopentane (-
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80°C). Brains were then sectioned (20- micron slices) using a cryostat and mounted on 
charged glass slides. After preparation, slices were imaged using the fluorescence filters 
of a Leica DMI 6000B microscope. Images were acquired in grayscale using a Retiga 
2000R camera at a variety of exposure times to allow visualization of signal in the 
smaller tumor-bearing slices and to prevent signal saturation in the larger tumor-bearing 
slices. The individual images were acquired using QImaging QCapture Pro v 6.0 
software, compiled using Microsoft Image Composite Editor and then color was 
synthetically applied using Adobe Photoshop.  
 
6.2.3.2     GBM10 AND U87 XENOGRAFT MODEL 
GBM10 and U87 cells used for BBB integrity studies were not GFP-enhanced tumors. 
TRD (1.5 mg/animal) was administered via tail vein. After allowing circulation for 10 
minutes, the animal was perfused with extracellular fluid buffer (ECF buffer) at a rate of 
10 mL/min. Following perfusion, whole brains were harvested and frozen in ice-cold 
isopentane at -80C. Brains were then sectioned (20-micron) into slices and mounted on 
glass slides. Brains were imaged for Texas Red and Brightfield. The extent of tumor 
growth was confirmed by cresyl violet staining. Briefly, the glass slides were fixed in 4% 
paraformaldehyde in PBS for 10 minutes and immersed in 0.1% cresyl violet acetate for 
15 minutes. The sections were then processed for dehydration and cleaning in 70% 
ethanol for 15 seconds and 90% ethanol for 10 seconds. Bright field images were then 
captured using Retiga 2000R camera (Leica DMI 6000B microscope). 
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6.2.4         CYTOTOXICITY STUDIES 
Cytotoxicity studies were conducted in all 3 cell lines; GL261, GBM10 and U87.  
 
6.2.4.1     GL261 AND U87 CELL LINE 
GNE-317 and GDC-0980 were added to cells (75% confluent) in 96-well plate in 
increasing concentrations (0.0001-1000 μM, <0.05% DMSO). The plates were incubated 
at 37°C for 48 hours. Following incubation, tumor growth potential was determined using 
MTS cytotoxicity assay (Promega, Madison, WI). 40 μL of tetrazolium dye was added to 
each well and further incubated for 2 hrs. Plates were analyzed for colorimetric changes 
and optical density was read at an absorbance of 490 nm using Synergy 2 microplate 
reader and Gen5 v 2.04 software. Plates were read to determine the degree of cell 
survival. Numerical values from treated wells were normalized to the values of vehicle-
treated wells to gain percent survival.  
 
6.2.4.2     GBM10 CELL LINE 
GNE-317 and GDC-0980 were tested for cytotoxicity in GBM10 cells. Cells were seeded 
in 96-well plates at a cell density of 5000 cells per well (n=3 plates for each drug) and 
incubated for 24 hours to allow cell attachment. The cells were then incubated for 48 
hours with increasing concentrations of GNE-317 or GDC-0980 (0.015uM to 100uM), 
DMSO control and vehicle control. Following incubation, cells were washed with PBS 
and 40uL of MTT reagent (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium 
bromide) (Alfa Chemical Corp.) at a concentration of 5 mg/mL was added to each well. 
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After an additional 3 hrs of incubation at 37°C at 60 rpm, 100μL of DMSO was added to 
each well. The plates were continuously agitated on an orbital shaker for 1 hr at 60 rpm, 
37°C.  The absorbance of each well was determined using a plate reader at a wavelength 
of 570 nM. Viability was determined as the amount of purple formazan produced. The 
percent survival was normalized to the percentage of absorbance of cells treated with 
DMSO control. The percentage of DMSO was less than 0.01% for all drug solutions.  
 
 
6.2.5     IN-VIVO STUDIES 
Mice were handled according to the guidelines set by the National institute of Health 
(NIH) and experiments were conducted in accordance with the Institutional Animal care 
and Use Committee (IACUC) at the University of Minnesota or the Mayo Institutional 
Animal Care and Use Committee. 
 
Single oral dose brain distribution studies and steady-state brain distribution studies for 
both GNE-317 and GDC-0980 were conducted in non-tumor bearing Friend Leukemia 
virus strain B (FVB) mouse of either sex in wild-type and in transgenic mice “triple-
knockout” mice (TKO), mice lacking both P-gp and Bcrp (Mdr1a/b(-/-)Bcrp1(-/-)) (8-10 
weeks old). Mice were obtained from Taconic farms (Germantown, NY) and maintained 
under temperature controlled conditions with 12 hour dark-12 hour light cycle and 
unlimited access to food and water. 
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Tumor distribution studies and survival studies were conducted in GL261 syngeneic 
model (C57BL/6 mice, female (~7 weeks old purchased from Jackson Labs), GBM10 
patient-derived xenograft model and U87 cell line derived xenograft model (athymic 
nude mice). 
 
 
6.2.5.1     PLASMA AND BRAIN DISTRIBUTION OF GNE-317 AND GDC-0980 
IN FVB MICE 
GNE-317 (30 mg/kg) and GDC-0980 (7.5 mg/kg) drug solutions were prepared freshly 
on the day of the experiment as a suspension in 0.5% methylcellulose and 0.2% tween 80. 
All mice were administered the drugs simultaneously in two separate syringes by oral 
gavage and euthanized using carbon-dioxide chamber at desired time points, i.e., 1, 4, 6 
or 8 and 16 hrs after dose (n=3-4 at each time point). Following euthanasia, blood was 
collected by cardiac puncture and transferred to tubes containing 20μL of 100 units/mL 
heparinized saline. Plasma was separated by centrifugation at 3500 rpm at 4°C for 15 
minutes. Brain was harvested, rinsed with ice-cold buffer and flash frozen in liquid 
nitrogen. Brain samples were transferred to pre-weighed tubes.  Plasma and brain 
samples were stored in -80°C until analysis by LC-MS/MS. 
 
At the time of analysis, brain samples were thawed at room temperature and brain 
weights were obtained. Brains were homogenized with 3 volumes of 5% bovine serum 
albumin (BSA) prepared in phosphate buffer saline (PBS) (pH=7.4) using a tissue 
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homogenizer (PowerGen 125, Fisher Scientific, Pittsburgh, PA). Brain concentrations 
were determined by correcting for the brain vascular space in FVB mice (1.4 % of the 
whole brain volume (Dai et al.). 
 
Noncompartmental analysis was performed using Phoenix WinNonlin 6.1 (Pharsight, 
Mountain View, CA). The area under the concentration time curve till the last measured 
time point (AUC 0-tlast) was calculated for both plasma and brain concentration time 
profiles using the log-linear trapezoidal approximation method. In addition, we 
determined the brain partition coefficient, Kp, given by the AUC ratio of brain to plasma 
for both wild-type and TKO mice. We also examined the drug targeting index (DTI) 
which is given by the AUC brain-to-plasma ratio in TKO mice divided by the AUC 
brain-to-plasma ratio in the wild-type mice, written as, 
                                             DTI = AUC brain/Plasma (TKO)/AUC brain/Plasma (wild-type) 
 
 
6.2.5.2     PLASMA AND BRAIN STEADY-STATE PHARMACOKINETICS OF 
GNE-317 AND GDC-0980 IN FVB MICE 
The steady state brain-to-plasma ratio (Kp) for both GNE-317 and GDC-0980 were 
determined in mice using Alzet osmotic minipumps (Durect Corporation, Cupertino, 
CA). A 5 mg/ml solution of GNE-317 and 10 mg/ml solution of GDC-0980 was prepared 
in dimethylsulfoxide and osmotic minipumps (model 1003D) were filled with 100 μL of 
either drug solution. The pumps were allowed to equilibrate overnight by soaking them in 
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a sterile saline solution at 370C. On the day of the experiment, mice were anesthetized 
with 5% isoflurane (Boynton Health Service Pharmacy, University of Minnesota, 
Minneapolis, MN) and maintained under anesthesia with 2% isoflurane in oxygen during 
surgery. The primed pumps were surgically implanted in the peritoneal cavity of the 
mice, after which the mice were allowed to recover on a heated pad. Each pump operates 
at a rate of 1 µL/hr, which yielded a constant intraperitoneal infusion of 5 µg/hr for GNE-
317 or 10 µg/hr for GDC-0980. All animals were euthanized 48 hrs post surgery and 
blood was collected via cardiac puncture and whole brain was harvested. Blood and brain 
were processed as described above. On the day of the analysis, brain samples were 
prepared as described above. Steady state brain-to-plasma ratios were determined for 
both GNE-317 and GDC-0980 in wild-type and TKO mice. 
 
 
6.2.6          REGIONAL BRAIN DISTRIBUTION OF GNE-317 AND GDC-0980 IN 
GLIOBLASTOMA MOUSE MODELS 
6.2.6.1         GL261 MODEL 
Presence of GFP in tumor cells aided in dissecting the brain into three parts - the tumor 
core, the brain around the core and the contralateral hemisphere as illustrated in Figure 
6.2. Tumor-bearing mice were randomly assigned to one of the three groups (n=6 per 
group), (a) control (vehicle treated), (b) GDC-0980 (7.5 mg/kg) and (c) GNE-317 (30 
mg/kg). Drug solutions were prepared in 0.5% methylcellulose with 0.2% tween 80.  All 
mice were administered one of the three treatments orally for 3 consecutive days. All 
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mice were sacrificed either 1hr after the last dose or 6hr after the last dose, following 
which brain and plasma were harvested. Brains were sectioned into three regions: the 
tumor core, the brain around the tumor and the contralateral hemisphere. Brain samples 
were prepared as described previously. Tissue specimens from each group were analyzed 
for drug concentrations using LC-MS/MS.  
 
Figure 6.2: GFP-enhanced GL261 mouse brain 
Qualitative figure showing the dissection of the tumor core, rim and the contralateral 
hemisphere in a GL261 mouse glioma model. The tumor cells are enhanced green by 
GFP and dissected using GFP-goggles. 
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6.2.6.2              GBM10 AND U87 MODEL 
Female athymic nude mice (Ncr-nu/nu) bearing GFP-labeled GBM10 (n=3) and GFP-
labeled U87 (n=5) tumor were treated with both GNE-317 (30 mg/kg) and GDC-0980 
(7.5 mg/kg) simultaneously. Drug solutions were prepared in 0.5% methylcellulose and 
0.2% tween 80. Mice were sacrificed 1 hr after the dose and plasma and brains were 
harvested. GFP-labeling aided in dissecting the brain into three parts – the core, the brain 
around the tumor core and the contralateral hemisphere. For GBM10-treated group, 
plasma samples were not collected.  
 
 
6.2.7       QUANTIFICATION OF GNE-317 AND GDC-0980 IN MOUSE BRAIN 
AND PLASMA BY LC-MS/MS 
The plasma and brain concentrations of GNE-317 and GDC-0980 were determined using 
high-performance liquid chromatography-tandem mass spectrometry (LS-MS/MS). On 
the day of the analysis, frozen brain samples were thawed at room temperature. Brain 
weights were determined as described above and samples were homogenized using 3 
volumes of 5% ice-cold bovine serum albumin prepared in phosphate-buffer saline (PBS) 
(pH= 7.4).  
 
Drug concentrations in GNE-317 alone or GDC-0980 alone treated groups were analyzed 
as follows: 100 µL of plasma or 200 µL of brain homogenate sample were taken in 
microcentrifuge tubes containing 10 µL of 2 µg/mL of internal standard (GNE-317: 
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AG1478 (4-[3-chloroanilino]-6,7-dimethoxyquinazoline) and GDC-0980: dasatinib, free 
base) and extracted via vigorous vortexing with 500 µL of ice-cold ethyl acetate. 
Following centrifugation at 7500 rpm for 15 minutes at 4°C, 400 µL of the supernatant 
was transferred to microcentrifuge tubes and dried under nitrogen. Dried samples were 
re-constituted with 100 µL of mobile phase for GNE-317 (60:40:0.1, v/v%, 20 mM 
ammonium formate, pH 3.5: acetonitrile: formic acid) or GDC-0980 (72:28:0.1, v/v%, 20 
mM ammonium formate, pH 3.5: acetonitrile: formic acid) and transferred to glass 
autosampler vials. 5 µL of the sample was injected into LC-MS/MS. Chromatographic 
system consisted of Agilent Technologies model 1200 separation system (Santa Clara, 
CA). Separation of the analyte was achieved using Agilent ZORBAX XDB Eclipse C18 
column (4.6 x 50 mm, 1.8 µm). The LC-system was linked to TSQ Quantum triple 
quadrupole mass spectrometer (Thermo Finnigan, San Jose, CA) and data analysis was 
performed using Xcalibur software, version 2.0.7. The instrument was equipped with 
selected reaction monitoring (SRM) mode with an electrospray ionization source (ESI) 
operated in positive ion mode at a spray voltage of 5000 V for both GNE-317 and GDC-
0980. The mobile phase flow rate was 0.25 mL/min. The mass-to-charge transitions were 
programmed for GNE-317 (415.11  385.13) and internal standard, AG1478 (317.03  
300.98) and GDC-0980 (499.24  340.98) and internal standard dasatinib (499 401). 
The total run time was 10 minutes and 12 minutes for GNE-317 and GDC-0980, 
respectively. The assay was linear over a range of 1.9 ng/ml to 1000 ng/ml with a 
coefficient of variation lower that 20% throughout the entire range.   
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Dual GNE-317 and GDC-0980 quantification method 
For groups treated with both GNE-317 and GDC-0980 simultaneously, quantification of 
GNE-317 and GDC-0980 was performed using the dual gradient method as follows: 100 
µL of plasma sample and 200 µL of brain homogenate was spiked with 10 µL of 2 
µg/mL internal standard, AG1478 (4-[3-chloroanilino]-6,7-dimethoxyquinazoline) and 
extracted using 500 µL of ice-cold ethyl acetate. Samples were shaken vigorously at 7500 
rpm at 4°C for 15 minutes, following which 400 μL of the supernatant was transferred to 
another tube and dried under a gentle stream of nitrogen. Samples were reconstituted in 
100μL of mobile phase (72:28:0.1, v/v%, 20mM ammonium formate, pH=3.5 (A): 
acetonitrile (B): formic acid (A)) and transferred to glass autosampler vials. 5uL of the 
sample was injected into LC-MS/MS. The LC-system and TSQ Quantum triple 
quadrupole mass spectrometer system similar as described above. A gradient elution 
method was used starting at 28% B for 5 minutes (0.25 mL/min), followed by 100% B 
for 2.5 minutes (0.25 mL/min). A linear gradient was applied from 7.9 -11.5 minutes 
(28% B) at a flow rate of 0.5 mL/min. The total run time was 11 minutes. The mass-to-
charge (m/z) transitions were 499.24  340.98, 499.24  340.98 and 317.03  300.98 
for GDC-0980, GNE-317 and AG1478, respectively. The assay was linear over a range 
of 1.9 ng/ml to 1000 ng/ml with a coefficient of variation lower that 20% throughout the 
entire range.  
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6.2.8     PHARMACODYNAMIC EFFECTS OF GNE-317 AND GDC-0980 USING   
IMMUNOHISTOCHEMISTRY IN GL261-LUC-GFP LABELED 
GLIOMA MODEL 
To determine efficacy of dual PI3K/AKT/mTOR inhibitors, GNE-317 and GDC-0980, 
GL261-luc-GFP labeled tumor bearing mice (5*107 photons/sec/cm2/Sr) were 
randomized into three groups (n=5-6 per group), (a) control (vehicle treated), (b) GDC-
0980 (7.5 mg/kg) and (c) GNE-317 (30 mg/kg). Drug solutions were prepared in 0.5% 
methylcellulose with 0.2% tween 80. Mice were administered one of the three treatments 
orally for 3 consecutive days, following which all mice were sacrificed either 1hr after 
the last dose or 6hr after the last dose. Brains were harvested as described previously and 
perfused with 30 mL PBS buffer. Brains were stored in 10% buffered formalin for 24 
hours and then switched to 70% ethanol. Standard processing was used to paraffin embed 
tissues for slicing onto charged glass slides. Using a microtome, brains were sectioned 
into 5-μm slices. Formalin-fixed, paraffin-embedded tissue sections were deparaffinized 
with xylene, rinsed with ethanol and rehydrated. Immunohistochemistry (IHC) staining 
was performed using the following antibodies: Akt (1:200, Cell Signaling), p-Akt Ser473 
(1:50, Cell Signaling), S6 (1:100, Cell Signaling), pS6 Ser235/236  (1:100, Cell Signaling), 
4EBP1 (1:1000, Cell Signaling) and, p4EBP1Thr37/46 (1:1000, Cell Signaling). Non-
specific binding of antibody was achieved using 3% bovine serum albumin. The 
universal secondary protocol and DAB MAP kit (Vector Laboratories, Burlingame, CA) 
was used to detect the signal with one exception; we used a biotinylated secondary 
antibody followed by the application of VectaStain Elite ABC for 
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enhancement/amplification of signal.  We also performed a brief 30-second hematoxylin 
staining to provide background for antibody staining. The tissues were dehydrated and 
mounted using Permount (Fisher Scientific). Darker staining of the tumor cells when 
treated with antibody corresponds to relative overexpression of the target. The slides 
were imaged using Nikon AZ100 Macrofluorescence microscope and associated NIS 
elements software was used to automatically stitch individual pictures and analyze 
horseradish peroxidase (HRP) staining intensity.  
 
 
6.2.9       EFFICACY STUDIES IN GLIOMA MODELS 
In-vivo efficacy studies were conducted in all three glioma models, GL261, GBM10 and 
U87-tumor bearing mice. All mice were randomized into three groups; (1) placebo 
(vehicle control), (2) GNE-317 (30 mg/kg) and (3) GDC-0980 (7.5 mg/kg) (n=10 
mice/per group) and received one of the three treatments via oral gavage once daily with 
experimental end point being death or moribund state of mice. Drug solutions were 
prepared in 0.5% methylcellulose and 0.2% tween 80. 
 
 
6.2.10      BIOLUMINESCENCE IMAGING 
Animals bearing GFP-luc-GL261 tumors were monitored for tumor growth and effect of 
treatment with GNE-317 and GDC-0980. Bioluminescence imaging was based on the 
conversion of luciferin to light-emitting oxyluciferin by an enzyme, luciferase. Mice were 
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intraperitoneally injected with 100 μL of D-luciferin (28.5 mg/mL, Gold Bio), a substrate 
for luciferase enzyme. After 10 minutes, mice were anesthetized with 5% isoflurane 
using nosecones within the imager and placed in IVIS Xenogen 50 imager (Perkin 
Elmer). After the end of exposure period (1 second), a grey-scale image was obtained 
which was overlaid with a 5-minute luminescent exposure taken with the imager’s 
Xenogen camera. Luciferase activity was analyzed using Living Image Software 
according to the manufacturer’s instructions (Perkin Elmer, USA). All measurements 
were performed under the same experimental settings of camera. The signals were 
quantified and plotted as radiance (photons/sec/cm2/sr) with respect to the time, starting 
7 days after surgery on the first day of treatment (GNE-317 or GDC-0980) or no 
treatment (placebo). 
 
 
6.2.11      STATISTICAL ANALYSIS 
The unpaired two-sample t-test was used to compare between two groups. One-way 
ANOVA, followed by Bonferroni’s test was conducted to test for significance among 
multiple groups. Significance was declared at p<0.05 for all tests.  All tests were done 
using GraphPad Prism 5.01, San Diego, CA. Survival probabilities were estimated using 
Kaplan Meier survival curves. The treatment groups were compared using log-rank test. 
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6.3            RESULTS 
6.3.1  REGIONAL BREAKDOWN OF THE ENDOTHELIAL TIGHT 
JUNCTIONS IN THE BLOOD-BRAIN BARRIER 
Heterogeneity in blood-brain barrier (BBB) disruption was evaluated using a 
permeability marker, Texas Red 3kDa dextran (TRD). TRD is an intravascular marker 
which can permeate through a disrupted membrane only. The normal permeability of the 
BBB is restricted to molecules <500 Da, therefore, a molecule such as TRD (molecular 
weight = 3000 Da) would only permeate when the tight junctions are disrupted. After i.v. 
administration, TRD was allowed to circulate for 10 minutes following which the mouse 
was anaesthetized, given rapid perfusion of ECF buffer and brain was harvested. Brain 
penetration of TRD was analyzed in 20-micron thick sections of the whole brain. For 
GL261-luc-GFP model, the TRD staining was visualized at four different time points 
(5x10-5, 5x10-6, 5x10-7 and 5x10-8 p/sec/cm2/sr) as assessed by bioluminescent imaging. 
At all signal strengths, heterogeneity in BBB disruption was apparent. As the tumor 
progressed (5x10-8 p/sec/cm2/sr), characteristic features of GBM became more visible. 
These features included absence of a clear tumor boundary and heterogeneity in BBB 
disruption in the tumor brain compared to the normal brain. Representative qualitative 
images showing Texas Red dextran accumulation in GL261 mouse brain from four 
different animals that had different signal strengths is shown in figure 6.3 (a). Results 
from this analysis suggest that GL261 mouse model resembles spatial heterogeneity in 
BBB breakdown similar to that observed in human GBM. 
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Figure 6.3 (a): BBB permeability in GL261, GBM10 and U87 is visualized using  
Texas Red dextran. We used TRD is a permeability marker. Presence of the tumor 
region was detected using GFP in GL261 and cresyl violet and bright field in GBM10 
and U87.  
(a) GFP-luc-GL261 tumor bearing mice were assessed for different signal strengths 
using luciferase imaging. Representative images show heterogeneity in accumulation 
of TRD. Green represents GFP-enhanced tumor region. These images show higher 
accumulation of TRD in tumor region compared to non-tumor region. Within the 
tumor regions, there is heterogeneity in TRD accumulation suggesting heterogeneous 
breakdown of BBB in GL261, comparable to human GBM. 
 
           GFP                  Texas Red Dextran         Overlay 
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Figure 6.3 (b) BBB disruption in GBM10 and U87. GBM10 shows heterogeneity in BBB 
disruption, unlike in U87, which shows a homogenous breakdown of BBB. Also shown are 
Cresyl violet staining of the tumors and TRD accumulation in GBM10 and U87 with 
corresponding brightfield images of the tumor. 
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Similarly in GBM10, microscopic examination of TRD brain penetration revealed areas 
of heterogeneity within the brain tumor core and less accumulation of TRD in the 
growing edge of the tumor (Figure 6.3 (b)). On the other hand, TRD accumulation in 
U87 micro-dissected tumors did not reveal heterogeneity in BBB disruption. The 
disruption of BBB as shown by TRD brain penetration suggested a homogenous 
breakdown of the barrier (figure 6.3 (c)). There was significant background for TRD in 
U87. However, tumors in U87 glioma model had sharply demarcated edge of the tumor 
separated from the adjacent brain, unlike the tumors in GL261 and GBM10 model. It is 
critical to understanding and evaluate the heterogeneity in BBB breakdown as it can 
mislead interpretation of drug concentrations in the core vs. the adjacent brain as different 
brain-to-plasma ratios will be observed in these regions of the brain. 
 
6.3.2       CYTOTOXICITY ASSAY 
In-vitro efficacy of GNE-317 and GDC-0980 was determined in all three cell lines.  
Similar trends were observed across all three glioma models.  Treatment with GNE-317 
and GDC-0980 in-vitro resulted in a dose dependent inhibition of tumor cells as 
measured by the MTS and MTT assays. Both the drugs showed similar efficacy in in-
vitro as observed by similar IC50’s (Table 6.1 and Figure 6.4). IC50 in this case was 
defined as the concentration that results in 50% of maximal inhibition.  
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Table 6.1: Cytotoxicity results   
 
 GNE-317 (µM) GDC-0980 (µM) 
GL261 cells 0.46 0.70 
GBM10 cells 0.4 0.9 
U87 cells 0.77 1.1 
 
 
 
 
Figure 6.4   Cytotoxicity studies of GNE-317 and GDC-0980 in GL261, GBM10 and 
U87 cells in in-vitro 
Figures (a-c) show percent viability curves of GNE-317 and GDC-0980 in all three 
glioma cell lines. The IC50s are shown in the figure. The figure shows similar trend of 
GNE-317 and GDC-0980 in all three cell lines suggesting both drugs have similar 
potency in-vitro. 
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6.3.3     PLASMA AND BRAIN DISTRIBUTION OF GNE-317 AND GDC-0980 
AFTER SINGLE ORAL DOSE IN FVB MICE 
GNE-317 and GDC-0980 pharmacokinetics were determined after a single oral 
administration of both drugs in FVB-wild type and TKO mice. The brain and plasma 
concentration time profiles of GNE-317 and GDC-0980 in FVB-wild type and TKO mice 
are shown in Figure 6.5.  
 
The brain concentrations of GNE-317 closely followed plasma concentrations in both 
wild-type and TKO mice, suggesting that both P-gp and Bcrp do not influence brain 
distribution of GNE-317 (Figure 6.5 (a) and (b)). The maximum plasma concentrations 
were observed at 1 hr in both wild-type and TKO mice. The brain-to-plasma 
concentration ratios were ~1 at all measured time points in both strains of mice (Figure 
6.5 (c)). The area under the concentration time curve to the last measured time point 
(AUC0-t) in both plasma and brain of the wild-type mice were 10.59 ± 0.81 h-µg/mL and 
10.06 ± 0.9 h-µg/mL respectively. In the absence of P-gp and Bcrp, the AUC0-t was 11.99 
± 1.65 h-µg/ml and 12.80 ± 1.24 h-µg/ml in the plasma and brain, respectively. Similar 
AUCs in plasma and brain in both wild-type and TKO mice indicate that GNE-317 brain 
distribution is not restricted by active efflux at the blood brain barrier. The brain partition 
coefficient, Kp, given by the AUC ratio in brain to AUC ratio in plasma was ~1 (0.95 in 
wild type and 1.07 in TKO), implying that there is equal partitioning in the brain as in the 
plasma. The observed drug targeting index value for GNE-317 was 1.13. This indicates 
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that both P-gp and Bcrp do not play a role in restricting the brain distribution of GNE-
317. 
 
On the other hand, brain concentrations of GDC-0980 were significantly lower than the 
corresponding plasma concentrations in wild-type mice at all measured time points 
(p<0.05), whereas, brain concentrations in TKO mice were greater than the plasma 
concentrations, indicating that both P-gp and Bcrp limit brain distribution of GDC-0980 
(figure 6.5 (d) and (e)). The brain-to-plasma ratio vs. time graph showed an increase 
before reaching a plateau, suggesting that a pseudo-distributional equilibrium has been 
achieved (figure 6.5 (f)). The AUC0-tlast in the wild-type plasma (10.56 ± 1.47 h-µg/ml) 
and TKO plasma (4.51 ± 1.15 h-µg/mL) were significantly different from each other, 
although the plasma concentrations at all measured time points except 16 hr were not 
significantly different (Table 6.2).  The brain distribution coefficient of GDC-0980 in 
wild type was 0.05 and increased by a drug targeting index of ~35 fold to 1.75 in the 
TKO mice.  
 
These results are comparable to those observed by Salphati and colleagues in two 
separate publications on GNE-317 (Salphati et al., 2012a) and GDC-0980 (Salphati et al., 
2012b) suggesting that the difference in targeting potential of GNE-317 is due to its 
higher brain permeability compared to drugs of similar class such as GDC-0980 that are 
liable to active efflux by P-gp and Bcrp at the BBB. 
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Figure 6.5 (a-c): plasma and brain concentration-time profiles of GNE-317 (30 mg/kg) 
and GDC-0980 (7.5 mg/kg) in FVBn wild-type and TKO mice after a single 
simultaneous oral dose 
Plasma and brain concentration time profiles of GNE-317 in wild type (a) and TKO 
mice (b). Corresponding brain-to-plasma ratio with respect to time is shown in (c) for 
both wild type and TKO mice. 
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Figure 6.5 (d-f): plasma and brain concentration-time profiles of GNE-317 (30 mg/kg) and 
GDC-0980 (7.5 mg/kg) in FVBn wild-type and TKO mice after a single simultaneous oral dose 
Panel (d) and (e) show plasma and brain concentration time profiles of GDC-0980 in wild type 
and TKO mice, respectively. Corresponding brain-to-plasma ratios with time are shown in (f). 
Data represent mean ± S.D. (n= 3-4 at each time point). 
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Table 6.2: Plasma and brain pharmacokinetic parameters determined by non-compartmental analysis after simultaneous 
administration of a single oral dose of GNE-317 (30 mg/kg) and GDC-0980 (7.5 mg/kg) in wild-type and 
Mdr1a/b(−/−)Bcrp1(−/−) mice. Results are expressed as mean ± S.D. n = 3 – 4 at each time point. 
 
 
 
 
 
 
 
  GNE-317 GDC-0980 
 Parameter 
(units) 
Wild-type Mdr1a/b(-/-)Bcrp1(-/-) Wild-type Mdr1a/b(-/-)Bcrp1(-/-) 
 
 
 
Plasma 
 
Cmax  
(µg/mL) 
1.7 ± 0.20 1.41 ± 0.21 1.76 ± 0.58 0.81 ± 0.27 
Tmax  
(hr) 
1 1 1 1 
AUC 0-tlast 
(h.µg/mL) 
10.59 ± 0.81 11.99 ± 1.65 10.56 ± 1.47 4.51 ± 1.15 
 
 
 
Brain 
 
Cmax  
(µg/mL) 
1.84 ± 0.29 2.07 ± 0.36 0.083 ±0.023 1.25 ± 0.27 
Tmax  
(hr)  
1 1 1 1 
AUC 0-tlast 
(h.µg/mL) 
10.06 ± 0.9 12.80 ± 1.24 0.52 ± 0.06 7.91 ± 1.44 
 Kp = 
AUC brain 
/AUCplasma 
0.95 1.07 0.05 1.75 
 DTI  1.13 35 
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6.3.4      PLASMA AND BRAIN DISTRIBUTION OF GNE-317 AND GDC-0980 
AFTER STEADY-STATE IN FVB MICE 
The influence of P-gp and Bcrp on brain distribution of GNE-317 and GDC-0980 was 
determined by studying the steady state plasma and brain distribution in FVB-wild type 
and TKO mice. A continuous intraperitoneal infusion was administered at a constant rate 
of 5 μg/hr for GNE-317 or 10 μg/hr for GDC-0980 lasting 48 hrs. The steady-state 
plasma and brain concentrations for GNE-317 were not significantly different between 
wild type and TKO mice. The mean steady-state plasma concentrations for GNE-317 in 
the wild type and TKO mice were 3.12 ± 1.39 ng/mL and 3.81 ± 2.32 ng/mL, 
respectively and the corresponding steady-state brain concentrations were 2.69 ± 2.00 
ng/gm and 2.98 ± 1.89 ng/gm, respectively (Figure 6.6 (a) and (b)). The resulting brain-
to-plasma ratios were comparable between wild-type and TKO mice (0.81±0.28 (WT) vs. 
0.98 ± 0.78 (TKO)). These results suggest that both P-gp and Bcrp do not play a 
significant role in altering the systemic clearance as well as brain distribution of GNE-
317 (figure 6.6 (c)).  
 
The mean steady-state plasma concentrations for GDC-0980 did not differ significantly 
between the wild type (25.99 ± 9.5 ng/mL) and TKO mice (58.42 ± 24.9 ng/mL) 
indicating that both P-gp and Bcrp do not influence the systemic clearance of GDC-0980 
(Figure 6.6 (d)). However, the steady-state brain concentration in the wild-type mice (2.5 
± 0.70 ng/gm) was significantly lower than the TKO mice (58.06 ± 19.4 ng/gm) (p<0.05) 
(figure 6.6 (e)). The corresponding steady-state brain-to-plasma ratio was 0.1 ± 0.02 in 
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wild-type mice and increased to 1.03 ± 0.27 in TKO mice, a ~10-fold increase in brain 
distribution when both P-gp and Bcrp are absent (figure 6.6 (f) and table 6.3). 
 
These results are in agreement with the previous reports by Salphati et al. for both GNE-
317 (Salphati et al., 2012a) and GDC-0980 (Salphati et al., 2012b).The authors showed in 
two separate investigations that GNE-317 is not liable to active efflux at the BBB 
whereas GDC-0980 has limited distribution to the brain due to active efflux by both P-gp 
and Bcrp at the BBB.  
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Figure 6.6 (a-c): Steady state (a) plasma concentrations and (b) brain concentrations 
of GNE-317 in FVBn wild-type and TKO mice after a continuous intraperitoneal 
infusion at a rate of 5 μg/hr for 48 hours; (c) corresponding steady-state brain-to-
plasma concentration ratio. Values are represented as mean ± S.D. (n= 4 per group)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 201  
    
Figure 6.6 (d-f):  Steady state (d) plasma concentrations and (e) brain concentrations 
of GDC-0980 in FVBn wild-type and TKO mice after a continuous intraperitoneal 
infusion at a rate of 10 μg/hr for 48 hours; (f) corresponding steady-state brain-to-
plasma concentration ratio. Values are represented as mean ± S.D. (n= 4 per group), 
***p<0.05 compared to wild-type. 
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Table 6.3:  Steady state plasma and brain concentrations of GNE-317 and GDC-0980 
in wild-type and Mdr1a/b(−/−)Bcrp1(−/−) mice after a constant intraperitoneal 
infusion of GNE-317 at a rate of 5 µg/hr or GDC-0980 at a rate of 10 µg/hr for 48 hrs 
(n =4 each group). *Data presented as mean ± S.D., #P < 0.005 compared to wild-type.  
 
 
 
 
 
 
 
 GNE-317 GDC-0980 
 Wild-type Mdr1a/b(-/-) 
Bcrp1(-/-) 
 
Wild-type Mdr1a/b(-/-) 
Bcrp1(-/-) 
Plasma Css 
(ng/mL) 
3.12 ± 1.38 3.81 ± 2.32 25.99 ± 9.45 58.42 ± 24.9 
Brain Css 
(ng/gm) 
2.69 ± 2.00 2.98 ± 1.89 2.53 ± 0.7 58.06 ± 19.4 
Brain/Plasma 
ratio 
0.81 ± 0.28 0.98 ± 0.77 0.1 ± 0.02 1.03 ± 0.27# 
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6.3.5       DIFFERENTIAL BRAIN DISTRIBUTION OF GNE-317 AND GDC-0980 
IN GLIOMA MODELS 
We assessed the ability of the BBB to restrict the brain distribution of molecularly 
targeted agents to different regions of a tumor brain in all three glioma models guided by 
GFP-labeled tumor cells. This was achieved using two dual PI3K/mTOR inhibitors, 
GNE-317 and GDC-0980. Each of these drugs has different liabilities for active efflux by 
P-gp and Bcrp at the BBB. GFP-guided tumor dissection allowed the tumor brain to be 
divided into three sections - the tumor core, the brain around the tumor (“rim”) and the 
contralateral hemisphere (“normal brain”) (Figure 6.2).  
 
 
6.3.5.1      GL261-LUC-GFP LABELED MICE 
Mice were either administered vehicle, GNE-317 or GDC-0980 once daily for three 
consecutive days and plasma and brain were harvested at 1 hr or 6 hr after the last oral 
dose. Comparison of brain concentrations in the tumor core vs. the rim vs. the 
contralateral hemisphere suggests that there is significant heterogeneity in brain 
distribution due to the tumor and the accompanying changed in BBB disruption.  
 
As shown in figure 6.7 (a), after 1 hr and 6 hr post last oral dose, the brain concentrations 
in the tumor core vs. the rim vs. the normal brain were not significantly different for 
GNE-317.  The corresponding brain-to-plasma ratios at both 1hr and 6 hr for the three 
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brain penetration of GNE-317 (figure 6.7 (b) and table 6.4). 
 
On the contrary, brain concentrations for GDC-0980 were significantly different amongst 
the different regions of the brain. The mean GDC-0980 brain concentrations in the tumor 
core at 1 hr after the last oral dose was 0.72 ± 0.28 μg/gm and decreased to 0.16 ± 0.10 
μg/gm in the rim and 0.078 ± 0.037 μg/gm in the contralateral hemisphere at 1 hr post 
last oral dose. Similar trend was observed at 6 hours post dose. The mean brain 
concentrations in the tumor core (0.20 ± 0.11 μg/gm) were higher than in the brain 
around the tumor (0.04 ± 0.02 μg/gm) and the contralateral hemisphere (0.07 ± 0.04 
μg/gm) (figure 6.7 (c) and table 6.4).  
 
The corresponding brain-to-plasma concentration ratio at 1 hr and 6 hr post oral dose was 
0.59 ± 0.17 and 0.33 ± 0.22, respectively in the tumor core and decreased significantly in 
the tumor rim and contralateral hemisphere (p<0.05). At both 1 hr and 6 hr, the brain-to-
plasma ratios in the tumor rim (0.12 ± 0.04 and 0.05 ± 0.02) and in the contralateral 
hemisphere (0.05 ± 0.01 and 0.12 ± 0.08) were not significantly different (figure 6.7 (d)). 
These results indicate that although BBB integrity is disrupted in the tumor core and drug 
can penetrate this region, the intact BBB in the regions beyond the core (the tumor rim 
and the contralateral hemisphere) restricts delivery of drugs.  
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Figure 6.7 (a-b): Regional brain distribution of GNE-317 (30 mg/kg) in GFP-luc-
GL261 syngeneic mouse glioma model. (a) Brain concentrations of GNE-317 were not 
significantly different from each other in the core, brain around the core and the 
contralateral hemisphere. The brain concentrations closely followed plasma 
concentrations at both 1 hr and 6 hr after the last oral dose. The corresponding brain-
to-plasma ratios are shown in (b .) Data represented as Mean ± S.D. (n=6 per time 
point per drug). 
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Figure 6.7 (c-d): Regional brain distribution of GNE-317 (30 mg/kg) and GDC-0980 
(7.5 mg/kg) in GFP-luc-GL261 syngeneic mouse glioma model. (c) brain 
concentrations of GDC-0980 were significantly higher than the brain concentrations 
in the rim and the contralateral hemisphere at both 1 hr and 6 hr after the last oral 
dose. The corresponding brain-to-plasma ratios are shown in (d). All values are 
represented as mean ± S.D. (n= 6 at each time point per drug). *p<0.05 compared to 
concentrations in the core, #p<0.05 compared to plasma concentrations 
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Table 6.4: plasma and brain concentrations of GNE-317 (30 mg/kg) and GDC-0980 
(7.5 mg/kg) after 3 consecutive doses once daily in GFP-luc-GL261 mouse glioma 
model. Values represent mean ± S.D. (n= 6 per time point pretreatment). 
NB= normal contralateral hemisphere 
 
GDC-0980 
 Concentrations B/P ratio 
Plasma 
(μg/mL) 
Core 
(μg/gm) 
Rim 
(μg/gm) 
NB 
(μg/gm) 
Core 
(μg/gm) 
Rim 
(μg/gm) 
NB 
(μg/gm) 
1 
hr 
1.3 ± 
0.58 
0.72  ± 
0.28 
0.16  ± 
0.10 
0.08  ± 
0.04 
0.6  ± 0.2 0.12  ± 
0.04 
0.05  ± 
0.01 
6 
hr 
0.58  ± 
0.22 
0.20  ± 
0.11 
0.04  ± 
0.02 
0.07  ± 
0.04 
0.33  ± 
0.22 
0.05  ± 
0.02 
0.12  ± 
0.08 
 
GNE-317 
1 
hr 
1.3 ± 
0.74 
1.8  ± 
0.53 
1.7  ± 
0.58 
1.7  ± 
0.44 
1.58 ± 
0.59 
1.45 ± 
0.46 
1.73 ± 
1.08 
6 
hr 
0.74 ± 
0.19 
1.2 ± 
0.35 
1.0 ± 
0.32 
1.0 ± 
0.32 
1.58 ± 
0.26 
1.40 ± 
0.19 
1.39 ± 
0.23 
 
 
 
 
 
 
 
 
 
 
 
208  
    
6.3.5.2      GFP-LABELED GBM10 AND GFP-LABELED U87 MODEL 
Mice were administered a single oral dose of GNE-317 (30 mg/kg) and GDC-0980 (7.5 
mg/kg) simultaneously and plasma and brain were harvested 1 hr after the dose. For 
GBM10 glioma model, we did not harvest plasma. Drug concentrations were determined 
in brain core vs. rim vs. contralateral hemisphere as described previously. Figure 6.8 
shows plasma and brain concentrations of GNE-317 and GDC-0980 in U87 and GBM10 
glioma model. The brain concentrations of GNE-317 in the core, rim and contralateral 
hemisphere were not significantly different to each other and to plasma in the U87 model 
(figure 6.8 (a)). The brain concentrations for GDC-0980 in the core were higher than the 
brain concentrations in the rim and the contralateral hemisphere for U87 model, but they 
were not significantly different to each other. GDC-0980 brain concentrations in the core 
were significantly less than the corresponding plasma concentrations, suggesting limited 
brain penetration of GDC-0980 in the core. Similar trend was observed in GBM10 
orthotopic xenograft model (Figure 6.8 (c) and table 6.5). The brain concentrations of 
GNE-317 were ~1 in all the three regions of the brain. However, for GDC-0980, although 
brain concentrations were higher in the core compared to the rim and contralateral 
hemisphere, these concentrations were not significantly different from each other. The 
corresponding brain-to-plasma ratios for GNE-317 and GDC-0980 in U87 model are 
shown in Figure 6.8 (b).  
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Figure 6.8 (a-b): Regional brain distribution of GNE-317 (30 mg/kg) and GDC-0980 
(7.5 mg/kg) in U87 orthotopic xenograft model of glioblastoma after a single 
simultaneous oral dose. Brain and plasma concentrations of GNE-317 and GDC-0980 
are shown in (a) U87 model and (b) corresponding brain-to-plasma ratio at 1 hr after a 
single oral dose. Values are represented as mean ± S.D. (n=5 for U87). #p-value <0.05 
compared to plasma 
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Figure 6.8 (c): Regional brain distribution of GNE-317 (30 mg/kg) and GDC-0980 (7.5 
mg/kg) in GBM10 orthotopic xenograft model of glioblastoma after a single 
simultaneous oral dose at 1 hr post dose. Plasma concentrations are not shown, as 
plasma samples were not obtained. Values are represented as mean ± S.D. (n= 3 for 
GBM10). 
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Table 6.5: Plasma and brain concentrations of GNE-317 (30 mg/kg) and GDC-0980 (7.5 mg/kg) at 1 hr 
after a single simultaneous oral dose in GBM10 and U87 orthotopic xenograft models of glioblastoma. 
Values represent mean ± S.D. (n= 3 for GBM10 and n=5 for U87)  
 
 
 
GDC-0980 
 Concentrations B/P ratio 
Plasma 
(μg/mL)  
Core 
(μg/gm) 
Rim 
(μg/gm) 
NB (μg/gm) Core 
(μg/gm) 
Rim 
(μg/gm) 
NB 
(μg/gm) 
GBM10 NA 2.2 ± 1.3 0.55 ± 0.16 0.45 ± 0.15 NA NA NA 
U87 2.1 ± 0.37 0.34 ± 0.27 0.15 ± 0.09 0.13 ± 0.11 0.15 ± 0.12 0.07 ± 0.03 0.06 ± 0.05 
 
GNE-317 
GBM10 NA 2.2 ± 1.6 1.5 ± 0.48 1.6 ± 0.21 NA NA NA 
U87 1.8 ± 0.29 2.1 ± 0.67 1.7 ± 0.63 2.1 ± 0.30 1.2 ± 0.4 0.99 ± 0.45 1.2 ± 0.26 
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6.3.6     PHARMACODYNAMIC EFFICACY OF GNE-317 AND GDC-0980 IN 
THE BRAIN 
To determine the influence of drug delivery on targeting potential, GL261-luc-GFP 
labeled mice were randomized into three groups and dosed with (a) placebo (vehicle), (b) 
GNE-317 (30 mg/kg), or (c) GDC-0980 (7.5 mg/kg) for 3 consecutive days. Mice were 
euthanized 1 h (Figure 6.9 (a)) or 6 h  (Figure 6.9 (b)) after the third dose and brain was 
harvested. IHC was performed on 5µM thick sections for (phosphorylated) p-Akt, pS6 
and p4EBP1 and total-AKT, S6 and 4EBP4. Based on staining for specific antibodies, we 
observed by visual inspection that there was a decrease in the expression of pS6 and 
p4EBP1 on treatment with GNE-317 and GDC-0980 at both 1 hr and 6 hr after the last 
oral dose compared to control (no treatment group) in the core and the rim. There appears 
to be a greater decrease in staining of tissues treated with GNE-317 compared to GDC-
0980 treated group. No difference was observed in p-AKT and AKT expression in the 
control vs. the treated groups. The total levels of AKT, S6 and 4EBP1 did not change 
with treatment (Figure 6.9 (c) and (d)). Whole brain slices scale at 100 μm and inset 
scale at 15 μm. 
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Figure 6.9 (a): Immunohistochemistry of phosphorylated antibodies upregulated in 
GL261-luc-GFP syngeneic mouse model for (a) no treatment, (b) GDC-0980 alone and 
(c) GNE-317 alone at 1 hr after the last oral dose. Brown stain indicates presence of 
respective protein in the tissues. 
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Figure 6.9 (b): Immunohistochemistry of phosphorylated antibodies upregulated in 
GL261-luc-GFP syngeneic mouse model for (a) no treatment, (b) GDC-0980 alone and 
(c) GNE-317 alone at 6 hr after the last oral dose. Brown stain indicates presence of 
respective protein in the tissues. 
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Figure 6.9 (c): Immunohistochemistry of total levels of intracellular targets in GL261-
luc-GFP syngeneic mouse model for (a) no treatment, (b) GDC-0980 alone and (c) 
GNE-317 alone at 1 hr after the last oral dose. Brown stain indicates presence of 
respective protein in the tissues. 
 
 216  
    
 
Figure 6.9 (d): Immunohistochemistry of total levels of intracellular targets in GL261-
luc-GFP syngeneic mouse model for (a) no treatment, (b) GDC-0980 alone and (c) 
GNE-317 alone at 6 hr after the last oral dose. Brown stain indicates presence of 
respective protein in the tissues. 
 
217  
    
6.3.7       SURVIVAL BENEFIT IN GLIOMA MODELS 
Therapeutic efficacy of both GNE-317 and GDC-0980 was studied in all three glioma 
models where mice were treated with control (vehicle) or GNE-317 (30 mg/kg) or GDC-
0980 (7.5mg/kg) until moribund or dead. Survival studies in U87 glioma model showed 
no difference in survival in GNE-317 treated group vs. GDC-0980 treated group 
(p=0.12), but both treatments were significantly different from placebo (p<0.0005) 
(figure 6.10 (a)).  
 
Figure 6.10: Survival efficacy of GNE-317 and GDC-0980 in (a) U87, (b) GBM10 and 
(c) GL261 mouse glioma models. Mice were randomized into three groups, placebo 
(vehicle control), GNE-317 (30 mg/kg) and GDC-0980 (7.5 mg/kg). Survival is 
represented as a cumulative survival of 10 mice in each group. Time scale indicates 
time from the first day of treatment.  
(a) U87 
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Survival in GBM10 xenografts also showed similar trend wherein there was no 
significant difference in survival between GNE-317 and GDC-0980 treated groups 
(p=0.071) but both treatments dramatically extended survival compared to placebo 
vehicle control (placebo vs. GNE <0.0001 and placebo vs. GDC <0.035) (figure 6.10 
(b)).  
 
Figure 6.10 (b): Survival efficacy of GNE-317 and GDC-0980 in GBM10 
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On the other hand, results in GL261 model showed that there was no difference in 
survival in any of the treatment groups (figure 6.10 (c) and table 6.6). The GDC-0980 
treated group showed earlier deaths compared to GNE-317 treated group. The median 
bioluminescence values were similar across all groups (Figure 6.10 (d)). This suggested 
that the tumor burden was not affected by treatment and earlier deaths in GDC-0980 
treated group could be attributed to toxicity in GL261 model over once daily dosing 
regimen (figure 6.10 (d)). Results from GL261 model require further investigation. It 
appears that although both GNE-317 and GDC-0980 have similar potency in-vitro 
(similar IC50s), none of the drugs showed improvement in efficacy when administered 
in-vivo. This could be attributed to differences in dosing, as both the drugs were given at 
the maximally tolerated dose (as suggested by Genentech). It is also likely that the 
GL261 tumor is less sensitive to PI3K driven pathway. 
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Figure 6.10 (c): Survival efficacy of GNE-317 and GDC-0980 in GL261 
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Figure 6.10 (d): shows the corresponding tumor burden as measured by 
bioluminescence in GFP-luc-GL261 mouse model. The figure shows that there was no 
decrease in the tumor burden on treatment with GNE-317 or GDC-0980 compared to 
no treatment (placebo) suggesting that GNE-317 and GDC-0980 were not effective 
against GL261 model. 
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Table 6.6: Survival probabilities of GNE-317 and GDC-0980 in U87, GBM10 and 
GL261 mouse model of glioblastoma.  
 
 
P-value vs. Placebo by log-rank test 
Treatment N U87 GBM10 GL261 
GNE-317 10 <0.0003 < 0.0001 <0.64 
GDC-0980 10 <0.0004 < 0.035 <0.72 
GNE-317 vs. 
GDC-0980 
10 =0.12 = 0.071 =0.27 
 
 
 
The results from survival study show that both GNE-317 and GDC-0980 are 
therapeutically effective in improving survival compared to placebo in GBM10 and U87 
xenografts but these drugs were not different from each other. The failure of these drugs 
to show difference in efficacy compared to each other could be due to limited single 
agent efficacy of GNE-317 compared to GDC-0980, despite better BBB permeability. 
Both GNE-317 and GDC-0980 did not show any survival benefit in GL261 syngeneic 
model suggesting that these drugs may not be efficacious in this model.  
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6.4       DISCUSSION 
Glioblastoma multiforme (GBM) is a grade IV astrocytoma with poor prognosis and 
median survival of 12-15 months despite multi-model treatment options. The infiltrative 
nature of the disease makes it particularly challenging to treat the tumor cells that lie in 
areas centimeters away from the tumor core. Drug delivery-related issues have often not 
been considered a plausible explanation because high drug concentrations are observed in 
the tumor core, indicating a disrupted BBB. The objective of this study was (a) to 
investigate whether the BBB is heterogeneously disrupted in GL261, GBM10 and U87 
mouse models of glioma, which recapitulates the pathology of human GBM. This is 
important to fully understand the influence of BBB in drug delivery to GBM, (b) 
although the BBB is disrupted in the tumor core, presence of an intact BBB in the area 
around the tumor core and in the contralateral hemisphere, can severely restrict delivery 
of molecularly targeted agents intracellularly and (c) there is a need of not only effective 
delivery but also an effective drug to target the tumor cells. 
 
GBM is a highly aggressive and invasive brain tumor and in order to assess success of 
therapy it is important to identify appropriate models that share the same invasive and 
heterogeneity properties as human GBM. GL261 is a syngeneic model that closely 
mimics GBM in invasiveness and angiogenic properties (Newcomb and Zagzag, 2009). 
Newcomb and Zagzag have shown that similar to the human GBM, the GL261 murine 
model also demonstrates an irregularly shaped heterogeneous mass with disrupted BBB 
(Newcomb and Zagzag, 2009; Zagzag et al., 2000). There are several studies that have 
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shown that drug concentrations in the resected tumor core are higher comparable to the 
concentrations in the regions non-enhanced on contrast imaging. In a seminal study by 
Blakeley and colleagues, the authors showed that methotrexate concentrations in the 
tumor core were ten-fold higher than in the regions beyond the core (Blakeley et al., 
2009). Similar results have been reported for other anti-cancer agents such as paclitaxel 
(Fine et al., 2006) and temozolomide (Rosso et al., 2009). Previously our group has 
reported similar results for erlotinib (Agarwal et al., 2013) and dasatinib (Agarwal et al., 
2012) in both, a spontaneous and a xenograft glioma model. We have demonstrated that 
the lack of efficacy and overall survival were related to the presence of Bcrp/P-gp in the 
intact BBB in areas away from the tumor core in the wild type tumor bearing mice 
compared to P-gp/Bcrp knockout mice. 
 
PI3K/mTOR/AKT is one of the most frequently dysregulated pathways in GBM. Some 
drugs targeting this pathway have shown limited distribution across the BBB due to 
activity of the efflux transporters, P-gp and Bcrp (Chu et al., 2009; Salphati et al., 2010). 
To fully evaluate the role of active efflux at the BBB, we conducted brain distribution 
studies in non-tumor bearing (FVBn) and tumor bearing syngeneic (GL261-luc-GFP) 
glioma model and xenograft models (GBM10 and U87) using two structurally related 
dual PI3K/AKT/mTOR inhibitors, GNE-317 and GDC-0980, with different substrate 
affinities for active efflux transporters, P-gp and Bcrp.  
 
Our studies show that the BBB is disrupted in the tumor core. The accumulation of Texas 
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Red dextran (TRD), a vascular marker, varied in the brain with higher accumulation in 
the tumor core and no accumulation in the contralateral hemisphere. Such differences in 
BBB disruption suggests that the drug concentrations observed in the tumor core do not 
fully represent the true whole brain concentrations and this could mislead our 
interpretation for inadequacy in drug delivery. The brain distribution studies in non-tumor 
and tumor bearing mice indicate that GNE-317 has better brain delivery than GDC-0980. 
The steady-state brain-to-plasma concentration ratio of GNE-317 was similar in FVBn-
wild type (0.81 ± 0.28) vs. TKO mice (0.98 ± 0.77). However, the steady-state brain-to-
plasma concentration ratio of GDC-0980 was ~10 fold higher in TKO mice (0.1 ± 0.02 
(Wild-type) vs. 1.03 ± 0.27 (TKO)). The steady-state brain-to-plasma ratios for both 
GNE-317 and GDC-0980 obtained after administering both drugs separately in mice 
were comparable to the brain partition coefficient (Kp) obtained after a single oral dose 
of both drugs administered simultaneously in wild-type and TKO mice. This suggests 
linear distribution kinetics of both GNE-317 and GDC-0980 and clarifies potential for 
any pharmacokinetic interaction between the two drugs when administered 
simultaneously. 
 
Tumor brain distribution studies show that brain concentrations of GNE-317 are similar 
in the core vs. the brain around the core vs. the contralateral hemisphere. Thus, the brain-
to-plasma ratio is ~1 across all regions of the brain in U87 and GL261 model. We could 
not determine brain-to-plasma ratios for GBM10 as we did not obtain plasma specimens. 
However, the brain concentrations of GDC-0980 in the core were higher compared to the 
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regions beyond the core (rim and the contralateral hemisphere) in all the three glioma 
models studied. The difference in brain concentrations was significant in GL261 mouse 
model but not in GBM10 and U87 mouse models. Thus the brain-to-plasma ratios of 
GDC-0980 vary across all regions of the brain. These results demonstrate the functional 
importance of active efflux on an intact BBB in the tumor periphery, which harbors 
invasive tumor cells. Results from the tumor distribution studies in glioma mouse models 
suggest that brain distribution of GNE-317 is not limited by active efflux at the BBB 
whereas GDC-0980 has restricted brain penetration in the areas around the tumor core 
and in the contralateral hemisphere. 
 
However, differences in tumor distribution of GNE-317 and GDC-0980 did not affect 
efficacy in-vivo between the two groups in all glioma mouse models investigated (GL261 
syngeneic mouse model, patient-derived xenograft GBM10 and cell-line derived U87 
mouse model). In both GBM10 and U87, although both treatment groups were 
significantly different from placebo and improved survival, we did not see a significant 
difference in efficacy of GNE-317 vs. the GDC-0980 treated group. This discrepancy in 
efficacy of GNE-317 vs. GDC-0980 in GBM10 and U87 suggest that GNE-317 may not 
have sufficient single agent activity against PI3K and mTORs (mTORC1 and mTORC2). 
There could also be issues related to the intestinal absorption and bioavailability of GNE-
317 compared to GDC-0980 due to differences in dosing, although both GNE-317 and 
GDC-0980 had equivalent AUCs in plasma. We administered maximal tolerated dose for 
both GNE-317 and GDC-0980 in all the studies as suggested by Genentech. In GL261 
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mouse model there was no effect of either drug in improving the survival of mice. 
Despite similar targeting potential of these drugs in-vitro, and reduction in expression of 
targets such as p-S6 and p-EBP41 in immunohistochemical analysis, we did not observe 
any efficacy in in-vivo. A plausible explanation for this could be that GL261 tumor is not 
a PI3K driven tumor and hence these drugs did not show expected pharmacodynamic 
effects on improving survival in-vivo. These studies indicate that although the blood brain 
barrier is an impediment to drug delivery, it is also important to consider a drug with 
right efficacy and targeting potential.  Moreover, in order to better understand these 
aspects of drug delivery, it is critical that we use an appropriate animal model that will 
help us delineate the role of a targeted agent against a pathway. One alternative is to use 
spontaneous glioma models which are driven by a particular gene such as PTEN(-/-) 
driven tumor bearing mice.  
 
 
6.5      CONCLUSIONS 
In summary, this study underlines the importance of the BBB in restricting delivery of 
anti-cancer agents to the tumor cells for treatment of GBM. The heterogeneity in BBB 
integrity in GL261 and GBM10 model illustrates accurate representation of an invasive 
tumor like GBM. Disruption of BBB in the tumor core vs. the tumor periphery and the 
contralateral hemisphere emphasizes the fact that drug concentrations measured in the 
tumor core do not represent true brain concentrations and believing that the BBB is not 
an impediment to drug delivery for GBM is misleading. This could be one of the 
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plausible reasons for failure of several drugs in clinical trials and higher rates of tumor 
recurrence.  
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CHAPTER  VII 
 
 
 
RECAPITULATION 
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Glioblastoma multiforme (GBM) is a devastating and incurable primary brain tumor. 
Despite advances in treatments such as surgery, radiation and chemotherapy, recurrence 
of the tumor is inevitable leading to patient death. The median overall survival in GBM 
patients is 12-18 months and after recurrence, the survival is 5-7 months. With advances 
in research, several new molecularly-targeted agents have been evaluated in GBM 
patients, but they have shown limited clinical benefit in prolonging overall survival. 
Treatment of GBM becomes challenging due to two major factors; (a) the invasive 
growth pattern of GBM that results in infiltration of tumor cells to areas centimeters away 
from the tumor core, resulting in formation of satellite lesions in the brain which are 
capable of tumor regrowth; (b) the presence of intact blood brain barrier (BBB) in the 
areas surrounding the tumor core that shield the tumor cells from chemotherapy. The 
blood-brain barrier such as, through a combination of endothelial tight junctions and 
active efflux transporters, P-glycoprotein (P-gp) and breast cancer resistance protein 
(BCRP), acts as a protective barrier that limits therapeutic efficacy of many 
chemotherapeutic drugs.  
 
The most important aspect of GBM treatment lies in understanding the fact GBM is a 
highly invasive and infiltrative tumor wherein the tumor cells reside behind an intact 
BBB in areas away from the bulk tumor mass. It is important to acknowledge that 
although the BBB is disrupted in the tumor core, presence of intact BBB in the brain 
around the core (“rim”) and the normal contralateral hemisphere makes GBM a disease 
of the whole brain and this makes the need to effectively deliver drugs across the BBB 
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imperative. The heart of this thesis project is to investigate the role of active efflux 
transporters in brain distribution of molecularly-targeted agents in non-tumor bearing and 
glioma-tumor bearing mice.  
 
The first part of this project dealt with development and validation of an analytical assay 
for determination of mouse plasma and brain tissue concentrations of sunitinib, an anti-
VEGFR inhibitor, using liquid chromatography tandem mass spectrometry (LC-MS/MS) 
(chapter 2). Consequently, this assay was utilized to determine sunitinib concentrations 
in FVB mice (chapter 3). Earlier our lab and several other researchers have reported and 
demonstrated that P-gp and Bcrp limit brain distribution of molecularly-targeted agents 
such as sorafenib, gefitinib, erlotinib, imatinib, cediranib and dasatinib. In this project we 
pharmacokinetically examined the role of active efflux by P-gp and Bcrp on the brain 
distribution of sunitinib in FVB-wild type, Mdr1a/b(-/-), Bcrp1(-/-) and Mdr1a/b(-/-
)Bcrp1(-/-) mice. We compared the brain partition coefficient of sunitinib in all four 
genotypes after a single oral dose and at steady state after continuous intraperitoneal 
infusion. These brain-to-plasma ratios, called as brain partition coefficient (Kp) were 
compared to the transient steady state ratios for all genotypes. The transient steady state 
is defined as the point in time, after a single dose, at which the rate of drug entry into the 
brain is equal to the rate of exit from the brain. For a system that follows linear 
distribution kinetics, these ratios will be similar. Results from these studies indicated that 
both absence of both P-gp and Bcrp increased brain penetration of sunitinib resulting in a 
drug targeting index (DTI) of ~49 fold. This suggests that both P-gp and Bcrp play a role 
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in restricting the brain distribution of sunitinib into the brain. We further evaluated the 
influence of administering pharmacological inhibitors of active efflux transporters. We 
observed that dual inhibition of P-gp/Bcrp1 via administration of elacridar (GF120918) 
resulted in similar brain-to-plasma ratio at 1 hr post oral dose of sunitinib (~12 fold 
increase) as observed in Mdr1a/b(-/-)Bcrp1(-/-) mice at 1 hr post oral dose (~17.3 fold 
increase).  
 
In an one-point-per-animal study designs, a naïve-pooled approach is used to estimate 
AUCs in plasma and the tissue and the AUC ratio is used to estimate the brain partition 
coefficient (Kp). Kp is obtained as a point estimate and such ratios ignore within-animal 
correlations; in addition, they are not associated with any statistical certainty.  We 
proposed a novel statistical analysis approach method using a non-linear mixed effect 
modeling approach (NONMEM) (chapter 4) to estimate variability in the brain partition 
coefficient for brain distribution studies in a serial-sacrifice design. In this chapter, we 
used the sunitinib study reported in chapter 3 as a model case study. We developed a 
pharmacokinetic model to simultaneously depict plasma and brain concentrations, thus 
maintaining within-animal correlations. Our results indicate that the predicted plasma and 
brain concentrations closely followed the observed values in all four genotypes. 
Additionally, the Kp ratios obtained from the model were comparable to the Kp ratios 
obtained from the NCA analysis. Furthermore, we evaluated bias and precision in 
estimation of Kp under the influence of study design elements such as between-animal 
variability and sample size at each time point using a stochastic simulation and estimation 
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method (SSE). Our results suggest that the assumptions regarding the magnitude of bias 
and sample size do not influence Kp, but precision is affected by sample size.  
 
The final chapter of this thesis project examined the role of active efflux in glioma tumor 
bearing mice using two dual PI3K/mTOR inhibitors with different BBB permeability 
characteristics (chapter 5). GNE-317 is designed to evade active efflux and penetrate the 
BBB, while GDC-0980 has limited brain permeability due to active efflux by P-gp and 
Bcrp. We used a GL261-luc-GFP labeled syngeneic mouse model, a patient-derived 
GBM10 orthotopic xenograft mouse model, and a cell-line derived U87 orthotopic 
xenograft mouse model. We showed that the BBB is heterogeneously disrupted within 
the tumor core and this could mislead our interpretation for drug distribution into the 
tumor. Using GFP-labeled tumor models we investigated the brain distribution of GNE-
317 and GDC-0980 in the tumor core, the rim (brain around the tumor), and the 
contralateral brain tissue.  The results showed that the brain distribution of GNE-317 was 
similar in the three regions of the brain. On the other hand, for GDC-0980, higher drug 
concentrations were observed in the tumor core compared to the areas surrounding the 
tumor core, that is, the rim and contralateral hemisphere. This indicated that the BBB is 
intact in areas away from the core, thereby limiting brain distribution of drugs with 
limited permeability across the brain capillary endothelial cells. We further examined the 
influence of drug efflux mechanisms on the efficacy of GNE-317 and GDC-0980 in all 
three glioma models. Results from GBM10 and U87 study suggested that both GNE-317 
and GDC-0980 improved survival compared to placebo, although both treatments were 
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not significantly different from one another. However, in GL261, there was no difference 
between the treatment groups and placebo. These results suggest that for treating an 
invasive tumor such as GBM, it is critical to not only acknowledge the importance of 
effective drug delivery but also to use a drug that is effective once it engages the target. 
 
Future work on this project will examine the influence of anti-angiogenic therapy (AAT) 
on the tumor delivery of concomitantly administered drugs for treatment of GBM.  An 
anti-angiogenic therapy may be considered a paradox as it could restore the low 
permeability characteristics of the BBB via vessel normalization. This AAT-mediated 
restoration of BBB integrity could influence the delivery of drugs with low BBB 
permeability such as GDC-0980. It would be interesting to investigate the influence of 
the dual PI3K/mTOR inhibitors themselves on BBB integrity, as it has been reported that 
this class of drugs also exhibits anti-angiogenic properties.  
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NONMEM CODE for chapter 5 
 
 
;Model Desc: SAME AS 106 BSV 20% 
;Project Name: rajneet 
;Project ID: NO PROJECT DESCRIPTION 
 
 
 
;Project ID: NO PROJECT DESCRIPTION 
  
$PROB RUN# 602 
$INPUT C ID TIME DV AMT MDV TYPE CMT RATE EVID POIP 
$DATA SUNITINIBPLBRNP_new.CSV IGNORE=C 
$SUBROUTINES ADVAN6 TRANS1 TOL=6 
$MODEL  
   COMP=(PODEPOT)  
   COMP=(PLASMA) 
   COMP=(BRAIN) 
   COMP=(IPDEPOT) 
$PK 
   KA=THETA(1) 
   CL=THETA(2)*EXP(ETA(1)) 
   V=THETA(3)*EXP(ETA(2)) 
   CLIN=THETA(4)*EXP(ETA(3)) 
   S2=V  
 
IF (TYPE.EQ.1) THEN 
   KP = THETA(5) 
ELSEIF (TYPE.EQ.2) THEN 
   KP = THETA(6) 
ELSEIF (TYPE.EQ.3) THEN 
   KP = THETA(7) 
ELSE  
   KP = THETA(8) 
ENDIF 
KP1=KP*EXP(ETA(4)) 
F1=THETA(9) 
CLOUT=CLIN/KP1 
HL=0.693*V/CL 
SID=TYPE 
TAD=TIME 
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$DES 
CP=A(2)/V 
CBR=A(3) 
   DADT(1) = -KA*A(1) 
   DADT(2) = KA*A(1) + KA*A(4) - CL*CP 
   DADT(3) = CLIN*CP-CLOUT*CBR 
   DADT(4) = -KA*A(4) 
 
$ERROR 
IF(CMT.EQ.2) THEN 
   Y = F + F*ERR(1) 
ELSE 
   Y = F+F*ERR(2) 
ENDIF 
 IPRE=F 
 
$EST PRINT=5 MAX=9999 SIG=2 SIGL=6 METHOD=1 MSFO=602.msf  
$COV 
$THETA  
  (1.0 FIX) ;[KA] 
  (0 .1) ;[CL] 
  (0 .5) ;[V] 
  (0 2) ;[CLin] 
  (0 .5) ;[KP WT] 
  (0 2.3) ;[KP PKO] 
  (0 .8) ;[KP BKO] 
  (0 17) ;[KP TKO] 
  (0 .5 1) ;[F4 IP] 
 
$OMEGA  
  0.04 FIX ;[P] 
  0.04 FIX ;[P] 
  0.04 FIX ;[P] 
  0.04 FIX ;[P] 
$SIGMA 
  0.0225 ;[P] 
  0.04 ;[P] 
 
$TABLE ID TIME TAD SID CMT POIP TYPE IPRE CWRES HL CL V KP1 CLIN 
CLOUT ONEHEADER NOPRINT FILE=602.tab 
$TABLE ID CL V CLIN KP1 FIRSTONLY NOAPPEND NOPRINT FILE=602.PAR 
$TABLE ID ETA1 ETA2 ETA3 ETA4 FIRSTONLY NOAPPEND NOPRINT 
FILE=602.eta 
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